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Tau is an intrinsically disordered, microtubule associated protein and is 
responsible for the promotion of microtubule (MT) formation and stabilization. The 
human Tau protein has six different isoforms, which are expressed in neurons of the 
central nervous system. A precise understanding of the molecular mechanism involved in 
the Tau-MT interaction is highly relevant to the study of neurodegenerative states as 
irregularities in the function of these proteins may lead to neuronal loss and cell death. 
For instance, the hyperphosphorylation of Tau leads to the depolymerization of MTs and 
formation of neurofibrillary tangles of Tau which is one of the hallmarks in 
neurodegenerative diseases.  
Although the function of Tau and MTs had been studied previously, it was still 
unclear how Tau binds to microtubules and high resolution information allowing the 
structural characterization of microtubule-bound Tau was missing. The aim of the thesis 
was to perform an in-depth study of the Tau-MT interaction and to determine the MT-
bound conformation of the Tau protein. Furthermore, the identification of the binding 
sites of Tau on MTs will provide a three-dimensional view of the MT-bound Tau 
structure.  
Among the available techniques to derive structural information, NMR is the only 
method that allows structural description in near-physiological conditions and at atomic 
resolution. A divide-and-conquer approach in combination with exchange-transferred 
NMR methods were employed to overcome the size limitations in NMR and to establish 
the three-dimensional structure of MT-bound Tau. 
This thesis covers the detailed NMR characterization of different Tau isoforms, mutants 
and shorter Tau constructs, thereby identifying the potential binding hot spots of Tau 
involved in MT interaction. This allowed the structure determination of highly 
independent and dynamic binding domains of MT-bound Tau using a ‘divide and 
conquer’ strategy and tr-NOE method. Sufficient experimental evidences obtained using 
NMR and other biophysical methods proved that the shorter Tau fragments used for 
structure determination can function similar to the full-length Tau protein. The influence 
of site-specific mutations and phosphorylation of Tau and Tau fragments is correlated 
X 
 
with the structure that we identified. The obtained three-dimensional structure thus 
provides insights into the structure-function relationship of MT-bound Tau. Competition 
experiments using Tau fragments and MT targeting drugs in combination with tr-NOE, 
STD and Inpharma experiments revealed that the Tau binding domains compete against 
each other for binding to a single binding site on tubulin near the binding site of 
vinblastine. The results are supported by chemical cross linking coupled with mass 
spectrometry. Together with this information, it is possible to suggest a three-
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1.1 Neurodegenerative diseases 
The native conformation of a protein is essential for its normal function. The loss 
of structural identity of individual proteins leads to protein aggregation and thereby 
several diseases commonly known as protein misfolding diseases. Neurodegenerative 
diseases, the progressive loss of structure or function of neurons including neuronal 
death are a class of protein misfolding diseases where the protein aggregation occurs in 
the brain. These include neuronal pathologic forms in which a progressive loss of either 
structure or function of neurons is observed. This leads to the neuronal death and 
associated diseases. Many neurodegenerative diseases are caused by genetic mutations of 
related proteins. Some of the widely discussed proteins in neurodegenerative diseases 
include alpha Synuclein (in Parkinson disease), amyloid beta peptide and Tau (in 
Alzheimer disease), prion protein (in Prion disease) and huntingtin (in Huntington’s 
disease) and so on.  
The neurodegenerative diseases related to Tau protein are also known as 
Tauopathies where predominantly the aggregates of Tau occur. Tauopathies are group of 
disorders that includes Alzheimer disease (AD), supranuclear palsy, corticobasal 
degeneration, Pick’s disease and frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17). The mechanisms of the formation of aggregates from 
soluble Tau have been studied in great detail, particularly in AD and FTDP-17 
(Esmaeliazad, Mccarty et al. 1994, Lee, Goedert et al. 2001). Dementia is one of the 
widely discussed and common disorders in elder people as a result of aging. It has 







1.1.1 Alzheimer disease  
In 1907 Dr. Alois Alzheimer, a German psychiatrist, described the presence of 
plaques and tangles in the brain of a demented patient, which were found to be the 
pathological hallmarks. This class of neurodegenerative disease was later named as 
Alzheimer disease (AD) (Alzheimer 1907). More than half of the dementia affected 
people suffer from Alzheimer disease (Fratiglioni, De Ronchi et al. 1999). The previous 
research in AD highlights the presence of extracellular deposits of amyloid β as plaques 
and intracellular neurofibrillary tangles (NFTs) of Tau as the hallmarks in AD (Grundke-
Iqbal, Iqbal et al. 1989) (Figure 1). 
 
Figure 1: Pictorial representation of the abnormal cellular deposits found in Alzheimer disease. AD 
is characterized by the presence of two abnormal structures in the brain, (i) extracellular amyloid plaques 
and (ii) intracellular neurofibrillary tangles (NFTs). The amyloid plaques are composed of the insoluble 
aggregates of Aβ, a small proteolytic fragment from the amyloid precursor protein (APP). NFTs are 
composed of the insoluble aggregates of Tau in the form of paired helical filaments (PHFs) or fibers. 
(Image courtesy of the National Institute of Health)    
1.1.2 Tau and Alzheimer disease  
It has been established that Tau is necessary for the neuronal development and 
maintenance of the nervous system. Abnormal Tau behavior results in many 
neurodegenerative diseases, including AD and several other dementias (Spillantini, 
Tolnay et al. 1999, Spillantini, Van Swieten et al. 2000, Goedert and Spillantini 2006, 






From the neuropathological point of view AD is characterized by the presence of 
two abnormal structures in the brain. The amyloid plaques are composed of the insoluble 
aggregates of Aβ, a small proteolytic fragment from the amyloid precursor protein 
(APP). NFTs are composed of the insoluble aggregates of Tau in the form of paired 
helical filaments (PHFs) or fibers (Grundke-Iqbal, Iqbal et al. 1986, Grundke-Iqbal and 
Iqbal 1989, Grundke-Iqbal, Iqbal et al. 1989). There are many other neurodegenerative 
diseases which are caused by the insoluble Tau NFTs named as “Tauopathies” (Hutton, 
Lendon et al. 1998, Spillantini, Murrell et al. 1998) such as FTDP-17, progressive 
supranuclear palsy (PSP) and corticobasal degeneration (CBD).  
 
Figure 2: Tau neurofibrillary tangles in healthy and diseased neurons. In a healthy neuron 
microtubules are stabilized by Tau and thereby support axonal transport of vesicles and organelles. 
Whereas in a diseased neuron the hyperphosphorylation of Tau leads to microtubule disintegration and 
disrupt microtubule supported cellular transport. The hyper phosphorylated Tau detaches from 
microtubules and forms paired helical filaments (NFTs). These NFTs are found to be the intracellular 
deposits in the form of neurofibrillary tangles which are one of the hallmarks in Alzheimer’s disease. 
(Image courtesy of the National Institutes of Health)    
A number of studies have shown that many neurodegenerative Tauopathies are 
connected to the hyperphosphorylation and other post translational modifications of Tau 
that leads to the detachment of Tau from the microtubules and the formation of NFTs of 
Tau (Wittmann, Wszolek et al. 2001, Noble, Olm et al. 2003). NFTs consist of 
aggregated straight or paired helical filaments (PHFs) of aberrantly phosphorylated 






1.2 Tau protein 
1.2.1 Tau: A neuronal microtubule associated protein 
Tau is an intrinsically disordered, microtubule associated protein and is 
responsible for the promotion of microtubule (MT) formation and stabilization. Tau 
protein was initially identified by Weingarten and co-workers in 1975 as a protein 
belonging to a heat stable family of microtubule-associated proteins that co-purify with 
tubulin (Gaskin, Cantor et al. 1974, Weingarten, Lockwood et al. 1975). Later on it was 
realized that Tau restores the microtubule assembly competence of phosphocellulose-
purified (PC) tubulin that is essentially devoid of MAPs (Weingarten, Lockwood et al. 
1975). Another remarkable finding was that Tau functions stoichiometrically rather than 
catalytically (Weingarten, Lockwood et al. 1975). In other words it is a characteristic 
feature of Tau to bind to tubulin and promote microtubule assembly (Weingarten, 
Lockwood et al. 1975). 
The human Tau gene is located on chromosome 17 and it includes 16 exons 
(Kosik, Joachim et al. 1986, Neve, Harris et al. 1986). Alternative splicing of Tau 
mRNA from this single Tau gene generates six different Tau isoforms in the central 
nervous system (CNS) ranging from 352 to 441 amino acids, and several further variants 
in the peripheral nerve system (Goedert 1996, Andreadis 2005). In fetal neurons only the 
smallest isoform is expressed and all six isoforms are expressed in adult human brain. 
These six isoforms possess either three or four 18 amino acid long imperfect repeats, 
which are separated by shorter inter repeats, depending on the exclusion or inclusion of 
the exon 10 encoded sequences. These 18 amino acid long repeats were combined with 
the inter repeats to further simplify them as 31 or 32 amino acid long repeats. It has been 
shown that these repeats are important for the MT binding and other regulatory activities 
(Butner and Kirschner 1991, Gustke, Trinczek et al. 1994, Trinczek, Biernat et al. 1995). 
In addition to these, alternative splicing of exons 2 and 3 leads to the presence of one, 
two or none 29 amino acid long inserts in the N-terminal region of the protein (Himmler, 
Drechsel et al. 1989). A diagram of the domain organization of the six Tau isoforms is 









Figure 3: Domain organization of the six different isoforms of Tau in the CNS. Tau isoforms in the 
CNS are represented with the organization of domains. The N-terminal region of Tau upto the proline rich 
region is termed as projection domain. Microtubule assembly domain includes three or four repeats (31 
residues each, R1-R4), which together with the pseudo repeat R` and proline-rich flanking regions (P1 and 
P2) constitute the microtubule binding region.  
 
 
1.2.2 Tau: An intrinsically disordered protein 
Proteins that lack a rigid secondary and tertiary structure under physiological 
conditions are called intrinsically disordered proteins. However, another characteristic 
feature of IDPs is that they may have certain secondary structure propensities albeit a 
continuous amino acid stretch of protein is disordered. Although disordered in the 
isolated state, many of them acquire a well-defined conformation upon interaction with 
their partners.  
Tau is an intrinsically disordered protein. Tau is highly soluble protein with a 
small number of hydrophobic amino acid residues. The percentage of hydrophobic 
residues is ~15% in contrast to globular proteins where it is about 30% (von Bergen, 
Barghorn et al. 2005). The relatively higher number of positively charged residues 
together with other features like resulting in a pI of 8.3-10.0 depending on the isoform 
makes it intrinsically disordered protein (Uversky, Gillespie et al. 2000). Tau is one of 







1.2.3 Tau structure, function and regulation 
The intricate wiring of the nervous system is established on the basis of terminal 
neuronal differentiation that is characterized by the formation of specialized cytoplasmic 
domains such as axons and dendrites. Microtubules have spatially and temporally 
distinct properties within each subcellular compartment (Ahmad, Pienkowski et al. 
1993). Within the body of elongating axonal projections, stable microtubules are 
organized in a polarized array. The distinctive and specific properties of microtubules in 
selected neuronal compartments arise in part from the regulated expression and 
subcellular localization of the structural microtubule associated proteins like Tau, MAP1, 
and MAP2 (Caceres, Mautino et al. 1992, Gordonweeks 1993, Esmaeliazad, Mccarty et 
al. 1994). 
Tau protein has been best characterized on the basis of their abilities to bind 
directly to microtubules, promote MT assembly and regulation of MT dynamics (Paglini, 
Peris et al. 2000, Feinstein and Wilson 2005). Within neuronal cells functions of 
microtubules are regulated by Tau protein. The Tau functions are regulated by both 
alternative RNA splicing and phosphorylation (Himmler, Drechsel et al. 1989). The 
phosphorylation takes place at a number of sites that regulates the binding properties 
(Hanger, Betts et al. 1998, Gong, Liu et al. 2006). Different Tau isoforms present in CNS 
are listed in Table 1. 
The domains of Tau are broadly divided into an acidic N-terminal ‘Projection 
domain’ (M1-Y197) and a C-terminal ‘assembly domain’ (S198- L441) based on limited 
proteolysis and the involvement of Tau domains in the microtubule binding ability 
(Gustke, Trinczek et al. 1994). Tau domains are further defined based on the character of 
the primary sequence. The N-terminal region with amino acids M1-G120 constitutes the 
acidic domain. This domain includes two insert domains that are alternatively spliced (I1 
and I2; E42-A103). The region G120-Q244 is basic in nature and contains many proline 
residues. Hence it is named as proline rich region with further subdivision into P1and P2 
at Y197. The region T244-K368 is characterized by three or four imperfect repeats (R1-







Table 1: List of Tau isoforms present in CNS. Tau isoforms present in CNS listed by name, 
denotation based on the presence or absence of I and R domains, number of amino acids and the 
molecular weight (this table is reproduced from Goedert et al., 1989). 
 




hTau23 0I/3R 352 36750 
hTau37 1I/3R 381 39720 
hTau39 2I/3R 410 42603 
hTau24 0I/4R 383 40007 
hTau34 1I/4R 412 42967 
hTau40 2I/4R 441 45850 
 
1.2.4 Structure of Tau in solution  
It was noticed in the beginning that Tau has an unusual character as a protein with 
very high resistance to heat and acid treatment without losing its functionality and 
possess very low secondary structure throughout the sequence (Cleveland, Hwo et al. 
1977). Tau behaves as an “intrinsically disordered” protein in solution (Schweers, 
Schonbrunn-Hanebeck et al. 1994) and it adopts a “paperclip” conformation, whereby 
the N- and C-terminal domains approach each other and the repeat domain as well 
(Jeganathan, von Bergen et al. 2006, Jeganathan, Hascher et al. 2008). Several 
observations suggest that Tau cannot simply be a “random coil” in the strict sense. Small 
angle x-ray scattering (SAXS) and Forster resonance energy transfer (FRET) were used 
to obtain further insights into the structure of the Tau protein (Jeganathan, von Bergen et 
al. 2006, Mylonas, Hascher et al. 2008). Although Tau has been studied for many years, 
very little structural information is available (Harbison, Bhattacharya et al. 2012). 
In fact NMR is the only method that allows the investigation of conformation and 
dynamics of intrinsically disordered proteins with atomic resolution (Dyson and Wright 
2005). Using the divide and conquer strategy different Tau constructs were used for the 
solution NMR investigations and overcame the NMR size limitation and severe signal 







Figure 4: Conformation of monomeric hTau40 in solution. (a) The domain organization diagram of 
hTau40 with transient secondary structures. Secondary structure propensities are represented as red alpha 
helix, yellow beta strands and poly proline stretches are coloured green. (b) An ensemble structure of 
hTau40 calculated from PRE data with the colour coding according to the domain organization diagram. 
(Figure modified from(Mukrasch, Bibow et al. 2009)). 
 
methods (Mukrasch, Bibow et al. 2009, Narayanan, Dürr et al. 2010).  It was revealed 
that 441-residue Tau is highly dynamic in solution (Figure 4) with a distinct domain 
overlap. The complete resonance assignment was achieved using the advanced NMR 
character and an intricate network of transient long-range contacts important for 
pathogenic aggregation. An ensemble description of monomeric Tau in solution was 
determined in single-residue view provided by the NMR analysis (Mukrasch, Bibow et 
al. 2009) based on paramagnetic relaxation enhancement (PRE). Tau possess high 
propensity for the turn conformations in the repeat region within the residue stretches 
DLKN, DLSN, DLSK and DLFD (Mukrasch, Markwick et al. 2007). 
 
Hyperphosphorylated Tau is found to be the major constituent of paired helical 
filaments (PHFs) separated from AD brains. It is to be noticed that this conclusion has 
been drawn based on the creation and characterization of monoclonal antibodies raised 
against PHFs. These antibodies can be classified into three categories: (1) those which 
recognize unmodified primary sequences of Tau, (2) those which recognize 






dependent epitopes on Tau. Of these antibodies, only the conformation-dependent 
antibodies appear to be capable of distinguishing normal Tau from PHF-Tau in solution. 
Phosphorylation of serine and threonine residues in proline-rich sequences induces a 
conformational change to a type II polyproline helix (Bielska and Zondlo 2006). The N- 
and C-terminal sections around the core of the Tau filament consists of over 200 amino 
acids form the fuzzy coat. The dynamic structure of this fuzzy coat was characterized 
using NMR and the binding of conformation specific antibodies to the Tau protein 
(Bibow, Mukrasch et al. 2011). 
1.2.5 Multiple functions of Tau 
Although Tau has been well characterized as a microtubule associated protein 
(Weingarten, Lockwood et al. 1975, Witman, Cleveland et al. 1976), recent studies have 
given further insights into its multifunctional properties (Tortosa, Santa-Maria et al. 
2009, Morris, Maeda et al. 2011). Tau has many other binding partners such as signaling 
molecules, cytoskeletal elements and lipids (Surridge and Burns 1994, Fleming, 
Weisgraber et al. 1996, Fulga, Elson-Schwab et al. 2007, Morris, Maeda et al. 2011). 
Another class of Tau interacting partners includes heat shock proteins such as Hsp90 
chaperones (Tortosa, Santa-Maria et al. 2009). Tau interact with motor proteins such as 
dynein and kinesin (Ebneth, Godemann et al. 1998, Dixit, Ross et al. 2008) increasing 
the efficiency of axonal transport. Tau regulates the MT stability not only by binding 
directly to MTs but also through indirect mechanism where it acts as a direct enzyme 
inhibitor (Perez, Santa-Maria et al. 2009). Albeit the wide range of interacting partners, 
MTs have got significant attention.  
1.2.6 Physiological and pathological roles of Tau 
Taken together Tau phosphorylation plays both physiological and pathological 
roles in the cell. When the phosphorylation state of Tau is appropriately coordinated, it 
plays critical role in many cellular functions. Tau regulates neurite outgrowth (Biernat 
and Mandelkow 1999, Biernat, Wu et al. 2002), axonal transport (Tatebayashi, Iqbal et 
al. 1999, Spittaels, Van den Haute et al. 2000) and microtubule stability and dynamics).  






phosphorylation of Tau, it causes the Tau filament formation (Abraha, Ghoshal et al. 
2000), disrupt microtubule-based molecular transport. Tau hyperphosphorylation and 
MT destabilization can even cause neuronal loss and increase cell death (Fath, 
Eidenmuller et al. 2002). All the possible events related to Tau phosphorylation are 




Figure 5: Physiological and pathological roles of Tau. Tau phosphorylation plays both physiological 
and pathological roles in the cell. When the phosphorylation state of Tau is appropriately coordinated, it 
regulates neurite outgrowth, axonal transport and microtubule dynamics. However, in pathological 
conditions upon hyperphosphorylation of Tau, it can cause Tau filament formation, disrupt microtubule 












1.3.1 MT structure and function 
Microtubules (MT) constitute one of the three primary elements of the eukaryotic 
cytoskeleton, which performs a wide range of physiological functions. For example, due 
to their mechanical strength and stability, microtubules contribute to the maintenance of 
cell shape and provide a scaffold for intracellular transport. MTs are composed of the 
internetworked α-β tubulin heterodimers (Weisenberg 1972) - or simply as tubulin. 
Tubulin assembles into a tubular framework with ~13 protofilaments, which together 
form a tubular and polarized polymer with ~25nm in diameter (Figure 6). The typical 
length of MTs varies from 10-50 µm. Prominent cell functions are regulated with the 
help of MTs such as cell morphology. In addition, they serve as tracks for the cellular 
transport of intracellular cargos and organelles via motor proteins like kinesin and 
dynein. Mitotic cell division is controlled by the formation of spindle MTs (Hirokawa 
and Takemura 2005, Konzack, Thies et al. 2007). During mitosis, microtubules play an 
important role to pull apart the aligned chromosomes. During these processes, 
microtubules are highly dynamic in terms of assembly and disassembly, which is 




Figure 6: Polymerization of tubulin to form microtubules. α-β tubulin heterodimers assemble in a head 
to tail fashion to form a microtubule nucleus followed by elongation to form cylindrical microtubules. A 
typical microtubule is composed of 13 protofilaments with ~24nm diameter. (Figure taken from (Jordan 






MTs are highly dynamic in nature undergoing continual assembly and 
disassembly (Desai and Mitchison 1997) and the dynamic nature of MTs is due to the 
two kinds of mechanisms namely treadmilling (Wilson and Margolis 1978, Margolis and 
Wilson 1981, Margolis and Wilson 1998, Panda, Miller et al. 1999) and dynamic 
instability (Kirschner and Mitchison 1986, Vale and Hotani 1988). MT plus ends have 
been investigated in detail and are found to be kinetically more favorable in terms of 
their dynamic nature (Kirschner and Mitchison 1986, Goedert, Wischik et al. 1988). In 
short, the tubulin heterogeneity and differential and distinct binding features of MAPs 
and function are considered as the primary molecular mechanisms regulating 
microtubule cellular function (Mandelkow, Lange et al. 1988). 
1.3.2 Microtubule assembly and dynamics 
In solution, tubulin exists in a dynamic equilibrium between tubulin dimer and 
polymers; any tubulin present above a defined critical concentration will form polymers 
(Mitchison and Kirschner 1984, Desai and Mitchison 1997, Hyman and Karsenti 1998). 
As shown in Figure 7 , microtubule assembly takes place through two phases, nucleation 
and elongation. γ tubulin is a third very minor species of tubulin (Oakley and Oakley 
1989). In vivo, γ tubulin is found solely in microtubule organizing centers (MTOC) 
(Mitchison and Kirschner 1984, Mcintosh, Roos et al. 1985) and participates in the 
nucleation of microtubule polymers (Zheng, Wong et al. 1995). In de novo tubulin 
polymerization in the absence of MTOCs, either preformed MTs or MAPs are able to 
fulfill the nucleation process (Bre and Karsenti 1990). The microtubule polymerization 
rate is controlled by the binding constant of GTP tubulin to the tubulin ends. However, 
experiments using GTP analogs indicate that GTP hydrolysis is required only for 
microtubule depolymerization and not for microtubule assembly (Mandelkow, 
Mandelkow et al. 1991, Hyman, Salser et al. 1992).  
 
A steady exchange of αβ heterodimers occurs at the microtubule ends. The 
microtubules under these conditions are said to be at “steady state” and during which due 
to the different rates of assembly at the two microtubule ends, there is a net addition of 
tubulin subunits at the plus ends of the microtubules. Microtubules, therefore, assume 






shortening phases (Jordan, Walker et al. 1998). Microtubules are significantly more 
dynamic at the plus end. In comparison to minus ends, plus ends exhibit greater changes 
in length over time due to higher rates of elongation, higher frequencies of catastrophe 
and a lower frequency of rescue (Desai and Mitchison 1997). Another factor influencing 
the level of dynamic behavior is the presence of the structural microtubule associated 
proteins. The structural MAPs including Tau effectively stabilize microtubule dynamics, 
primarily by reducing the rate of shortening even at low molar ratios (Panda, Goode et al. 
1995, Trinczek, Biernat et al. 1995, Goode, Denis et al. 1997).   
 
 
Figure 7: Microtubule structure and dynamic instability. (a-b) Polymerization steps involved in MT 
assembly. Tubulin α-β dimer assembles in a polar head to tail fashion to form the protofilaments and ~13 
protofilaments arrange in parallel to form the microtubules. (c) Diagram showing the different steps 
involved in MT dynamic instability. The polymerization and depolymerization are driven by the binding, 
hydrolysis and exchange of a guanine nucleotide on β-tubulin. The process of catastrophe and rescue that 
happens between the growing and shortening stages of MT assembly are represented through the 
polymerization-depolymerization cycle (Akhmanova and Steinmetz 2008) (Figure taken from 






1.3.3 Dynamic instability of MTs 
Under steady state conditions MTs appear to be stable and intact. The stochastic 
switching of MTs between the polymerized and depolymerized phases is referred to as 
dynamic instability of MTs (Mitchison and Kirschner 1984). This dynamic instability 
has significant relevance to coordinate and facilitate the remodeling of the microtubule 
cytoskeleton to fulfill the various roles of MTs.  
Tubulin nucleotide interactions are important in the dynamic instability of MTs. 
During polymerization, both the α- and β-subunits of the tubulin dimer are bound to a 
molecule of GTP  and the GTP bound to β-tubulin may be hydrolyzed to GDP shortly 
after assembly resulting in the addition of new dimers  (Weisenberg 1972). All these 
events are represented in the Figure 7. 
Together with GTP hydrolysis at the tip of the microtubule, a rapid 
depolymerization and shrinkage begins. This kind of shrinking phase is called 
‘catastrophe’. GTP-bound tubulin can begin adding to the tip of the microtubule again, 
protecting the microtubule from shrinking phase and is referred to as ‘rescue’ (Figure 7). 
 
Thus due to the intrinsic instability of microtubules, they are considered to be in 
a dynamic equilibrium or steady state (Akhmanova and Steinmetz 2008). This dynamic 
instability of MTs is influenced by microtubule associated proteins (MAPs) by binding 
and stabilizing events (Cleveland 1977). The changes in the physicochemical 
environment such as pH, temperature, ionic strength presence of small molecules, 
protein partners and drugs can also influence the dynamics of MTs.  
MTs are involved in many cellular processes such as cell division, intracellular 
transport of vesicles and organelles and they also function as the basic element of 
cytoskeleton architecture. All these functions are regulated by the specific feature, 







1.3.4 MT dynamics and neuronal cells  
The highly dynamic nature of MTs to undergo continuous assembly and 
disassembly (Desai and Mitchison 1997) is due to the two kinds of mechanisms 
treadmilling (Wilson and Margolis 1978, Margolis and Wilson 1981, Margolis and 
Wilson 1998) and dynamic instability (Kirschner and Mitchison 1986). In neuronal cells 
significant number of cellular processes like axonal transport, stability etc are controlled 
by MT dynamics. Irrespective of the intrinsic properties of MTs such as dynamic 
instability and treadmilling, the highly specific dynamic features and specific functions 
are to a great extent controlled by Tau and other MAPs (Dehmelt 2003, Feinstein 2005). 
It has been shown that a proper regulation of neuronal MT dynamics is necessary for the 
normal functioning of neurons (Baas, Pienkowski et al. 1991) which are modulated by 
Tau and related MAPs. 
1.3.5 Stabilization by MAPs 
A series of MAPs have been identified in different cell types with distinct 
functions such as both stabilizing and destabilizing MTs, guiding MTs towards specific 
cellular locations, cross-linking microtubules and mediating the interactions of 
microtubules with other proteins in the cell. MAPs are broadly classified into type I and 
type II MAPs. Type I MAPs, also called MAP1 family, bind differently to MTs than 
other MAPs utilizing their charge as the driving force for the interaction (Mandelkow 
and Mandelkow 1995). Type II MAPs include MAP2, MAP4 and Tau. MAPs can be 
further classified into MT stabilizing and destabilizing MAPs. Specific examples are Tau 
and stathmin, which fall under the classification of stabilizing and destabilizing MAPs 
respectively. It has been found that Tau and stathmin are widely studied MAPs due to 
their significant roles in many physiological functions and involvement in many 
neurodegenerative diseases. The stabilizing and destabilizing properties of MAPs and 







Figure 8: Effects of microtubule associated proteins (MAPs) and tubulin-binding agents on 
microtubule stability. Microtubule stabilizing proteins like Tau bind and stabilize MTs whereas 
destabilizing MAPs like stathmin sequester MT assembly. In the same way MT stabilizing drugs like taxol 
and epothilones stabilize MTs whereas destabilizing drugs promote MT depolymerization. (Figure taken 
from Kavallaris M, Nat Rev Cancer 2010). 
 
One of the other MAPs that stabilize MTs is Doublecortin that is essential for 
neuronal migration during human brain development (Moores, Perderiset et al. 2004). 
Doublecortin stabilizes microtubules and stimulates their polymerization but there is no 
homology with any other MAPs like Tau. It was also identified by cryo-EM studies that 
they bind in between the protofilaments and specifically target the 13-protofilament MTs 
(Moores, Perderiset et al. 2004). 
 
1.3.6 Microtubule binding drugs  
A number of naturally occurring and synthetic compounds bind to tubulin or 
microtubules. Their ability to alter the microtubule dynamics and stability brought them 
into the category of MT drugs (Cocca, Dorado et al. 2009, Perez 2009, Reiner, de las 
Pozas et al. 2009). These small molecules are alkaloids, macrolides or peptides which 
bind to tubulin and play significant roles in MT assembly or disassembly (Jordan and 
Wilson 2004). Some of the compounds compete for binding and other act synergistically. 
The interaction of tubulin-binding agents with tubulin/MT and their effects on 
microtubule dynamics are complex. Like MAPs, these are classified into two main 
groups based on their effects as microtubule destabilizing agents, which include the 






microtubule-stabilizing agents, which include the clinically important taxanes (paclitaxel 
and docetaxel) and epothilones (Jordan and Wilson 2004). 
 The binding sites of some of the important MT drugs have been studied in detail 
and they fall into three regions in the tubulin heterodimers (Wilson and Jordan 2004). 
The major classification is known as the vinca domain, the colchicine domain and the 
taxane site.  In addition a systematic classification of tubulin drugs lists them on the basis 
of polymerizing and depolymerizing abilities. The compounds were further classified 
into four on the basis of the binding sites (Amos 2011). Some of the well studied MT 
drugs include Paclitaxel (taxol), Baccatin, Epothilone, Thalidomide, Vinblastine, 
Colchicine etc. These compounds are exploited for a wide range of clinical applications 
such as in the treatment of cancer, gout etc (Cocca, Dorado et al. 2009, Perez 2009, Perez 
2009, Reiner, de las Pozas et al. 2009). 
 
Figure 9: Diverse binding sites of microtubule drugs. Different antimitotic drugs bind at different 
positions on microtubules. (a) Vinblastine binds at the microtubule plus end on alpha tubulin and binds in 
between the heterodimer. (b) Colchicine binds in between the dimer and attached to beta tubulin. (c) An 
interior view of microtubule is shown with taxol binding site. Taxol binds near the M-loop on beta tubulin.  










1.4 Tau-MT interaction 
The primary function of Tau is to bind and stabilize microtubules. Tau is also 
responsible to nucleate and promote MT assembly. It has been established quantitatively 
that Tau is an important MAP that regulates MT dynamics both in vitro and in cells. The 
effects of Tau upon MT dynamics was examined at high Tau:tubulin ratios (1:30-1:2) 
and showed that 4R wild type Tau increased the rate and extent of MT growth (Drechsel, 
Hyman et al. 1992). The recombinant human 4R and 3R Tau isoforms exhibited the 
similar observations at higher tubulin concentrations under various conditions and it was 
additionally shown that 4R Tau is a more potent regulator of MTs (Trinczek, Biernat et 
al. 1995). Later several studies compared the microtubule dynamics regulatory abilities 
of both 3R and 4R Tau isoforms both in vitro and in cells and showed quantitative 
differences in their properties (Panda, Goode et al. 1995, Panda, Samuel et al. 2003, 
Bunker, Wilson et al. 2004, Levy, LeBoeuf et al. 2005). It was also demonstrated 
qualitatively how the Tau:tubulin ratios affect the regulation of MT assembly. That is at 
lower Tau:tubulin ratios 3R Tau is less active by reducing the MT growth rate whereas 
4R Tau exhibit enhancement in MT growth rate. In contrast to this observation, at higher 
Tau:tubulin ratios both 3R and 4R Tau have increased MT growth rates (Levy, LeBoeuf 
et al. 2005). Mechanistically, both 3R and 4R Tau bind directly to microtubules, 
stimulate microtubule polymerization, and regulate microtubule dynamics (Trinczek, 
Biernat et al. 1995). Both quantitative and qualitative mechanistic differences exist 
between the two isoform classes and it can be generalized that 4R Tau is more potent 
than 3-repeat Tau (Goode, Chau et al. 2000).   
 
The capabilities of different 3R and 4R Tau isoforms were compared in different 
ways and a model for Tau-MT binding was proposed where the first two repeats and the 
inter repeats form a core MT binding domain (Goode, Chau et al. 2000). This proposed 
model was supported by many other studies where a number of FTDP-17 and related 
dementia mutations, which are the basis of neurodegeneration fall in this region. Later on 
this model was reconsidered and suggested that there is a possibility for this core region 
that might be composed of different mechanistic capabilities  and influenced by other 







The regulation of MT dynamic properties of wild type Tau isoforms were 
compared with their site specific mutated isoforms, especially with the substitution and 
deletion mutations found in FTDP-17 dementia (Bunker, Kamath et al. 2006, LeBoeuf, 
Levy et al. 2008). It was demonstrated that significant reduction in the MT binding and 
regulating properties are associated with specific mutations suggesting that many 
neurodegenerative diseases are directly correlated to the loss-of-function of Tau in which 
both amino acid substitutions and altered mRNA splicing in Tau lead to 
neurodegeneration by diminishing the ability of Tau to properly regulate microtubule 
dynamics. 
The Tau-MT interaction was investigated using NMR spectroscopy using the 
shorter Tau constructs and full length Tau protein and revealed the MT interacting 
regions at atomic resolution. It identified the shorter linear motifs of Tau involved in 
binding which include the domains outside MT binding repeats known as the “Jaws” of 
the Tau-MT interaction (Mukrasch, von Bergen et al. 2007, Mukrasch, Bibow et al. 
2009). 
It was suggested that Tau self-assembles by association of the microtubule 
binding domains of Tau as a result of the abnormal hyperphosphorylation that promotes 
the self-assembly of Tau into PHFs. This self assembly can occur by neutralizing the 
inhibitory basic charges of the flanking regions (Alonso, Zaidi et al. 2001). The two 
hexapeptides, in the repeats R2 and R3 of Tau is found to be important in the formation 
of PHFs. A recent study using solid state NMR revealed the presence of the rigid core of 
the fibrils lies in the third repeat with three beta strands (Daebel, Chinnathambi et al. 
2012). The surprising and questionable discrepancy has been reported in terms of the 
Tau-MT interaction that MTs can induce the formation of PHFs (Duan and Goodson 
2012). 
 
1.4.1 Phosphorylation as a mean to regulate Tau-MT interaction 
Another most important aspect to be investigated is the effects of phosphorylation 






phosphorylated Tau by cdk5 or MARK upon the regulation of MT dynamics were 
investigated (Trinczek, Biernat et al. 1995) and it was shown that there is significant 
reduction in their activity between phosphorylated and non-phosphorylated Tau. The 
variety of Tau functions of Tau are regulated by its phosphorylation state. The longest 
isoform of human Tau hTau40 contains 80 Ser or Thr residues and five Tyr residues, and 
hence 20% of the protein has the tendency to be phosphorylated. There are many 
phosphorylating agents like kinases and Tau is considered as a “universal phosphate 
acceptor” (Stoothoff and Johnson 2005).  
Phosphorylation at Ser262, Ser214 and T231 result in strong reduction of ability 
of Tau to bind microtubules (Brandt, Lee et al. 1994, Drewes, Ebneth et al. 1997, 
Ebneth, Drewes et al. 1999) and phosphorylation at these sites they are always found in 
AD (Gustke, Steiner et al. 1992, Mandelkow and Mandelkow 1995, Mandelkow and 
Mandelkow 1998). It was shown by NMR studies that the phosphorylation of Ser262 
causes conformational change and leads to disruption of Tau-MT binding where the 
experiment was performed by me (Fischer, Mukrasch et al. 2009, Schwalbe, Biernat et 
al. 2013). Enhanced phosphorylation at several SP/TP motifs and at S214 has been 
shown in mitotic cells(Illenberger, Drewes et al. 1996). In addition, phosphorylation of 
Ser214, the major protein kinase-A target site in the proline-rich domain of Tau, 
decreases the MT-stabilizing and MT-nucleating effects exerted by Tau. This S214 
phosphorylation reduces the affinity of Tau from microtubules and thereby, increases the 
dynamics of MTs. These studies underline the role of Tau and its phosphorylation in the 
regulation of microtubule dynamics. 
On the other hand in Alzheimer’s disease the hyperphosphorylated Tau was 
found in abnormal fibers, which are one of the histopathological hallmarks of this type of 
dementia in brain (Buee, Bussiere et al. 2000, Lee, Goedert et al. 2001). The effect of 
hyperphosphorylation in MT binding and Tau PHF formation is shown in Figure 10. 
The hyperphosphorylation of Tau protein in physiological conditions may not lead to 
pathologic forms and some unknown factors in the pathological conditions of Alzheimer 
disease are able to direct hyperphosphorylated protein Tau into abnormal fibers. Tau 
drug developing strategy to prevent hyperphosphorylation of Tau was studied with 
selected kinases as drug targets through the three most relevant kinases GSK3β, CDK5 






The neuronal MAP Tau is found to be expressed in neuronal cells. The level of 
Tau expression and molecular complexities are found to be increasing during the 
developmental stage (Drubin and Kirschner 1986, Caceres and Kosik 1990, Knops, 
Kosik et al. 1991, Feinstein and Wilson 2005). It is known by previous studies that it is 
critical to have Tau for promoting the neuronal cell polarity and axonal outgrowth during 
the developmental stage (Caceres and Kosik 1990, Caceres, Potrebic et al. 1991). It was 
further shown that Tau is required for neurite outgrowth, the accumulation of 
microtubule mass and neurite stability (Esmaeliazad, Mccarty et al. 1994). It has also 
been shown that Tau is able to promote microtubule assembly, stability and bundling 
(Drubin and Kirschner 1986, Drubin, Kobayashi et al. 1986, Takemura, Okabe et al. 
1992). Together with a series of findings related to Tau and neuronal outgrowth it can be 
generalized as Tau is important in proper neuronal development by regulating 
microtubule dynamics and axonal stability. 
 
Figure 10: Effect of phosphorylation of Tau on Tau-MT interaction and Tau pathology. Tau 
stabilizes microtubules using the microtubule binding domains. Phosphorylation in the abnormal rate 
attenuates Tau binding to microtubules and form paired helical filaments. Proteolytic processing leads to 
formation of Tau oligomers and aggregates in the form of neurofibrillary tangles (NFTs). (Figure adapted 






1.5 Structure of MT-bound Tau 
The major function of Tau is to bind and stabilize microtubules. Hence it was 
expected that the binding of Tau to microtubules induce conformational changes. Several 
studies based on different biophysical methods such as electron microscopy studies 
showed that Tau is mainly found on the outer surface of MTs (Hirokawa, Shiomura et al. 
1988). Later on several attempts were done to establish a structural view of MT-bound 
Tau using cryo-EM studies and image reconstruction (Kar, Fan et al. 2003, Santarella, 
Skiniotis et al. 2004).  
It was discussed before that Tau becomes more compact upon binding with 
microtubules (Butner and Kirschner 1991) where 3 or 4 repeats of Tau were considered 
as independent tubulin binding domains thereby proposing a model as multiple repeats 
cross-link the tubulin sub units. Whereas other studies indicated that even in the MT-
bound state Tau retains much of its disordered state (Al-Bassam, Ozer et al. 2002, 
Santarella, Skiniotis et al. 2004). A recent study based on atomic force microscopy 
showed that at saturating concentrations, Tau forms a ~1nm thick layer around the MTs 
by binding along the protofilaments and leaving the elasticity of MTs unaffected 
(Schaap, Hoffmann et al. 2007). Nevertheless, NMR analysis of Tau-microtubule 
interactions highlighted binding of several linear motifs of amino acid residues in Tau, 
especially in the repeat domains and the flanking regions to microtubules. The residues 
275VQIINKKLDLS285 strongly contribute to binding to the microtubules along with 
clusters of positively charged residues upstream of the PGGG motifs (Mukrasch, Biernat 
et al. 2005, Mukrasch, Markwick et al. 2007).  
The Tau-MT/tubulin interaction was studied for the first time using the 
thermodynamic point of view by isothermal titration calorimetry (ITC) provided similar 
isotherms within the temperature range of 10ºC and 37ºC (Tsvetkov, Makarov et al. 
2012). At all temperature conditions two stoichiometric values obtained, 0.8 and 0.2, 
suggested the possible binding mechanism involved in Tau-tubulin interaction where it 
does not depend on the type of the polymer formed. The model proposed is in good 
agreement with the longitudinal binding mode of Tau along the protofilaments outside 







1.6 Binding site of Tau on Microtubules  
Considering the Tau-MT interaction and the mechanism involved therein, a 
number of questions arise such as how Tau interact with MTs, what is the driving force, 
where do they interact and what are the conformational changes happening during 
interaction. In terms of the binding site of Tau on MTs different binding sites and 
binding models have been proposed. Many studies showed that Tau binds to MTs on 
their outer surface being the negatively charged carboxyl termini of tubulin as the 
binding site (Chau, Radeke et al. 1998, Ackmann, Wiech et al. 2000, Al-Bassam, Ozer et 
al. 2002). The interaction between the positively charged microtubule binding domain 
and the negatively charged c-terminal domain of tubulin was the underlying mechanism 
behind this model. 
The surface decoration model of Tau on MTs (Santarella, Skiniotis et al. 2004) 
again suggested Tau binds more or less outside the MTs by retaining their unfolded 
nature.  Though it was suggested to be the outer surface another remarkable observation 
is it is α-tubulin. This further explains the mutual independence in binding between 
kinesin and Tau, where the former is supposed to bind on β-tubulin and Tau on α-
tubulin. 
Another model suggests that that Tau binds at the inner surface of MTs near the M-
loop of β-tubulin, which is the binding site for taxol (Kar, Fan et al. 2003). In this model 
the repeats of Tau bind at the inner side near the M-loop and the positively charged 
proline rich region of Tau binds at the C-terminus of tubulin (Kar, Fan et al. 2003). On 
the other hand, high-resolution metal-shadowing and cryo-electron microscopy using full-
length Tau suggested that Tau is not only largely disordered when bound to microtubules but 
also it binds exclusively to the outer surface of the microtubules (Marx, Muller et al. 2005). 
All the proposed models were on the basis of experiments performed in different 
conditions as well as using different methods. It is therefore still unclear which binding 
site is biologically relevant in terms of their structure and function. However there are 
different tubulin targeting drugs with highly specific binding sites like taxane binding 
site, vinca ligand binding site and colchicine binding site as reported (Amos 2011, 
Canales, Rodriguez-Salarichs et al. 2011) and the possibility for sharing the binding site 






1.7 Protein NMR Spectroscopy 
 
Both liquid- and solid-state NMR have become major techniques in structural 
biology. Liquid-state NMR is a powerful, robust and noninvasive technique to 
investigate soluble proteins at atomic resolution (Wüthrich 1990). Compared to X-ray 
crystallography, solution NMR allows not only to investigate the protein structures in a 
nearly physiological environment, but is also to determine their dynamic properties. 
Moreover, solution NMR technique allows the study protein-ligand and protein-protein 
interactions, protein folding, kinetics, catalysis and moreover structure determination. 
1.7.1 Relevance of structure determination using NMR 
Many biological activities are regulated by the interaction of proteins with nucleic 
acids and other biomacromolecules. Therefore it is quite essential to study these 
interactions both spatially and temporally. On top of that, it is important to investigate 
the mechanism involved in interactions including the specificity and selectivity. 
Structural analysis at atomic-resolution will give deep insight in understanding these 
aspects. X-ray crystallography and NMR are the widely used techniques for structural 
analysis of biomacromolecules. X-ray crystallography is most suitable for high 
molecular weight systems where crystallization is possible. Whereas NMR is highly 
flexible and robust in terms of sample conditions and handling although there is a certain 
degree of size limitation. 
It is becoming more relevant to study the protein-protein interactions that form 
even macromolecular complexes as many biological processes are mediated by 
interactions between proteins. The involvement of protein interactions with its partner 
proteins, peptides and drugs makes it important to study them at a molecular level which 






1.7.2  Application of NMR to structure determination of 
biomacromolecules 
Structure determination of protein complexes using NMR has certain size 
limitations and is generally upto ~ 40kDa. The implementation of Transverse Relaxation 
Optimized SpectroscopY (TROSY) (Pervushin, Riek et al. 1997) in the traditional NMR 
methods and other NMR methodologies brought the size limitation near 100kDa 
(Pervushin, Riek et al. 1997, Riek, Wider et al. 1999, Riek, Fiaux et al. 2002). Isotope 
labeling and other methodological developments are the accelerating factors in NMR 
based structural calculations. NMR based 3D structure determination of biomolecules is 
usually performed by distance geometry calculations or simulated annealing (Güntert, 
Mumenthaler et al. 1997, GÜNTERT 1998, Schwieters, Kuszewski et al. 2003). 
Structural constraints can be derived from NOE, J-coupling, Residual Dipolar Couplings 
(RDC), Paramagnetic Relaxation Enhancement (PRE) etc. Another feasible approach is 
to map the binding interface of large complexes if the exchange is in the NMR time scale 
is suitable for signal detection. 
The strategy of structure determination by NMR depends on the timescales of 
chemical or conformational exchange processes, which may affect line shapes, relaxation 
rates, and chemical shifts of resonances.  Depending on the strength of the interaction of 
a complex, it can be broadly classified into slow exchange, intermediate exchange and 
fast exchange. That is strong binding, weak binding and the intermediate exchange case, 
called coalescence. 
1.7.3 Protein-ligand interactions  by NMR spectroscopy  
NMR spectroscopy is a useful technique in studying protein-protein and protein-
ligand interaction. The study of these interactions can be broadly classified into two 
classes on the basis of the target resonances in-study. (1) Focusing the protein resonances 
and (2) Ligand resonance studies (Carlomagno 2005). There are several factors that 
determine this selection. In the case of target resonance detected experiments it relies on 
the availability of the isotopically labeled target and the size of which is suitable to detect 






two dimensional heteronuclear correlation experiments (eg: HSQC) (Bodenhausen and 
Ruben 1980). Whereas in the ligand detected methods such as transferred NOE (tr-
NOE), saturation transfer difference (STD) (Mayer and Meyer 1999, Viegas, Manso et 
al. 2011), NOE pumping (Chen and Shapiro 1998), Water LOGSY (Dalvit, Pevarello et 
al. 2000) and INPHARMA (Sánchez-Pedregal, Reese et al. 2005, Orts, Griesinger et al. 
2009), only the resonances of the ligand is observed and is exclusively applicable for the 
ligands in the low affinity range (millimolar range). Latter approach is highly desirable 
when the target is either too large to be detected by NMR or not available in the 
isotopically labeled form. Binding interface information can be obtained by following 
NMR spectral parameters: 
(a) Line broadening 
(b) Chemical shift perturbation 
(c) Change in NOE 
(d) Intermolecular magnetization transfer 
 
NMR chemical shifts are very sensitive to variations in the local electronic 
environment, for example, due to binding. Hence it is possible to map the binding 
interface of weakly binding ligand and protein receptor using the small changes in 1H 
and 15N shifts in a calibrated titration. The ligand can either be a protein, peptide or small 
molecule. No chemical shift changes will be observed for residues that do not participate 
in the interaction and those resonances that are shifted highlight the residues involved in 
the binding interface or are affected by minor conformational rearrangements caused by 
the interaction. Here, the intensity of the resonances will be varying according to the 
exchange rate and if it is near coalescence condition there will have severe line 
broadening that will again reflect the involvement of the respective regions of protein 
involved in binding. 
Considering the Tau-tubulin/MT interaction, where tubulin is ~100kDa and MTs 
is in the range of several megadaltons it is beyond the limit of NMR detection. The 
application of sophisticated NMR methods is very much limited in the case of tubulin as 
it cannot be obtained in the isotopically labelled form. Till now the recombinant 
expression of tubulin in significant amount is unsuccessful because of their complexity 






tubulin and its binding partners as smaller drug molecules, peptides where the exchange 
transferred methods (Carlomagno 2005, Sánchez-Pedregal, Reese et al. 2005, Orts, 
Griesinger et al. 2009) have been employed. These include tr-NOE, STD-NMR, tr-CCR 
and INPHARMA and are detailed in the section methods. 
1.8 Aim of the study 
The majority of the functions of MTs are regulated by the interaction with its 
partners. To gain insights into the different aspects of physiological processes and 
mechanisms involved in the interaction between MTs and its binding partners several 
biophysical techniques have been used. In particular, detailed information regarding the 
role of MT and associated proteins and drugs is possible via structural investigation. 
Among the available techniques to derive structural information, NMR is the only 
method that allows a structural description in near physiological conditions and at atomic 
resolution. 
As Tau is an intrinsically disordered protein (Dyson and Wright 2005) X-ray 
crystallography cannot be applied and NMR spectroscopy is the method that allows the 
description of its conformations. Although the function of Tau and Microtubules has 
been studied for many years, it is still unclear how Tau binds to microtubules. The 
intrinsically disordered Tau protein binds and stabilizes MTs. Though the ensemble of 
conformations that Tau populates in solution was described (Mukrasch, Bibow et al. 
2009), the high resolution structure of microtubule-bound Tau is still unknown. The aim 
of the project was therefore to perform an in depth study of the Tau-MT interaction and 
to determine the MT-bound conformation of the Tau protein. Furthermore, the 
identification of the binding sites of Tau on MTs will help to provide a three-dimensional 
view of the MT-bound Tau protein. To achieve these goals, I combined a “divide and 
conquer approach” with exchange-transferred NMR methods. Understanding the Tau-
MT interaction and the mechanism involved in the stabilization of MTs will shed new 
insights into the molecular mechanism of Tau-mediated neurodegeneration and also 
foster new ideas to increase the therapeutic efficiency of MT-targeting drugs, especially 













2 Materials and Methods 
2.1 Chemical compounds 
Taxol, Baccatin, Thalidomide, Vinblastine, Colchicine and GTP were purchased from 
Sigma Aldrich. 
2.2 Protein preparation and purification 
Cloning, expression and purification of wt and mutant hTau40, hTau23, K18 and F4 
proteins were performed by Dr. Jacek Biernat in collaboration with Prof. Mandelkow 
group, DZNE, Bonn. 
2.2.1 Tau constructs used in this study 
1. hTau40 (441 residues, I2R4) the largest human Tau isoform in the central 
nervous system, contains 2 amino terminal inserts (I2) and four C-terminal 
repeats (R4). 
2. hTau23 (352 residues, I0R3) the shortest human Tau isoform, doesn’t contain any 
amino terminal insert (I0) and contains three C-terminal repeats (R3). 
3. The human Tau constructs K18, representing the 4-repeat C-terminal assembly 
domain contains the amino acids:  Q244-E372 with amino terminal methionine.  
4. F4, construct published by Fauquant/Knossow et al. (2011) comprises the amino 
acids S208 – S324 with amino terminal methionine. 
All residue numbers refer to hTau40.  
Tau constructs K18 and F4 were generated using PCR method on the template of hTau40 
DNA sequence and provided with NdeI and BamHI restriction enzyme recognition sites. 
hTau40, hTau23, K18 and F4 were introduced into pNG2 vector, a derivative of 
commercial plasmid pET-3a (Merck-Novagen, Darmstadt) using the NdeI and BamHI 
resrtiction sites. 




2.2.2 Protein expression in E.coli 
pNG2 plasmids with inserted hTau40, hTau23, K18 and F4 coding sequences 
were transformed into E.coli  strain BL21(DE3) (Merck-Novagen, Darmstadt). These 
bacterial strains were used for protein expression. The expressed proteins were purified 
from bacterial extract by making use of the heat stability of the Tau protein and by FPLC 
SP-Sepharose ion exchange chromatography (GE Healthcare, Freiburg). 
The bacterial pellet was resuspended in the boiling-extraction buffer (50 mM 
MES, 500 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 5 mM DTT, pH 6.8) complemented 
with protease inhibitor coctail. The cells were disrupted with a French pressure cell and 
subsequently boiled for 20 min. The  soluble extract was isolated by centrifugation, the 
supernatant was dialyzed against  two changes of cation exchange chromatography 
buffer  A (20 mM MES, 50 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM 
PMSF, pH 6.8) and loaded on FPLC SP-Sepharose column.  The proteins  were eluted 
by a linear gradient of cation exchange chromatography buffer B  (20 mM MES, 1 M 
NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF, pH 6.8).  
In the case of hTau isoforms hTau23 and hTau40, Tau breakdown products were 
separated in the second chromatography step using gel filtration method on Superdex 
G200 column (GE Healthcare, Freiburg). PBS buffer was used  for gel filtration column 
(137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7,4) with 1 mM DTT 
(freshly added) . 
2.2.3 Protein expression in E.coli with isotope labeling 
To label the Tau proteins with 15N and 13C isotopes, the E.coli cultures were grown in a 
M9 minimal medium with 15NH4Cl (1g/liter) and 13C glucose (4g/liter) (Eurisotop, 
Saarbrücken). 
Protein samples uniformly enriched in 15N were prepared by growing E.coli bacteria in 
minimal medium containing 1g/liter of 15NH4Cl exclusively.  
For isotope labeling of Tau proteins for NMR experiments  a rapid and efficient 
approach for preparing isotopically labeled recombinant proteins was used, the general 
“Marley” protocol based on Marley, J and Bracken, C.  J.Biomolec. NMR 20, 71(2001). 




This production method generates cell mass using unlabeled rich media followed by 
exchange into a small volume of labeled media at high cell density. Following a short 
period for growth recovery and unlabeled metabolite clearance, the cells were induced 
with 0.8 mM IPTG. The expression yields obtained provide reduction in isotope costs. 
Example for 1L E.coli culture, bacteria were  grown in 1 L LB (Luria broth) at 37°C, 
upon reaching optical cell density at 600 nm (OD600) ~ 0.7. The cells were pelleted, 
washed using an M9 salt solution and the pellet was resuspended in 250 ml of 
isotopically labeled minimal medium. The culture was incubated for one hour to allow 
the recovery of growth and clearance of unlabeled metabolites. After this 1 h step protein 
expression was induced by addition IPTG to a concentration of 0.8 mM.  The cells were 
harvested after 4 hours of incubation.  The expressed proteins were purified from 
bacterial extract by method described for non isotopic expression protocol. 
2.2.4 Standard  5 x M9 Minimal Media salts without nitrogen source. 
For 1L 5xM9 salts:  
64g Na2HPO4-7H2O 
15g KH2PO4 and 2.5g NaCl 
Add H2O to final volume 1L and autoclave. 
2.2.5 Preparation of 500mL M9 minimal medium. 
100mL  5xM9 salts 
1 mL 1M MgSO4 
50 uL  1M CaCl2 
5 mL 100x Basal Medium Eagle Vitamin Solution (Gibco) 
2.5 mL filter sterilized NH4Cl (0.2 g/mL) or 0.5g dry 
10 mL 20% d-glucose or 2g dry 
2.2.6 Adaptation of E.coli bacteria for growing in D2O/minimal 
medium (M9) labeled with 15N NH4Cl 
Bacteria from E.coli colony containing pNG2/Tau construct plasmid growing on 
LB dish were inoculated and grown in 1 ml of M9/33%D2O medium over night. The 




bacteria were spun down and resuspended into M9/66% D2O medium and grown again 
over night. After centrifugation the bacteria were resuspended in M9/100% D2O medium 
and grown to 0.5-0.6 OD600 and induced for the expression with IPTG. After incubation 
the expressing cells for 3 hrs, the bacteria were harvested and purified from bacterial 
extract by method described for non-isotopic expression protocol. In the case of 
difficulties in growing E.coli expressing Tau construct in M9/100% D2O the content of 
D2O was reduced to 85%. 
2.3 Microtubule assembly 
Porcine brain tubulin was purified as described (Mandelkow, Herrmann et al. 
1985, Gustke, Trinczek et al. 1994). Tubulin polymerization was performed in MT 
assembly buffer 100 mM Na-PIPES, pH 6.9, 1 mM EGTA, 1 mM MgSO4, 1 mM GTP, 
1 mM DTT. Fixed concentration of tubulin (20-50μM) was incubated with equal 
concentration of taxol (paclitaxel) at 37°C for 20-30 min to induce microtubule 
formation. The suspensions of the samples were fractionated by ultracentrifugation at 
40,000 x g for 20 min. Resuspended the MT pellet to the required buffer. The stabilized 
microtubule solutions were then diluted to the desired concentration. 
2.4 Synthetic peptides 
A list of synthetic peptides used in this study is given in Table 2. TP2, TR1, TR2, 
TR3 and TP2_pT231 were purchased from EZBiolab, USA. Other Tau, tubulin and I19L 
peptides were synthesized by Kerstin Overkamp in Department of NMR-based Structural 
Biology, Max Planck Institute for Biophysical Chemistry in Göttingen. Synthesis was 
based on standard Fmoc-solid-phase peptide synthesis method using an ABI 433A 
synthesizer (Applied Biosystems). Peptides were synthesized with acetyl- and amide 
protection groups at the N- and C-termini, respectively. Peptides were further purified by 
reversed-phase HPLC and the pure product was lyophilized. All the peptides in Table 2 
are unlabeled.  
 
 




Table 2: Synthetic peptides used are listed with the sequence and nomenclature followed during the study. 
Peptide Sequence Name 
Tau162-188 QKGQA NATRI  PAKTPPAPKTPPSSGEP TP1 
Tau211-242 RTPSLPTPPTREPKKVAVVRTPPKSPSSAKSR TP2 














Tau52-69 TEDGSEEPGSETSDAKST  TN1 
Tau1-26 MAEP RQEFEVMEDHAGTYGLGDRKDQ TN2 
Tau403-422 TSPRHLSNVSSTGSIDMVDSP TC1 
α-Tubulin433-451 EEVGVDSVEGEGEEEGEEY aTubC 






In addition to these, single residue mutated and phosphorylated samples of selected Tau 








2.5 NMR Spectroscopy 
2.5.1 Interaction studies 
The different NMR interaction experiments performed are listed in Table 3. 
Table 3: Interaction studies performed using Tau and Tau constructs 
Protein Protein Receptor Interacting molecule 
HTau40 MT  
HTau40 Tubulin  
HTau23 MT  
HTau40 MT NaCl 
HTau40_Y310N MT  
Hatu40_Emutant MT  
Hatu40 MT Taxol 
Hatu40 MT Baccatin 
Hatu40 MT Thalidomide 
Hatu40 MT Vinblastine 
Hatu40 MT Colchicine 
Hatu40 MT TP2 
Hatu40 MT TR3 
Hatu40 MT TN1 
K18 Tubulin  
F4 Tubulin  
F4 MT  
F4 MT NaCl 
   
 
2.5.2 2-D NMR experiments 
2.5.2.1 Heteronuclear Single Quantum Coherence (HSQC) 
The Heteronuclear Single Quantum Coherence (HSQC) is one of the frequently 
used experiments in the protein NMR. This method gives one peak per pair of coupled 




nuclei, whose two coordinates are the chemical shifts of the two coupled atoms (Keeler). 
HSQC detects correlations between nuclei of two different types which are separated by 
one bond. Each residue of the protein except proline has an amide proton attached to a 
nitrogen in the peptide bond and the HSQC provides the correlation between the nitrogen 
and amide proton and each amide yields a peak in the HSQC spectrum. 
The protein-protein or protein ligand interactions can be well studied using the 
2D 1H-15N HSQC experiments, where one can probe the interaction with the help of 
change in chemical shifts (δ) of the resonances and line broadening. The HSQC spectrum 
of the 15N labeled protein will be recorded with and without the unlabeled receptor or 
ligand at stoichiometric or sub stoichiometric conditions. The modifications such as 
chemical shift perturbation, line broadening or signal disappearance of the cross peaks of 
specific residues involved in binding indicates the interaction between partners. These 
modifications depend on the size of the complex formed. In the case of Tau-MT/tubulin 
complex as the receptor is very large the binding residues experience extensive dipolar 
interaction as well as large correlation time, leading to severe line broadening.   
2.5.2.1.1 Chemical shift difference 
To compare the 2D 1H-15N HSQC chemical shifts from different samples, the differences 
in the resonance position was calculated using the formula: 
Δδ= ((ΔδN /5) 2+ (ΔδH )2)1/2 
2.5.2.1.2 Intensity ratio 
Peak intensities from the 2D 1H-15N HSQC experiments were collected and the line 
broadening was evaluated by calculating the intensity ratio of the NMR signals 
originating from the bound and free protein as Ibound/Ifree and was averaged over a 3 
residue window. 
2.5.2.1.3 Experimental procedure 
All 2D 1H-15N-HSQC experiments were recorded on a Bruker spectrometer 
(Bruker Karlsruhe, Germany) with 700, 800 or 900 MHz proton frequency. The 
spectrometers are equipped with a TCI cryo probe (Z-gradient). The HSQC pulse 
sequence contained a 3-9-19 watergate block for water suppression. The experiments 




were recorded with 600 increments in the indirect dimension and 2k points (cryo probe) 
in the direct dimension, zero filled to 4k and 1k points in the direct and indirect 
dimension, respectively and processed with a sine-squared bell window function shifted 
either by 90 degree (SSB=2 in TopSpin), or by 60 degree (SSB=3 in TopSpin). The 
nitrogen carrier frequency was set to 118 ppm and the spectral width was 24 ppm. For 
protons, the carrier was set to the water resonance frequency. The data were processed 
using TopSpin 3.0 (Bruker). 
2.5.2.2 TROSY and CRINEPT-HMQC-TROSY 
CRINEPT (cross-correlated relaxation-enhanced polarization transfer) provide 
more polarization transfer than INEPT. CRINEPT-HMQC-TROSY enables the detection 
of very high molecular weight proteins greater than 500kDa. Similar to the TROSY it 
detects the 1H-15N moieties but with CRINEPT (cross-correlated relaxation-enhanced 
polarization transfer) as the element for polarization transfer. Deuteration and TROSY 
element reduce transverse relaxation and CRINEPT further increase the sensitivity 
compared to INEPT transfer. Since decoupling is applied during t1 evolution but not 
during acquisition there will be two multiplet peaks per 1H-15N moiety. Unlike TROSY, 
where it enables to detect residues which are in the flexible region, CRINEPT-HMQC-
TROSY give peaks from both flexible and rigidly structured regions. For flexible parts 
one observes both multiple components whereas for the rigidly structured region of the 
protein the rapid transverse relaxation suppresses the fine structure component in the 
lower field. Thus it enables to detect and distinguish both the highly flexible and more 
rigidly structured region of the protein. If imperfect deuteration or size limitation 
suppress detection of any residues it indicates the presence of the highly rigid and 
structured region of the protein or protein complex. 
2.5.2.2.1 Experimental procedure 
All the CRINEPT-HMQC-TROSY experiments were done on 900 MHz 
spectrometer with a cryo probe at 30ºC. 2H, 15N labeled F4 was used for the experiments. 
Samples were prepared with a concentration of 40µM F4 and 120µM tubulin and 25µM 
F4 and 75µM MTs. The buffer contained 50 mM NaH2PO4/Na2HPO4, pH 6.8, 10% (v/v) 
D2O and was filled in a 3mm shigemi tube. The 2D 1H-15N- CRINEPT-HMQC-TROSY 




and TROSY experiments were recorded on a Bruker 900 MHz spectrometer equipped 
with a TCI cryoprobe (Z-gradient). The experiments were recorded with 128 increments 
in the indirect dimension and 2k points (cryo probe) in the direct dimension; zero filled 
to 4k and 1k points in the direct and indirect dimension, respectively. 
 
2.6 Structure determination of MT-bound Tau peptides 
Considering the Tau-tubulin/MT interaction and structural investigation, NMR 
has got size limitations where tubulin is ~100kDa and MTs in many MDa, it is beyond 
the limit of NMR detection. Together with the NMR size limitation and unavailability of 
the isotopically labeled tubulin, the structural investigation of MT-bound Tau can be 
done using shorter Tau peptides. The peptides which bind with low affinity act as a 
promising ligands with tubulin/MT and allow the structural investigation of the bound 
peptides with the aid of the exchange transferred NMR methods. The methods which are 
implemented in Tau peptide-MT/tubulin complex include tr-NOE, STD-NMR and 
INPHARMA.  
2.6.1 NMR structure determination of peptides 
The overall process involved in structure determination of peptides includes; 
1) Sequential resonance assignment of peptides 
2) Determination of distance restraints using tr-NOE 
3) 3D structure calculation of peptides using the specific algorithms 
The first step in NMR structure determination involves optimizing the sample 
conditions followed by collecting experimental data such as COSY, TOCSY and 
NOESY spectra of the peptide. It is necessary to fulfill the assignment of the resonances 
in the spectra beforehand which will be used to provide distance restraints between 
protons and finally to determine the three dimensional structure of the peptide.  
2.6.1.1 Assignment procedure  
NMR structural characterization of peptides and proteins requires resonance 
assignment of all the residues. In the case of shorter unlabeled peptides which are having 




the size of ~3 kDa, the proton (1H) assignments can be used for the structural 
characterization. To that end it is possible to use the through bond and through space 
correlation spectroscopy. A short description of the basic 2D experiments used for the 
assignment in the present study is given below.  
2.6.1.1.1 COSY (Correlation spectroscopy) 
Assignment of the peptide starts with the analysis of proton through bond connectivities 
with the help of COSY and TOCSY spectra and thereby achieves identification of the 
spin systems. This allows to separate different amino acid types present in the peptide 
sequence.   The COSY displays 1H-1H-correlations due to through-bond scalar 
couplings. Different amino acids possess characteristic positions of cross peaks in the 
spectrum. COSY is used to identify spins which are coupled to each other. 
2.6.1.1.2 TOCSY (Total correlation spectroscopy) 
The TOCSY experiment is similar to the COSY experiment, in that cross peaks 
of coupled protons are observed. However, cross peaks are observed not only for nuclei 
which are directly coupled, but also between nuclei which are connected by a chain of 
couplings. This makes it useful for identifying the larger interconnected networks of spin 
couplings. This ability is achieved by inserting a repetitive series of pulses which 
cause isotropic mixing during the mixing period. Longer isotropic mixing times cause the 
polarization to spread out through an increasing number of bonds (Keeler). A TOCSY 
experiment results in all cross peaks due to protons of the same spin system. Since no 
scalar coupling across the amide bond protons from different amino acids always belong 
to different spin systems. Thus it is possible to decide to which type of amino acids the 
spin system belongs. 
2.6.1.1.3 NOESY (Nuclear Overhauser Effect spectroscopy) 
NOESY cross peaks are originating from the dipolar couplings resulting from 
interactions of spins through space and hence only depend on the distance but not on the 
number of intervening bonds. Dipolar couplings are averaged to zero in solution but give 
rise to one of the very important relaxation phenomena called NOE (nuclear Overhauser 
effect). Thus the strong dependence of the cross peak intensity on the distance separation 




between the protons makes it an ultimate tool for the 3D structure determination of 
peptides and proteins. 
Sequential resonance assignment means connecting spin systems in their 
sequential order. In the next step it involves the sequential assignment where different 
spin systems identified are connected with the help of NOESY spectra. The sequential 
connectivity from ith residue to i+1th residue should be continued until the complete 
sequential resonance assignment of individual amino acids in the NOESY spectrum is 
achieved unambiguously. 
2.6.1.1.4 NMR spectroscopy for assignment of peptides 
 
 All unlabeled Tau peptides in Table 2 were assigned using two-dimensional 
1H,1H-DQF-COSY, 1H,1H-TOCSY and 1H,1H-NOESY spectra recorded at 5 ºC, either 
on Bruker 700 MHz spectrometer equipped with a cryo probe or 700 MHz oxford 
spectrometer with a room temperature probe. Samples were prepared with a 
concentration of 1 mM and the buffer contained 50 mM NaH2PO4/Na2HPO4, pH 6.8, 
10% (v/v) D2O. Acquisition parameters were commonly set to 40 transients, sweep 
widths of 12 x 12 ppm (F2 x F1), 2048 x 512 total points (F2 x F1), and mixing times of 
60 ms(DQF-COSY), 60 ms (TOCSY) or 150 ms (NOESY). The side chain proton 
assignments were confirmed by using the natural abundance 1H,13C-HSQC and 1H,15N-
HSQC spectra acquired. Spectra were processed using Topspin 3.0 or NMRPipe and 
analyzed using Sparky 3. 
 
 
2.6.1.2 Transferred-NOE (tr-NOE) 
The basic principle of the transferred detection methods depends on the transfer 
of relaxation properties from the bound state to the free state of the ligand that allows the 
detection of intra-ligand NOEs generated in the bound state which are transferred to the 
free ligands by means of chemical exchange and are finally observed. For tr-NOE 
detection the binding affinity should be relatively weak and there should be fast 
exchange between bound and free forms of ligands (Balaram, Bothnerb.Aa et al. 1972, 




Clore and Gronenborn 1982). It is a necessary condition to be fulfilled for the transferred 
techniques that there should be fast exchange between ligands in the bound and free 
states, with the dissociation constant (KD) is of the order of µM to mM range. Ligand is 
usually taken in large excess with varying ratios with receptor like 10:1 to 100:1.The 
resultant NOEs are expected to be relatively larger than those generated in the free ligand 
as a consequence of the slow molecular tumbling of the protein-ligand complex. The 
concept of tr-NOE is represented as a cartoon as shown in Figure 11. 
 
 
Figure 11: Pictorial representation of the ligand-receptor interaction and reversible binding of the ligand. 
The possible change in conformation upon binding will be observed as the population weighted averaging 
of the NMR observable NOE. The average of the NOE observed depends on the rotational correlation time 
of the ligand and complex. (figure reproduced from (Carlomagno 2005)) 
 
If a ligand having very short rotational correlation time(τc) is bound to a large 
receptor with long τc , the τc  of the ligand becomes equivalent to that of the receptor. 
The NOE developed in the bound state will be transferred back to free state as a result of 
the fast exchange. The observed NOE will be the population weighted average of the 
bound and free ligands and the information from the bound state will be dominant with 
all the information about the receptor bound conformation of the ligand. The tr-NOE 
cross peaks are finally treated as the normal NOEs to derive distance restraints to be used 
for structure determination. A detailed description of the NMR methods applicable for 
the weakly binding ligands and tr-NOE method is reviewed in (Carlomagno 2005, 
Clement, Savarin et al. 2010). Tr-NOE method is being used in a variety of systems like 
small molecules to peptides which are bound to macromolecules (Gizachew and Dratz , 
Adams, Dratz et al. 1997, Jiménez-Barbero, Canales et al. 2006, Canales, Rodriguez-




Salarichs et al. 2011, De Bona, Deshmukh et al. 2012). Finally tr-NOE allows 
determination of the 3D structure of MT-bound Tau peptides which are in fast exchange 
with the free peptides. 
2.6.1.3 Introduction to INPHARMA 
The basic principle of tr-NOESY experiment, where the magnetization from one 
ligand is transferred to protein and back to the same ligand, is applied to map the binding 
site of more than one ligand provided the binding orientation of one ligand is known 
(Sánchez-Pedregal, Reese et al. 2005, Orts, Griesinger et al. 2009). If both ligands are 
competing for a common binding site the magnetization transfer from one ligand is 
transferred to the protein and transferred back to the second ligand so that additional 
cross peaks can be observed between the two ligands as a result of the overall 
magnetization transfer between the two ligands. This method is particularly useful to 
determine the orientation of one ligand if the complex structure of another ligand bound 
to the protein is known from prior studies. This method works well with a low 
concentration of receptor protein and comparatively very high concentration of the 
ligands. This was demonstrated by Carlomagno to determine the tubulin bound 
conformation of taxoids (Carlomagno 2005, Orts, Griesinger et al. 2009).  A simple 
schematic diagram is shown in Figure 12. 






Figure 12: Basic principle of the Tr-NOE and INPHARMA experiment. Transferred NOE involves the 
transfer of magnetization from ligand A back to itself through the protein and back to another 
competitively binding ligand B is INPHARMA. Figure taken from (Frontiers in Bioscience 14, 4565-4574, 
January 1, 2009) 
 
2.6.1.3.1 Experimental details 
The tr-NOESY spectra of all the Tau peptides in the presence of MTs were performed at 
5 ºC, on a Bruker 900 MHz spectrometer equipped with a cryo probe. Samples were 
prepared with a concentration of 0.7 mM peptide and 35 μM MTs in the 20:1 ratio. The 
buffer contained 50 mM NaH2PO4/Na2HPO4, pH 6.8, 10% D2O. All the 2D tr-NOESY 
experiments were carried out with 2048 data points x 512 increments x 40-64 transients 
per FID. The sweep width of 12 x 12 ppm was used in both dimensions. The NOE 
mixing times of 30, 50, 80, 100, 150 and 250 ms were used for different peptides. The 
data were zero filled to 4096 x 1024 data matrix prior to Fourier transformation. All the 
spectra were processed using Topspin 3.1 or NMRPipe and analyzed using Sparky 3.114.  
 
 




2.6.2 Structure calculation 
Transferred-NOESY data acquired with shorter mixing time were used to extract 
distance restraints for quantitative structure calculations. The manually assigned cross 
peak intensities were calibrated using the automated calibration method ‘calibrate’ 
available in CYANA (Güntert, Mumenthaler et al. 1997, GÜNTERT 1998). NOE 
calibration converts NOESY cross-peak intensities into upper distance limits (UPL). A 
certain functional relationship is assumed between peak intensities and UPLs for a given 
group of peaks. The most common is NOE peak volume proportional to interproton 
distance to the minus six: 
V = A/d6 
where V is the peak volume (or intensity), d is the upper distance limit, and A is the 
calibration constant. Initial structure calculations were performed using CYANA 3.0 and 
200 conformers were calculated using the standard simulated annealing schedule with 
10000 torsion angle dynamics steps per conformer. Finally, the 20 conformers with the 
lowest final target function values were analyzed.  
 All the structures derived from CYANA were refined using XPLOR-NIH using 
the restrained simulated annealing protocol(Schwieters, Kuszewski et al. 2003). The 
distance restraints generated from CYANA were converted to the XPLOR format. The 
default values were used for all the force constants and molecular parameters that were 
involved. 200 conformers were calculated and 20 lowest energy conformers were 
selected for analysis. Structures were visualized using MOLMOL and PYMOL programs 
and images were produced using PYMOL. 
 
2.6.3 Saturation Transfer Difference (STD) 
The saturation transfer difference (STD) technique (26-28) allows the detection 
of small molecules which are binding transiently to the target and was initially designed 
to distinguish those ligands from a mixture of molecules that binds to a receptor protein 
(Mayer and Meyer 1999). The method is based on the selective saturation of 
macromolecule such as tubulin/MT, following which magnetization is transferred to the 
bound ligand, whose signals can be detected in a difference spectrum resulting from an 




on- and off resonance setup. The selective saturation of the receptor protons are done by 
applying a series of selective pulses and the receptor saturation frequency is applied at a 
frequency window where there is no ligand resonances are observed (eg: -0.5 or -2 ppm). 
The saturation is spread rapidly through spin diffusion throughout the receptor which is 
then transferred to the protons of the ligand in the binding interface with the aid of 
intermolecular 1H-1H cross relaxation. The schematic representation of the STD NMR 
principle is shown in Figure 13. 
 
Figure 13: Schematic representation of STD NMR spectroscopy. Selective saturation transfer of the 
magnetization from a protein to the binding region of the ligand. Ligands which are in the close proximity 
and binds to the protein will show STD NMR signal (brown triangle). STD signals from non-ligand 
(shown in the oval-shape) do not appear in the spectrum. For the binding ligand, the STD signal intensities 
of the proton closer to the protein (black circle) is higher than that from the proton far from the receptor 
(red circle). (Figure taken from Hiraishi N et.al, 2013 (Hiraishi, Tochio et al. 2013)) 
It is of great advantage that ligands in mixture can be screened on the basis of 
binding. Ligand’s binding epitope can be identified easily as the ligand protons or 
residues in peptides which are in close proximity to the receptor binding site show 
stronger STD signal. STD is a very powerful technique as small molecules or peptide 
ligands when the interaction of these with proteins is reversible and exhibit characteristic 
differences in the relaxation properties and molecular mobilities. These properties are 
much different from those of the other molecules which are having low or even no 
affinity. STD technique is applied in a wide range of applications (Mayer and Meyer 
2001, Streiff, Juranic et al. 2004, Martin-Pastor, Vega-Vazquez et al. 2006, Xia, Zhu et 
al. 2010, Canales, Rodriguez-Salarichs et al. 2011, Viegas, Manso et al. 2011, Fiege, 
Rademacher et al. 2012, Hiraishi, Tochio et al. 2013). 




2.6.3.1 Experimental set up 
All the samples contained Tau peptide/MT drugs in 1mM concentration and 
tubulin/MT in 25μM in 40:1 ratio. The samples were dissolved in 50 mM 
NaH2PO4/Na2HPO4, pH 6.8, 10% D2O. The table lists the ligands used for STD 
experiments. In all cases the STD NMR spectra of ligand (L1) were recorded with and 
without tubulin to characterize the binding. In competition experiments the second ligand 
(L2) was added to the solution and variation in the STD signal intensities of the first 
ligand were observed.  
All the STD spectra were recorded on 700 MHz spectrometer equipped with cryo 
probe. Prior to binding tests and screening, the parameters were carefully optimized. 
Spectra were acquired at 25ºC  by using a series of 40 equally spaced 50 ms Gaussian-
shaped pulses for saturation of the protein, with a total saturation time of 1.5 s. Different 
on-resonance irradiation frequencies were tested as -0.5, -2.0 and 10.0 ppm. The 
frequency of the on-resonance irradiation was chosen to achieve effective and selective 
saturation of the protein and for the competition experiments the protein saturation was 
applied at -0.5 ppm. In all cases, the off-resonance saturation frequency was set at 60.0 
ppm. A total of 1024 scans were collected for each experiment with recycle delay of 
1.5s. 
2.6.4 1D HRMAS experiment 
The 1D experiment for MTs under static and MAS conditions were recorded on the 900 
MHz spectrometer, equipped with a 4mm TXI high-resolution MAS (HRMAS) probe 
head (Z-gradient). The spectra were recorded at 5ºC and a spinning speed of 8 kHz was 
used for MAS conditions. 
2.6.5 Turbidity assays 
The turbidity assays were performed for hTau40, F4, TP1, TP2, TP2_pT231, 
TR1, TR2, TR3, TR23, TR’ and I19L. Tau/Tau fragment-induced microtubule assembly 
was monitored by light scattering in a FluoroMax spectrophotometer (HORIBA) by 
absorption at 350nm. 10µM PC-purified and cycled Tubulin were mixed with 5 µM Tau 




protein in RB-Buffer (100 mM PIPES pH 6.9, 1 mM DTT, 1mM MgSO4, 1mM EGTA, 
1 mM GTP). The polymerization was started by transferring the ice-cold Tubulin-Tau-
solution to the 37°C warm cuvette-holder at time point 0 minutes. The turbidity assay 
was monitored for 30 minutes.   
2.6.6 Electron Microscopy 
The Electron Microscopy was performed at the Facility for Transmission Electron 
Microscopy and the images were scanned by Heim Gudrun and Dr. Dietmar Riedel. The 
microtubules assembled were diluted to 10 μM in MT assembly buffer (PIPES buffer) at 
pH 6.9 and was placed on copper 600mesh grids covered with carbon film. The sample 
was stained with 2% uranyl acetate and examined on a CM12 transmission electron 
microscope. 
2.6.7 Chemical cross-linking and Mass spectrometry. 
Protein cross linking and mass spectrometry was performed in collaboration with R. 
Hofele and Prof. Henning Urlaub, Bioanalytical Mass Spectrometry group, MPIBPC.  
2.6.7.1 Tau-Tubulin cross-linking. 
 In all experiments, the optimal cross-linker to protein complex ratio was determined 
with a titration. Preincubated Tubulin-Tau complexes (TauF4-Tubulin dimer/hTau40-
Tubulin dimer/hTau40-microtubules) were mixed with freshly prepared cross-linker 
bis(sulfosuccinimidyl) suberate (BS3) at different cross-linker to protein ratios of 5, 10, 
25, 50, 100 and 200 as well as a control.  The cross-linking reaction was carried out for 
30 mins at room temperature and quenched with 2uL of 2M Tris pH 7.2. Cross-linked 
samples were visualized by coomasie stained SDS-PAGE and the ratio that exhibited 
maximum cross-linking yield and minimum formation of higher order aggregates was 
selected.  
For the identification of cross-linked peptides, the reaction was repeated at the 
determined optimal cross-linker to complex ratio. Pre-weighed vials of BS3 were freshly 
dissolved in DMSO and taken to final concentration with 50mM sodium phosphate 




buffer, pH 7.2. Reactions were performed in the same buffer. After quenching, samples 
were analyzed by SDS-PAGE in a 4-12% Bis-Tris gradient gel. Several lanes were 
pooled to increase sample amount. In gel digestion was performed as elsewhere 
(Shevchenko, Tomas et al. 2006). After extraction from the gel samples were 
immediately analyzed on the mass spectrometer. 
 
2.6.7.2 Nano-liquid chromatography separation and MS analysis. 
For LC-MS/MS analyses, samples were dissolved in 30 µL sample solvent (5% v/v 
acetonitrile, 1% v/v FA). 5 µL were injected onto a nano-liquid chromatography system 
(Agilent 1100 series, Agilent Technologies) including a ~2 cm long, 150 μm inner 
diameter C18 trapping column in-line with a ~15 cm long, 75 μm inner diameter C18 
analytical column (both packed in-house, C18 AQ 120 Å 5 μm, Dr. Maisch GmbH, 
Ammerbuch, Germany). Peptides were loaded on the trapping column at a flow rate of 
10 μL/min in buffer A (0.1% FA in H2O, v/v) and subsequently eluted and separated on 
the analytical column with a gradient of 7.5–37.5% buffer B (95% acetonitrile, 0.1% FA 
in H2O, v/v) with an elution time of 97 min and a flow rate of 300 nL/min. 
Online ESI-MS was performed with an LTQ-Orbitrap Velos instrument (Thermo 
Scientific), operated in data-dependant mode using a TOP8 method. MS scans were 
recorded in the m/z range of 300-1800 and a resolution of 100000. The 8 most intense 
ions were selected for subsequent MS/MS, and only charge state 3 and above were 
selected for fragmentation. Dynamic exclusion was enabled (30 second repeat duration, 
repeat count 1). Both Precursor ions as well as fragment ions were scanned in the 
Orbitrap. Fragment ions were generated by CID activation (normalized collision 
energy=37.5). As precursor ions as well as fragment ions were scanned in the Orbitrap, 
the resulting spectra were measured with high accuracy (< 5 ppm) both in the MS and 
MS/MS level. 




2.6.7.3 Identification of cross-linked peptides. 
Data analysis was performed with MassMatrix as described in their publications and 
manuals (Xu, Zhang et al. 2008, Xu and Freitas 2009, Xu, Hsu et al. 2010). Thermo 
Scientific Raw files were converted to the mzxmL data format with MMConverter and 
submitted to database search with the following parameters: peptide length between 6-40 
amino acid long, 10 ppm MS1 tolerance, and 0.02 Da MS2 tolerance, tryptic fragments 
with a maximum of 2 missed cleavages. Oxidation in methionine was set as a variable 
modification, whereas carbamidomethylation of cysteine was set as a fixed modification. 
Spectra were searched against a FASTA file composed of the sequences of Tau and 











3  Results 
3.1 Interaction of Tau and Tau fragments with tubulin and 
Microtubule 
To study the structural properties of MT-bound Tau, it is important to map the 
binding region of Tau on MTs. Here we investigated the features of Tau protein and Tau 
fragments either in the MT-bound or tubulin bound state. Two different isoforms of 
human Tau protein, hTau40 and hTau23, were used to study their interaction with MTs. 
We further used different Tau fragments like K18 and F4 having different binding 
affinities as well as mutated and psuedophosphorylated full length Tau to describe the 
properties of MT-bound Tau. 
3.2 Identification of the binding hot spots of the Tau-MT 
interaction  
3.2.1 Interaction of hTau40 with MT 
The Tau-MT interaction was probed by using NMR spectroscopy to get insight 
into the regions of Tau that interact with MTs. The binding of hTau40 to taxol-stabilized 
MTs was characterized using the 2D 1H-15N HSQC spectra measured at 278K. The 
spectra of free and MT-bound Tau were compared as shown in Figure 14, where the 
spectra showed poor proton chemical shift dispersion, a characteristic feature of unfolded 
proteins. The previously assigned resonance assignment of hTau40 was used for the 
analysis (Mukrasch, Bibow et al. 2009, Narayanan, Dürr et al. 2010). The line 





spectra were analyzed and it is found that a number of resonances were either 
disappeared or diminished in intensity. The ratio of the resonance intensities of the MT-
bound and unbound Tau was plotted against the residue number as shown in Figure 15 
and is similar to that reported before in the case of Tau-MT interaction at 298K 
(Mukrasch, Bibow et al. 2009). The non-uniform reduction in signal intensities in the 
spectra of hTau40 bound to MTs is caused by an exchange of Tau molecules between the 




Figure 14: Overlay of the 2D 1H-15N HSQC spectra of hTau40 without (blue) and with MTs (red) at 2:1 






the binding domain include both the proline rich and the repeat domain in the full length 
Tau, especially the linear motifs 168ATRIPAKTPPA178, 225KVAVVRTPPKSPSS238, 
245TAPVPMPDL253, 275VQIINKKLDLSNV287, 306VQIVYKPVDLSKV318 and 




Figure 15: Tau-microtubule interaction. NMR signal intensity ratios between signals observed in the 
1H-15N HSQC spectra for MT-bound and free states of hTau40 acquired at 5 ºC with 2:1 stoichiometry of 
Tau:MT. The domain organization diagram is shown on top of the intensity ratio plot and distinct colour 
coding is used to highlight the binding hot spots involved in Tau-MT interaction. The ratio of Tau:MT is 
calculated on the basis of the initial concentration of tubulin chose for MT assembly. 
 
 
Figure 16: 1H-15N combined chemical shift difference observed for the NMR signals in the MT-bound 





identified residues is observed as represented in Figure 16.  The binding hot spots 
identified here are highly localized and are separated by highly flexible linkers. It was 
shown before that the Tau-MT binding involves both hydrophobic and charged residues 
(Mukrasch, Bibow et al. 2009). Whereas the intensities and chemical shift of the amino 
acid residues at the N-terminus remained unaffected, indicating that this region is not 
involved in binding. In short the binding interaction between Tau and MTs is mediated 
through residues from the proline rich region (PRR) to the pseudo repeat R` near the C-
terminal end of hTau40. The broadening observed for the residues in between the 
binding hot spots and at the C-terminus is due to the transient interaction of this region to 
the MTs and thereby having smaller transverse relaxation rate than that of the residues at 
the N-terminus in the Tau-MT complex. 
3.2.2 Isoform specific binding of Tau to MTs 
We investigated the isoform specific features in the binding of Tau to 
microtubules by comparing the binding profiles of hTau23 and hTau40 which are the 
shortest and longest isoforms of Tau in the human brain respectively. The 2D 1H-15N 
HSQC experiments were performed in the case of hTau23 at 278K at multiple 
hTau23:MT ratios. Analysis of the NMR spectra revealed that the interaction profile was 
in line with that of hatu40 as similar binding regions and residues were involved in 
binding.  The comparison of the intensity ratio profiles of hTau23 and hTau40 at 1:2 
ratio of Tau:MT is shown in Figure 17. At the same time, comparison of the NMR 
broadening profiles of hTau40 and hTau23 reveals a reduced signal intensity broadening 
in case of hTau23, pointing to a lower binding affinity of hTau23, in accord with the 








Figure 17: Similarities in the interaction of different isoforms of Tau and MTs. Comparison of Tau-
MT interaction in two different isoforms hTau23 and hTau40 of human Tau. NMR signal intensity ratios 
between signals observed in the 1H-15N HSQC spectra for MT-bound and free state of hTau23 (brown 
bars) and hTau40 (blue bars) with 1:2 stoichiometry of Tau:MT. The domain organization diagram is 
shown on top of the intensity ratio plot and distinct colour coding is used to highlight the binding hot spots 
involved in Tau-MT interaction. The grey line indicates the peak intensities in the noise level. 
 
The chemical shift perturbation observed for the amino acid resonances of both 
hTau40 and hTau23 upon interaction with MTs is compared in Figure 18. Similar 
residue stretches involved in MT binding are perturbed in both isoforms. 
 
 
Figure 18: Comparison of the 1H-15N combined chemical shift differences observed for hTau40 (blue) and 
hTau23 (brown) in the MT-bound state and free state. The amino acids are numbered with respect to 





3.2.3 Effect of overloading of MTs 
It was previously reported that at elevated Tau concentrations, Tau molecules 
might aggregate on top of each other similar to paired helical filament formation. It was 
proposed that the accumulation of Tau occur on top of each other in a non-saturable 
binding mode (Ackmann, Wiech et al. 2000). This kind of overloading of MTs was 
investigated by varying the stoichiometry from 2:1 to 1:2 and 1:3. Repeating the NMR 
titrations in different ratios, with excess of MTs has been shown that overloading of MTs 
does not lead to different interaction sites. The line broadening in the 1H-15N HSQC 
spectra of Tau with MTs at 2:1 and 1:3 ratios are compared in Figure 19. It is clear from 
the figure that similar region of the spectra are affected by the interaction with MTs, 
though a few residues beyond the MT binding region shows additional broadening at 
higher MT concentration. This is attributed to the fast relaxation associated with the 
large size of the Tau-MT complex and is pronounced at higher MT concentration.  The 
resonances of residues at the N-terminal projection domain remained largely unaffected 
without strong broadening. These experiments were performed in the shortest isoform 
hTau23 as well and it is noticed that similar binding sites are involved in two different 




Figure 19: Effect of overloading of MTs. NMR signal intensity ratios of hTau40 resonances in the 
presence and absence of MTs obtained  from the 1H-15N HSQC spectra is plotted against residue number, 







Figure 20: hTau23-MT interaction at different relative concentrations. Line broadening profiles of 
hTau23 obtained from the 1H-15N HSQC spectra with hTau23: MT ratio of 2:1 (brown) and 1:2 (blue). 
Amino acid residues are numbered with respect to hTau40. The regions without any bars indicate the 
absence of two N-terminal inserts I1 and I2 and repeat R2. 
 
3.2.4 Influence of ionic strength on Tau-MT binding  
The importance of electrostatic interactions in Tau-MT binding was investigated 
by performing the NMR interaction experiment at increasing ionic strength (Figure 21). 
In the presence of sodium chloride, the MT-binding strength of Tau was reduced in a salt 
concentration dependent manner: at salt concentration of ~150 mM NaCl in the Tau-MT 
solution the average ratio of Tau signal intensities was increased from 25% in the at 
lower salt concentration in 50mM sodium phosphate buffer to about 50%, while further 
increase to 300mM NaCl recovered the average ratio of signal intensities of MT-bound 
Tau to more than 90%. It is to be noticed that even at elevated ionic strength the 
hydrophobic residues in the second hexapeptide in repeat R3 showed partial broadening. 
These data indicate the important contribution of electrostatic interactions to MT-Tau 









Figure 21: Effect of ionic strength on Tau-MT interaction. Comparison of intensity ratio profiles of 
hTau40 with MTs by varying the ionic strength without NaCl (black), with 150mM NaCl (green) and with 
300mM NaCl (brown) 2:1 ratio of hTau40 and MTs. 
 
3.2.5 Interaction of hTau40 with tubulin 
The function of Tau to promote tubulin assembly and stabilize microtubules 
raises the question whether the mode of interaction is the same in both Tau-tubulin and 
Tau-MT interaction or not. The binding of hTau40 with unpolymerized tubulin was 
investigated using the 2D 1H-15N HSQC experiments as in the case of MTs. The ratio of 
the intensities (Figure 22) in the tubulin-bound and free Tau give the strong evidence 
that the binding features are the same, as the same set of residues as in the case of MT 
binding are affected. The titrations were done at different stoichiometric ratios and the 
intensity profiles at 1:2 ratio is compared to that of the interaction with MTs. The 
residues near the projection domain and the C-terminal domain of Tau are found to be 
less broadened by binding to tubulin than MT. This is either due to slight differences in 
the binding affinities in these regions or due to the smaller transverse relaxation rate of 
the Tau-tubulin complex when compared to that of the Tau-MT complex, which leads to 
less broadening in the regions that are next to the binding hot spots. The comparable 
binding profiles of Tau for MT and Tubulin suggest that the Tau binding site is largely 







Figure 22: Interaction of hTau40 with tubulin and MTs. Comparison of intensity ratio profiles of 
hTau40 with MTs (grey line) and unpolymerized tubulin (black bars) at 1:2 ratio of hTau40:MT/tubulin. 
 
3.2.6 Characterization of MTs using NMR 
The microtubules assembly, performed as described in the methods section, was 
confirmed with electron microscopy showing nice array of protofilaments (Figure 23a). 
The absence of unpolymerized tubulin in the sample during NMR experiments at low 
temperature was verified by employing High Resolution Magic Angle Spinning 
(HRMAS) NMR experiments. HR-MAS is an established technique for analyzing intact 
biological tissue samples. By spinning at the magic angle, susceptibility differences 
within the sample are removed resulting in high resolution quality spectra. The 1D 1H 
spectrum of 100μM MTs filled in the rotor in the static conditions showed only very 
broad lines characteristic of mega Dalton MTs. No sharp signals, in particular in the 
methyl region, that could originate from αβ-tubulin dimers of 100kDa molecular mass 
were observed. By spinning the sample at 8 kHz under MAS conditions averages out the 
stronger proton-proton and weaker proton-carbon/nitrogen dipolar interactions and the 
narrow signals are observed from the microtubules. The 1D 1H spectra of MTs obtained 






Figure 23: Characterization of MT assembly. (a) EM image of the microtubules assembled from PC 
tubulin (The EM image was recorded in the facility for Transmission Electron Microscopy, MPIBPC). (b) 
The 1D 1H NMR spectra of MTs both under static (red) and MAS conditions of 8 kHz (blue).  
 
3.3 Influence of mutation and phosphorylation 
3.3.1 Effect of mutation (Y310N) of Tau on MT binding 
 It has been shown that Tau-MT interaction is mediated through highly localized 
binding hot spots separated by flexible linkers. To understand the mechanism involved in 
Tau-MT binding, which is a combination of both electrostatic and hydrophobic 
interaction Tau protein with Y310N mutation was used. Y310 is one of the binding 
residues involved in the binding hot spot in repeat R3. Comparison of the intensity ratios 
derived from the wild type and Y310N mutated hTau40 in the MT bound state is shown 
in Figure 24. 
The data show that a single residue mutation doesn’t affect the overall binding. 
Although residues close to the site of Y310 mutation are slightly affected as evidenced 
from their intensities, no considerable long-range effect in the other binding hot spots 
was observed. The data suggest the independent nature of different linear motifs of Tau 







Figure 24: Influence of single residue mutation (Y310N) on MT binding. The NMR line broadening 
profiles of wt hTau40 (black bars) and Y310N mutated hTau40 (grey line) upon interaction with MTs is 
compared. The position of mutation is indicated by an arrow.   
 
3.3.2 Effect of pseudophosphorylation of Tau on MT binding 
It is known that hyperphosphorylation of Tau leads to detachment of Tau from 
the MT surface causing MT destabilization and thereby the formation of NFTs composed 
by Tau (Stoothoff and Johnson 2005, Mi and Johnson 2006). To probe the 
phosphorylation-dependent Tau-MT interaction we used hTau40 for which residues 
S199, S202, T205, T212, S214, S396 and S404 were mutated to glutamic acid. Mutation 
of serine to negatively charged aspartate or glutamate residue is widely used as a mimic 
of phosphorylation (Jeganathan, Hascher et al. 2008). The 7E mutation sites mentioned 
above form epitopes for the Alzheimer’s diagnostic antibodies AT8, AT100 and PHF1 
(Jeganathan, Hascher et al. 2008). The effect of phosphorylation was investigated by 
comparing the MT-induced line broadening in the case of wild-type hTau40 to that of 7E 
mutant of hTau40 as shown in Figure 25. 






Figure 25: Effect of phosphorylation on MT-binding. Intensity ratios for the hTau40-7E variant 
(brown line), which was pseudo-phosphorylated at the AT8, AT100 and PHF1 epitopes 
(indicated by yellow arrows), between the MT-bound and unbound state. MT-induced resonance 
broadening of non-phosphorylated wild-type hTau40 is shown for comparison (black bars). 
 
The results showed that the pseudo-phosphorylation at the AT8, AT100 and PHF1 
epitopes enhances the signal intensities of the nearby residues indicating that MT binding 
is weakened especially in the proline rich region and to a less extent in the R` around 
mutation sites S396 and S404. The repeat domains with other binding hot spots remain 
unaffected and the data underline one of the important features of Tau, possessing highly 
independent binding sites for MTs.   
 
 
3.4 Interaction of Tau fragments with tubulin/MT 
3.4.1 Interaction of K18 with tubulin 
To get further insights into the exact amino acid residues involved in binding and 
to extract detailed information regarding the mechanism involved in binding we used 2H, 
15N labeled K18. NMR investigation of 2H, 15N labeled K18 in complex with tubulin was 
performed using TROSY and CRINEPT-TROSY experiments that facilitate detection of 
signals from the large molecular weight systems. The analysis of TROSY spectra of 





additional line broadening as shown in Figure 26 consistent to the previously identified 
binding hot spots (Figure 15). Still the CRINEPT-TROSY couldn’t reveal information 
only from the completely bound state as the similar residues are found to be broad both 
in the TROSY and CRINEPT-TROSY spectra. Yet another observation is that the 
residues in the repeats R1, R2 and R3 showed severe line broadening, whereas repeat R4 
was less affected consistent to the observation as in the case of hTau40. R4 remained 




Figure 26: K18-Tubulin interaction. Intensity ratio of 2H, 15N labeled K18 calculated from the TROSY 
spectra recorded in the tubulin-bound and free state of K18 at 5°C.  The horizontal dashed line indicates 
the severe line broadening of residues in the NMR spectrum. 
 
3.4.2   Characterization of interaction of TauF4 with Tubulin/MT 
A new Tau fragment, TauF4 [S208-S324] that comprises the MTBR and the 
proline rich domain closest to the MTBR in Tau sequence was used for further 
investigation in the MT-bound state. The F4 fragment binds tightly to MTs and promotes 
MT assembly (Fauquant, Redeker et al. 2011). 2D 1H-15N HSQC spectra of F4 showed 
poor proton chemical shift dispersion as observed in the case of hTau40.  Assignment of 
the resonances in the F4 fragment was done with the help of the previously assigned 
K18, hTau23 and hTau40 and was confirmed with the assignment of F4 reported before 
(Sibille, Huvent et al. 2011). The interaction of F4 with MTs leads to overall reduction in 





binding. The experiments were performed with varying F4:MT stoichiometric conditions 
of 10:1, 5:1 and 1:2 with MTs. The residual intensity of the protein is found to be 
attenuated on increasing the concentration of tubulin/MT. The results indicate very high 
affinity of F4 to MTs thereby having very slow or even negligible exchange between the 
bound and free forms of F4 in solution. It can therefore be concluded that the signal 
disappearance is due to the immobilization of the F4 fragment on MTs. The complete 
signal attenuation is at the ratio of 1:2 which is the known stoichiometry of Tau:tubulin. 
 
 
Figure 27: Interaction of F4 with MTs. NMR signal intensity ratios of F4 resonances in the presence and 
absence of MTs obtained from the 1H-15N HSQC spectra is plotted against residue number, with F4:MT 
stoichiometry of 10:1 (blue) and 2:1(brown) acquired at 5°C. 
3.4.2.1   Effect of ionic strength on binding of F4 with tubulin/MTs 
 It is known that solution NMR spectroscopy cannot detect the signals of proteins 
in the complex with large molecular weight receptors since the NMR signals would be 
broadened beyond the detection limit of experiment. To further verify the influence of 
ionic strength in Tau-MT interaction (Figure 21), the effect of increasing ionic strength 
on F4-MT interaction was monitored through sodium chloride titration experiments. At 
120 mM NaCl most of the signals from the proline rich region and the signals of the 
other positively charged residues were found to be recovered as shown in Figure 28a. 
Further increase in the salt concentration to 500mM increased the overall signal 
intensities of all the residues including hydrophobic residues as shown in Figure 28b. 
Although the signals of all charged residues in NMR spectra were retained at higher salt 





R2 and R3 were found to be partially broadened indicating the contribution from 
hydrophobic residues. All the titrations were performed by varying the temperature and it 
has been found that there is no temperature dependence in the binding mode and binding 
affinity of F4 with MTs as the mode of interaction is similar at 278, 288 and 298K. 
 
Figure 28: Influence of ionic strength on F4-MT interaction. Superposition of the well resolved region 






Figure 29: Influence of ionic strength on F4-MT interaction. Comparison of intensity ratio profiles of 






The gain in the resonance intensities by changing the ionic strength is represented as the 
ratio of their intensities Figure 29. It is quite evident from these experiments that TauF4 
interact with tubulin/MT with higher affinity than full length Tau protein. 
3.4.2.2 MT assembly properties of F4 and hTau40 
It is clear from the interaction of both F4 and hTau40 with MTs that the binding 
affinity is relatively higher for F4. To further investigate their MT assembly capabilities, 
the polymerization assay of tubulin induced by F4 and hTau40 were measured 
turbidimetrically. The MT assembly properties of F4 were investigated by varying the 
concentrations of F4 from 5μM to 25μM and compared with that of 5 μM hTau40. A 
fixed tubulin concentration of 10uM, below its critical concentration for MT assembly if 
it is alone(Mitchison and Kirschner 1984), was used in all cases. In comparison to the 
wild type hTau40, F4 has less effect on MT assembly. The comparison is shown in 
Figure 30a. Tubulin with a concentration of 10 μM was used as control and was unable 
to assemble to MTs by itself as it is below the critical concentration for the tubulin self-
assembly. The EM images of the MTs formed by 5 μM of hTau40 and 25 μM of F4 are 
shown in Figure 30b and Figure 30c. F4 shows strong bundling effect on MTs.  
 
 
Figure 30: Comparison of the MT assembly efficiency of hTau40 and F4. (a) Turbidity at 350nm was 
recorded over time to monitor the microtubule assembly in the presence of hTau40 and F4. Assembly 
experiments were performed in the presence of 1 mM GTP at 37°C with a fixed tubulin concentration of 
10 µM. Intensities were normalized to the assembly in the presence of hTau40 (set to 100% in the plateau 
phase). 5 µM of hTau40 and 5, 10 and 25 µM of F4 were used. (b) EM image of MTs formed by 5 µM of 
hTau40 and (c) MTs formed by 25 µM of F4. (The experiments were performed by Dr. Satish Kumar, 






3.4.3  Information from the bound state 
3.4.3.1  CRINEPT-HMQC of 2H-15N F4 bound to tubulin  
The very tight binding of F4 fragment to MTs/tubulin allowed us for further 
structural investigation of high molecular weight complex using CRINEPT (cross-
correlated relaxation-enhanced polarization transfer) based experiments. We used 2H, 
15N labeled F4 in the tubulin bound state to see the bound form of the protein, where the 
complex formed has very high molecular weight of ~115 kDa. At 303K we could 
observe the signals arising only from the flexible linkers in the bound state. This 
observation provided further insights how Tau interacts with tubulin. The HSQC, 
TROSY and CRINEPT-HMQC provided consistent result that while the binding residues 
in the binding hot spots remained rigid on tubulin and invisible by solution NMR, the 
linkers remained highly flexible. Almost all the signals observed in the CRINEPT 
HMQC spectrum were visible in the 2D 1H-15N HSQC and 1H-15N TROSY spectra. The 
intensities of observed resonances in the tubulin bound and free states of F4 were 
analysed and the broadening profile Figure 31b largely resemble that observed in the 
case of hTau40 bound to tubulin/MT. The complete loss of flexibility of the residues 
from the binding region is reflected by the disappearance of the signals only from the 
binding hot spots. 
3.4.3.2 CRINEPT-HMQC of 2H-15N F4 bound to MTs 
 The interaction of F4 bound to MTs was investigated by employing the 
CRINEPT-HMQC-TROSY on 2H, 15N-labeled F4. It was found that the signals observed 
for F4 in the MT-bound state is much weaker than that observed in F4-tubulin complex. 
Further it is noticed that all the visible, albeit weaker, signals are originating from the 
highly flexible residues lying in between the binding hot spots. Overlay of the 
CRINEPT-HMQC-TROSY spectra of MT-bound and free F4 acquired using the 2H, 15N 
labeled F4 is shown in the Figure 31a with selected residues in the binding hot spots 
labeled. Unlike the tubulin-bound F4, MT-bound F4 is less sensitive for HSQC and 
TROSY-HSQC experiments and none of the resonances are clearly visible. This shows 
the influence of the size of the complex formed in the deterioration of the signal 





CRINEPT based polarization transfer compared to INEPT. It is much more clear from 
the analysis of the intensities derived from the CRINEPT-HMQC-TROSY spectra as 
shown in Figure 31c. In short the line broadening observed in the case of F4-MT 
complex is more prominent than that of F4-tubulin complex.  
 
 
Figure 31: (a) Superposition of the 1H-15N CRINEPT-HMQC-TROSY spectra of F4 in the free (blue) and 
MT-bound (red) state acquired at 30°C. (b) Interaction of TauF4 fragment with unpolymerized tubulin. 
Intensity ratio from the 1H-15N HSQC spectra of tubulin bound TauF4 at 1:4 ratio at 30°C. (c) Intensity 
ratio obtained for F4 from the 1H-15N CRINEPT-HMQC-TROSY spectra in the presence and absence of 
MTs at 30°C. The dashed grey line indicates the noise level of the spectra obtained.  
3.5 Structure determination of the MT-bound Tau 
One of the major functions of Tau is to bind and stabilize MTs and promote 
tubulin assembly. The results described in the previous sections (3.2 and 3.4) provide 
evidence for the active participation of Tau in binding and stabilization of MTs or 
promoting tubulin polymerization. Being intrinsically disordered in the free form in 
solution, it is important to understand the mechanism involved in MT stabilization. 
However the high resolution structural information of MT-bound Tau is missing. 
Extracting structural information from Tau-MT complex with size of the order of 1MDa 





structural description of systems like MT-bound Tau. If the size of the receptor is too 
large it is difficult to extract structural parameter from their NMR spectra.  
If the ligand is weakly bound and there exists fast exchange between free and 
bound forms of the ligands, detailed structural and dynamic information can be obtained 
by employing transferred NOEs and CCR rate measurements (Balaram, Bothnerb.Aa et 
al. 1972, Post 2003, Carlomagno 2005, Williamson 2006) (section 2.6). Application of 
these techniques to get the structure of MT-bound Tau is possible via the “divide and 
conquer strategy”. 
3.5.1 Selection of Tau peptides  
On the basis of the findings based on the interaction studies of Tau isoforms and 
other Tau constructs with MTs, it is exclusively evident that Tau possess highly localized 
linear motifs which independently bind to MTs and are separated by highly flexible 
linkers. This allowed us to use the “divide and conquer strategy” that is by using shorter 
Tau peptides to derive the MT-bound structure of Tau. A list of the Tau peptides used is 




Figure 32: Divide and conquer strategy. Pictorial representation of the selected peptide regions to 
determine the structure in the MT-bound state. The binding hot spots identified are extended to both N and 
C-terminus by a few residues to select the sequence. The yellow color coding is for the control peptides 
which are not expected to bind to MTs. 
 
The dissociation constant of Tau peptides used in this study are expected to be of the 
order of µM to mM range that enables fast exchange between the MT-bound and free 
peptides. This allowed us to implement tr-NOESY experiments to derive structural 







3.5.2 Assignment of the peptides 
To implement the divide and conquer strategy for the structure determination of 
MT-bound Tau, different Tau peptides were synthesized with reference to the binding 
hot spots identified. These peptides include TP1, TP2, TR1, TR2, TR3, TR23 and TR’. 
The primary requirement for the NMR based structure determination is the complete 
resonance assignment of the spectra. The sequential resonance assignment of all the 
residues was done using the standard Wuethrich method (section 2.6.1.1). The spin 
systems were identified using the TOCSY spectra at different mixing times together with 
the DQF-COSY spectra. TOCSY spectra at two different mixing times of 60 and 80 ms 
helped to identify the spin systems unambiguously. All the residues were sequentially 
connected by combining TOCSY and NOESY spectra. The natural abundance 13C and 
15N HSQC spectra acquired with these peptides provided the proton chemical shifts 
identical to those of full length Tau. These chemical shift information together with the 
sequential assignment from TOCSY and NOESY spectra provided highly reliable 
resonance assignment.  
 
3.5.3 Assignment of TR3 
The identification of different spin systems in TR3 was achieved unambiguously using 
TOCSY spectrum and a selected region of the spectrum is shown in Figure 33a. The 
sequential connectivity from ith residue to i+1th residue is shown in Figure 33b where the 
finger print region of the spectrum is displayed. Thus the complete resonance assignment 






Figure 33: Sequential resonance assignment of TR3 peptide. (a) Spin system identification. The finger 
print region of the TOCSY spectrum with selected spin systems labeled. The vertical lines indicate the 
complete spin system of a specific residue type. (b) Fingerprint region of NOESY spectrum of TR3 with 
HA-HN correlation peaks. The spin systems identified from the TOCSY spectrum are connected 
sequentially by arrows and selected peaks are assigned to show the connectivity. 
  
 
3.5.4 Tau peptides bind effectively to tubulin/MT: STD NMR 
STD NMR method yields the spectra if and only if there is binding and the 
binding should be relatively weak resulting in fast exchange regime between bound and 
free states of the ligands (Mayer and Meyer 1999).  The 1D STD NMR spectrum of MT-
bound TR3 is shown in Figure 34 and it clearly shows binding and gives indication 
about the exchange is fast enough to detect NMR observable developed in the bound 








Figure 34: TR3 binds to tubulin. Selected region of 1D 1H STD NMR spectrum of TR3 in the presence 
of tubulin with selective saturation of tubulin at -0.5 ppm. The most affected protons in TR3 upon selective 
saturation of tubulin are labeled. 
 
3.6 Structure of MT-bound Tau peptides 
To accomplish the central goal of the study, deriving the MT-bound structure, the 
tr-NOESY experiments were performed in the MT-bound state. The necessary and 
sufficient condition for the detection of transferred NOE such as the dissociation 
constant of the peptide-MT complex of the order of 10-6 to 10-3 M, peptide: MT ratio 
were satisfied. That is the chemical exchange of Tau peptides in the MT-bound and free 
state should be fast. One of the complimentary NMR methods that support detection of 
tr-NOEs is STD effect. STD NMR method yields the spectra if there exists weak binding 
and thereby fast exchange between bound and free states of the ligands.  The 1D STD 
NMR spectrum of MT-bound TR3 Figure 34 clearly shows binding and the exchange is 
fast enough to extract structural information from the bound state. The tr-NOESY spectra 
of the peptides were recorded with the NOE mixing time of 80 ms to avoid errors 
generating from spin diffusion and were used for the structure determination. 
The manually assigned NOEs were used for generating the distance restraints and 
further structure calculation. The initial NOE peak calibration, conversion of the NOEs 
to distances and structure calculation were done using CYANA 3.0 with the standard 





refined using the program Xplor-NIH using the restrained simulated annealing protocol. 
Twenty lowest energy structures were taken for the analysis and validation of the 
structures using PROCHECK and rmsd values were calculated for the back bone and 
heavy atoms using MOLMOL. Finally ten best fitting structures are displayed. 
 
3.6.1 Structure of MT-bound TR3 
3.6.1.1 Tr-NOESY NMR spectrum of TR3-MT complex 
The conformation of MT-bound TR3 was investigated using homonuclear 1H-1H 
tr-NOESY experiments. The tr-NOESY spectrum of TR3 peptide was acquired in the 
presence of MTs in 20:1 ratio of TR3:MT with 80 ms mixing time. The spectrum 
showed a number of intense cross peaks in comparison to the spectrum acquired in the 
absence of MTs. This indicates that the additional peaks in the MT-bound state of TR3 
are originating as a result of change in conformation induced by interaction. Figure 35a 
shows the overlay of the selected region of the tr-NOESY spectra of MT-bound and free 
TR3 and this region shows significant difference between the free and MT-bound TR3.  
 
 
Figure 35: a) Region of the NOESY spectrum of 1mM TR3 peptide alone (red) overlaid with the tr-
NOESY spectrum of 1mM TR3 peptide with 50uM MTs (blue) with a peptide to MT ratio of 20:1in 
50mM sodium phosphate buffer, pH 6.8. (b) Overlay of the NOESY (red) and tr-NOESY (blue) spectra of 






3.6.1.2 Tr-NOESY spectrum of TR4 (Tau327-353) 
In order to verify the tr-NOEs observed in the case of TR3, a control peptide TR4 
(Tau327-353) encompassing the region of hTau40, which is immediately after the TR3 
sequence, is selected. The residues in this region are less affected by signal broadening in 
the 2D 1H-15N HSQC experiments of hTau40 due to the interaction with MTs. Hence it 
is believed to be the flexible linker between two binding domains. The NOESY spectra 
of TR4 acquired in the MT-bound state doesn’t show tr-NOEs as shown in Figure 35b. 
3.6.1.3 Structure calculation 
Analysis of the tr-NOEs indicates the presence of a number of medium and even 
long range NOEs between the residues which belong to the amino acid stretch identified 
as the binding hot spot in repeat R3 as explained in section 3.2. The interaction of TR3 
with MTs is reflected by the detection of transferred NOEs. In the absence of MTs TR3 
only showed a small number of medium-range cross peaks in NOESY spectrum. Upon 
interaction with MTs significant number of NOE cross peaks were visible because of the 
rigidity in the conformation of TR3. As a result of the tr-NOESY experiment, it was 
possible to collect 319 distance restraints with 98 intra residue and 221 inter residue 
NOEs. These NOEs were further classified into 246 short-range, 60 medium-range and 
13 long-range NOEs. The NOE connectivity that are the hallmark for the secondary 
structure element and the number of NOEs per each residue are shown in Figure 36 with 
short range NOEs in white, medium in grey and long range NOEs in black color coding.  
The most striking observation is the presence of many medium- and long-range 
tr-NOE cross peaks, especially within the residues which are identified as the binding 
epitope. The long-range contacts are predominantly from P301 to V306, V309, V313, 
K311 and D314. In addition other long-range contacts identified are also highly specific 
in the MT-bound state. 
The initial structure calculations of MT-bound TR3 were performed with 
CYANA 3.0 using the distance restraints derived from tr-NOESY experiment. The 





protocol and 20 lowest energy structures were selected for analysis, the structural 
statistics of which are summarized in          Table 4. There were no violations larger than 
0.5Å observed in these structures. The 10 best structures are displayed in figure 22. The 
mean structure is displayed to show the side chain orientation of the structured region of 
the peptide. 
 
Figure 36: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TR3 peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 




It is to be noticed that most of the medium and long range NOEs observed are 
within the Val-300-Thr319 residues stretch of TR3. It is highly reflected from the 
convergence of the conformers displayed in Figure 37a and Figure 37b with an rmsd of 
1.09Å for the backbone atoms and 1.58Å for heavy atoms. One of the key features 
observed is that the presence of long range NOEs from P-301 to I-308, V-309, and V313. 
The side chains of these residues stabilize the turn conformation adopted by TR3 in the 
presence of MTs. A few residues involved in long range contacts are indicated in one of 









Table 4: Structural statistics of the MT-bound TR3 
Structural statistics for the 20 final conformers of MT-bound TR3 (26 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 
RMS deviations from the average structure 
Backbone atoms  
(Residues 300-301, 305-312) 
Heavy atoms 
319 
  98 
148 
  60 
  13 
 

















Figure 37: Structure of TR3 in the MT-bound state. (a) Backbone superposition of the ten best 
structures of the MT-bound TR3 as calculated from the tr-NOESY experiments. (b) Structured region of 
the MT-bound TR3 with side chains identified as binding epitopes. (c) The mean structure of the TR3 in 
the MT-bound state. The side chains of the residues involved in the long and medium range interactions 







3.6.2 Structure of MT-bound TR2 
The sequential assignment of NOESY spectra of TR2 was done as in the case of 
TR3. The tr-NOESY spectrum of TR2 in the MT-bound state was acquired with different 
mixing times and compared with the NOESY spectrum of TR2 in the free state. Albeit 
the fewer number of tr-NOE cross peaks, we could collect 131 intraresidue and 80 
interresidue NOE restraints in the presence of MTs. 10 medium and 11 long range NOEs 
were identified which defined the MT bound structure with a reasonable convergence of 
the backbone atoms.  
The remarkable NOEs in the tr-NOESY spectrum include the long range NOEs 
from Q269 and P270 to I278, K280, K281 and D283 etc. The residues in the structured 
part of the peptide are characterized by the medium range and long range tr-NOEs 
compared to other residues and it underlines the observation from the interaction studies 
where the amino acid residues in the structured region being the binding epitope. The 
structure calculations were done as in the case of TR3 and the final 20 lowest energy 
structures were selected for analysis.  
 
Figure 38: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TR2 peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 







Table 5: Structural statistics of the MT-bound TR2 
Structural statistics for the 20 final conformers of MT-bound TR2 (26 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 
RMS deviations from the average structure 
Backbone atoms  





  59 
  10 
  11 
 
















Figure 39: Structure of TR2 in the MT-bound state. (a) Main chain superposition of the ten best 
structures of the MT-bound TR2 as calculated from the tr-NOESY experiments. (b) Structured region of 
the MT-bound TR2 with side chains identified as binding epitopes. (c) The mean structure of the TR2 in 
the MT-bound state. The side chains of the residues involved in the long and medium range interactions 









3.6.3 Structure of MT-bound TR1 
The tr-NOESY spectrum of MT-bound TR1 was acquired in the presence of MTs 
in 20:1 ratio of TR1:MT and it showed a number of additional cross peaks in comparison 
to the spectrum acquired in the absence of MTs. The additional peaks in the MT-bound 
state of TR1 reflect its binding to MTs according to the principle of tr-NOE and thereby 
possess a conformation other than the free TR1. The complete resonance assignment of 
the peptide was done as explained in the case of TR3. As a result of the tr-NOESY 
experiment, it was possible to collect 253 distance restraints with 118 intra residue and 
135 interresidue NOEs. The effective binding of this peptide is shown by the presence of 
36 medium range and 8 long range NOEs.   
Structure of MT-bound TR1 was determined following the strategy used in the 
TR3 structure determination. The distance restraints were calibrated using CYANA 
automated calibration method and classified into 209 short, 36 medium and 8 long range 
NOEs. The NOE connectivities and the number of NOEs observed per each residue are 
shown in Figure 40. The initial structure calculation was done using CYANA and 
refined in XPLOR-NIH. 
 
Figure 40: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TR1 peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 
to the intensity of the observed NOE.  
The structural statistics of the 20 lowest energy structures is given in Table 6  and 10 





mean structure showing the side chain orientation.  The structured region of the peptide 
T245-K253 shows better convergence with an rmsd of  0.76Å for the back bone atoms 
and 1.32 Å for the heavy atoms. 
 
Table 6: Structural statistics of the MT-bound TR1 
Structural statistics for the 20 final conformers of MT-bound TR1 (29 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 
RMS deviations from the average structure 





  91 
  36 
    8 
 















Figure 41: Structure of TR1 in the MT-bound state. (a) Main chain superposition of the ten best 
structures of the MT-bound TR1 as calculated from the tr-NOESY experiments. (b) Structured region of 
the MT-bound TR1 with sidechains identified as binding epitopes. (c) The mean structure of the TR1 in 
the MT-bound state. The sidechains of the residues involved in the long and medium range interactions 






3.6.4 Structure of MT-bound TP2 
The peptide TP2 from the proline rich region of Tau is shown to be one of the 
important regions involved in MT binding. The relatively high positive charge of the 
peptide region was shown to be the driving force involved in binding. The structure of 
MT-bound TP2 was calculated by collecting 321 tr-NOE cross peaks with 134 intra 
residue and 187 inter residue NOEs. The distance restraints generated were classified 
into 270 short, 45 medium and 6 long range NOEs and were used in the structure 
calculation of MT-bound TP2 using the same protocol followed in the previous cases. 
The NOE connectivities and number of NOEs used per residue are shown in Figure 42. 
The structural statistics of the lowest 20 structures is given in Table 7 and the best 10 
structures are displayed in Figure 43. 
 
Figure 42: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TP2 peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 
to the intensity of the observed NOE. 
 
The rmsd of the structured part of the peptide is analysed and showed high degree of 
convergence within the regions K224-V228 and V228-P236. The back bone rmsd of 
0.68 Å is calculated in the V228-P236 region of the TP2 peptide. A number of medium 






Table 7: Structural statistics of the MT-bound TP2 
Structural statistics for the 20 final conformers of MT-bound TP2 (32 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 
RMS deviations from the average structure 
Backbone atoms (Residues 224-228) 
Heavy atoms 
Backbone atoms (Residues 228-236) 
Heavy atoms 





  45 
    6 
 


















Figure 43: Structure of TP2 in the MT-bound state. (a) Mainchain superposition of the ten best 
structures of the MT-bound TP2 as calculated from the tr-NOESY experiments. (b) Structured region of 
the MT-bound TP2 with sidechains identified as binding epitopes. (c) The mean structure of the TP2 in the 
MT-bound state. The sidechains of the residues involved in the long and medium range interactions within 






3.6.5 Structure of MT-bound TP1 
The structure of TP1 in the MT-bound state was calculated using the tr-NOE 
method. The comparison of the NOESY and tr-NOESY spectra shows that there are not 
many new NOE cross peaks in the MT-bound state, leaving a significant portion of the 
peptide unstructured. Out of the 210 tr-NOEs observed in the MT-bound state, 78 cross 
peaks were identified as intra residue and 132 inter residue NOEs. These NOE restraints 
were used for the structure determination by classifying them into 194 short range and 16 
medium range NOEs, without having any long range contact within the peptide residues. 
The structural statistics of the 20 low energy structures is shown in Table 8. There were 
no NOE violations larger than 0.5Å per structure.  
 
 
Figure 44: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TP1 peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 
to the intensity of the observed NOE. 
 
An ensemble structure of 10 best fitting conformers is shown in Figure 45. It was 
found that shorter amino acid stretches are structured in different regions after interaction 
with MTs. The back bone rmsd of 0.9 Å and heavy atom rmsd of 1.9 Å was calculated 







Table 8: Structural statistics of the MT-bound TP1  
(Structure of this TP1 was calculated by Dr. Mariusz Jaremko and Dr.Lukasz Jaremko). 
Structural statistics for the 20 final conformers of MT-bound TP1 (27 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 
RMS deviations from the average structure 




  78 
116 
  16 
    0 
 





  1.4% 










Figure 45: Structure of TP1 in the MT-bound state. (a) Mainchain superposition of the ten best 
structures of the MT-bound TP1 as calculated from the tr-NOESY experiments. (b) Structured region of 
the MT-bound TP1 with sidechains identified as binding epitopes. (c) The mean structure of the TP1 in the 
MT-bound state. The sidechains of the residues involved in the long and medium range interactions within 







3.6.6 Structure of MT-bound TRꞌ 
The peptide TR’ from the pseudo repeat region of Tau was shown as one of the 
important regions involved in MT binding. The comparison of tr-NOESY spectrum of 
TR’ with MTs and NOESY spectrum of free TR’ showed significant number of NOE 
cross peaks appeared in the MT-bound state, indicating the effective binding as well as a 
specific conformation in the MT-bound state. The structure of MT-bound TR’ was 
calculated by collecting 434 tr-NOE cross peaks with 107 intra residue and 327 inter 
residue NOEs. The distance restraints generated were classified into 278 short, 108 
medium and 48 long range NOEs and were used in the structure determination of MT-
bound TR’ using the same protocol followed in the previous cases. The NOE 
connectivities and number of NOEs used per residue are shown in Figure 46. The 
structural statistics of the lowest 20 structures is given in Table 9 and the best 10 
structures are displayed in Figure 47. 
 
Figure 46: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TR’ peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 








Table 9: Structural statistics of the MT-bound TR’ 
(Structure of this TP1 was calculated by Dr. Mariusz Jaremko and Dr. Lukasz Jaremko). 
Structural statistics for the 20 final conformers of MT-bound TR’ (35 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 







  48 
 





  7.2% 







Figure 47 : Structure of TR’ in the MT-bound state. (a) Main chain superposition of the ten best 
structures of the MT-bound TR’ as calculated from the tr-NOESY experiments. (b) Structured region of 
the MT-bound TR’ with side chains identified as binding epitopes. (c) The mean structure of the TR’ in the 
MT-bound state. The side chains of the residues involved in the long and medium range interactions within 







3.6.7 Structure of MT-bound TR23 
As explained before TR23 is the peptide that comprise of the binding regions of 
both TR2 and TR3 which are two nearest independent binding domains in hTau40. The 
tr-NOESY spectrum of TR23 peptide was acquired in the presence of MTs in 20:1 ratio 
of TR23:MT and it showed a number of intense cross peaks in comparison to the 
spectrum acquired in the absence of MTs. This indicates that the additional peaks in the 
MT-bound state of TR23 are originating as a result of effective binding and change in 
conformation in the MT-bound state. The combined effect of two interacting region is 
reflected from the number of tr-NOEs observed in comparison to the number of cross 
peaks observed in the free state of the peptide. It clearly indicates the net effect of two 
interacting fragments being together. 
A total of 652 tr-NOEs were used in the structure calculation which were assigned to 208 
intra residue and 444 inter residue NOEs. The distance restraints generated from these tr-
NOEs were classified into 460 short, 141 medium and 41 long range NOEs. The NOE 
connectivities and number of NOEs used per residue are shown in Figure 48. 
 
Figure 48: (a) The distribution of NOE interactions. Plots of the distribution of distance constraints as a 
function of their residue numbers for MT-bound TR23 peptide used for structure calculation. In the plot 
against the sequence upper distance limits are classified according to their range as intra and sequential 
constraints (white), medium range (grey) and long range (black) respectively. (b) Overview over sequential 
and medium-range 1H-1H NOEs in various secondary structural elements. Short distances are indicated by 
horizontal lines connecting the corresponding proton positions and the thickness of the bars is proportional 







The structure of MT-bound TR23 was determined using the similar protocol as 
explained in the previous cases and the structural statistics of 20 lowest energy structures 
are given in  
Table 10 and there were no violations larger than 0.5 Å per structure. The 
structured regions of the TR23 peptide are identical to the structured regions of TR2 and 
TR3 and are shown separately as an ensemble of 10 best fitting structures in Figure 49a 
and Figure 49b respectively. 
 
Table 10: Structural statistics of the MT-bound TR23 
Structural statistics for the 20 final conformers of MT-bound TR23 (46 residues) 
Number of restraints 
Intra residue NOE (|i-j| = 0) 
Sequential NOE (|i-j| = 1) 
Medium range NOE (1< |i-j| < 5) 
Long range NOE (|i-j| ≥ 5) 
 
NOE violations > 0.5 Å/structure 
 
Ramachandran plot statistics 
Residues in most favored regions 
Residues in additionally allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
 
RMS deviations from the average structure 
Backbone atoms (Residues 269-281)  
Heavy atoms   
Backbone atoms (Residues 299-311)  





  41 
 






  7.7% 
 
 
1.43 Å  
2.53 Å 






The two structured regions of the combined peptide TR23 were compared with the short 
individual peptides TR2 and TR3 as shown in Figure 49c and Figure 49d respectively, 






Figure 49: The structure of MT-bound Tau peptides is conserved in the longer Tau constructs. 
Structure of TR23 in the MT-bound state. (a and b) Structure of TR23 in the MT-bound state with 
superposition of the structured regions of 10 low energy conformers of TR23 peptide (cyan) with 
structured region of TR2 (green) and with TR3 (orange) respectively. 
 
3.7 Properties of Tau peptides 
3.7.1 Competition between Tau and Tau peptides for MT binding 
The observation that the binding regions of Tau on MT are independent of each 
other allowed to use shorter Tau fragments to perform competition experiments with full 
length Tau for MT binding. Shorter Tau fragments from the microtubule binding 
domains can bind, stabilize and/or promote MT assembly (Joly, Flynn et al. 1989). The 
previous study using different fragments showed that although all the peptides from the 
microtubule binding domain are able to bind to tubulin or MT not all of them promoted 
MT assembly (Joly, Flynn et al. 1989). The Tau fragments TP2 and TR3 are two 
important binding hot spots of Tau for MT binding and adopt well defined structure in 
the MT bound state (section 3.2). These peptides were chosen to compete with full 





3.7.1.1    Competition between TP2 and hTau40 for MT binding 
Titration of TP2 into the solution containing hTau40 and MTs in different ratios 
varying from 5, 10 and 15 times excess than hTau40 was done at a Tau concentration of 
50uM. The line broadening observed in the hTau40-MT complex was taken as the 
reference to specify the relative influence of TP2 and is shown in Figure 50a. 
Subsequent addition of TP2 reduces the overall line broadening observed in the Tau-MT 
complex indicates both hTau40 and TP2 are competitively targeting MTs for the same 
binding site. The reduction in line broadening indicates the presence of relatively high 
number of free Tau molecules in solution after the addition of TP2. An almost 60% 
reduction in the initial line broadening after 15 fold excess addition of TP2 indicates 
competition between Tau and TP2 highlighting the importance of proline rich region in 
MT binding. Most specific observation to be noticed is that a shorter peptide from P2 is 
competing with all other independent binding domains of Tau protein. 
3.7.1.2 Competition between TR3 and hTau40 for MT binding 
The ability of independent binding features of Tau domains in the repeat region 
was further tested with the help of TR3 peptide. We could see the similar behaviour as 
found in the case of TP2 when it was allowed to compete with hTau40 for MT binding. 
The peptide was added in the successive amounts of 250μM, 500μM and 750μM 
concentrations. At 15 fold excess concentration of TR3 in the hTau40-MT complex 
reduces the line broadening in the hsqc spectra upto ~40% with a relatively less effect 







Figure 50: Efficiency of Tau peptides for microtubule binding. (a) Residue specific NMR signal 
intensity ratios of hTau40 between the MT-bound and unbound state with a stoichiometry of 2:1 (black 
bars). TP2 peptide shows competition for MT binding against hTau40 and the decrease in line broadening 
is reflected in the intensity ratio plot between the ternary complex of hTau40, TP2 and MT and unbound 
hTau40(purple line). (b) Competition of TR3 peptide and hTau40 for MT binding is depicted in the 
intensity ratio plot of hTau40 alone bound to MTs(black bars) and hTau40 and TR3 peptide together bind 
to MTs(orange line). The colouring code in the domain organization diagram and the intensity plots 
represent the structured regions of corresponding peptides. (c) Addition of the control peptide TN1 from 
the N-terminal insert of the hTau40 to the Tau-MT complex has no effect on MT binding. The intensity of 
resonances of full length Tau bound to MTs (black bars) remains unaffected after the addition of TN1 
peptide (grey line). The Tau peptides were taken 15 times in excess of hTau40 in all three cases. 
 





To address whether these observations and results are specific or not, we 
performed the control experiment using the TN1 peptide (Tau52-69) from the N-terminal 
projection domain. The addition of TN1 to the hTau40-MT complex didn’t exhibit any 
competition for MT binding (Figure 50c). To summarize, the competition experiments 
described here between short Tau peptides and hTau40 for MT binding clearly indicate 
the independent binding of the Tau domains. 
3.7.2 Effect of phosphorylation and mutations in MT-binding 
3.7.2.1 Effect of phosphorylation (T231 phosphorylation) 
Phosphorylation of Tau protein is an integral part of its function in regulation of 
many cellular processes. Phosphorylation at specific sites (e.g. T231 phosphorylation) 
leads to detachment of Tau from MT, MT disassembly and formation of neurofibrillary 
tangles (NFTs). The effect of site-specific phosphorylation on MT binding was tested by 
acquiring the tr-NOESY spectrum of TP2_pT231 with MT. The overlay of the spectra in 
the presence and absence of MTs is compared with the tr-NOESY spectra of wild type 
TP2 as shown in Figure 51. 
 
Figure 51: Effect of Phosphorylation of Tau peptides on MT binding and assembly. (a) The lowest 
energy conformer of TP2 peptide for which the structure is determined in the presence of MTs, with side 
chain of T231 highlighted. (b) Overlay of NOESY spectra of 1mM TP2 alone  and TP2 in the presence of 
50uM MTs . (c) NOESY spectra of TP2 with T231  phosphorylated in the presence and absence of MTs. 
Phosphorylation of T231 significantly reduces the interaction with MTs and is reflected in the tr-NOESY 





It is clear that there are no transferred NOE peaks resulting from interaction of 
TP2_pT231 with MTs. Phosphorylation of T231 significantly reduces the interaction 
with MTs and is reflected in the tr-NOESY spectrum without showing newer tr-NOESY 
peaks or enhancement in the signal intensities.  
3.7.2.2 Effect of genetic mutation on MT binding 
Genetic mutations in Tau lead to a series of neurodegenerative disorders known 
as Tauopathies. Here, we are interested to understand how these effects are related to the 
structure and function of Tau, especially in terms of its binding to MTs. Among different 
regions of Tau sequence, mutations in exon 10 of the Tau gene have been widely 
investigated, which is further studied here. P301S mutation is known to be linked to the 
development of frontotemporal dementia (FTD) (Bugiani, Murrell et al. 1999). There are 
many missense mutations and deletion mutations like G272V, ΔK280 and G389R that 
lead to Tau dysfunction and lead to neurodegeneration (Bunker, Kamath et al. 2006).  
3.7.2.2.1 P301S  
To address how P301S mutations alter Tau binding to MTs, we prepared the 
P301S  variants of TR3 peptide and studied through tr-NOESY experiments. In 
comparison with wt-TR3, very weak cross peaks were found in the spectra of TR3_ 
P301S (Figure 52). It is evident from the spectra that the binding is relatively weak and 
is reflected in the whole tr-NOESY spectrum, where all the cross peaks are too weak to 







Figure 52: Superposition of region of the NOESY spectrum of 1mM TR3_P301S peptide alone (red) with 
the tr-NOESY spectrum of 1mM TR3_P301S with 50uM MTs (blue) with a peptide to MT ratio of 20:1in 
50mM sodium phosphate buffer, pH 6.8. . Similar results were obtained for TR3_P301L variant (not 
shown). 
3.7.2.2.2 ΔK280 mutation 
Deletion mutation of the residue K280 from the Tau sequence is found to be one 
of the hallmarks in certain neurodegenerative diseases. The MT binding properties of 
Tau is independent of this deletion mutation as it is evident from the tr-NOESY spectrum 
(Appendix Figure 1) of TR23_ΔK280. The comparison of NOESY spectra of MT-bound 
and unbound TR23_ΔK280 clearly showed that there is no significant effect of this 










3.7.3 MT assembly properties of Tau peptides 
Having the structure of Tau peptides in the MT-bound state it is possible to 
integrate these structures into the structure of MT-bound Tau which is supported by our 
findings that the Tau-MT interaction is highly localized and independent of different 
binding domains. In this context it has high relevance to investigate how these Tau 
peptides behave independently in MT assembly and binding. The ability of the individual 
Tau peptides to bind and promote MT assembly is a key question in comparison with full 
length Tau protein. It was reported before that some of the Tau fragments and short 
peptides bind and nucleate MT assembly (Ennulat, Liem et al. 1989, Joly, Flynn et al. 
1989, Gustke, Trinczek et al. 1994) and it should be considered that all the peptides 
which are binding with MTs may not necessarily promote tubulin polymerization. The 
experiments with shorter Tau fragments provided further evidence to bind, stabilize and 
promote MT assembly. These experiments were done by Dr. Satish Kumar and Dr. 
Katharina Tepper (Prof. E. Mandelkow group, DZNE, Bonn). 
3.7.3.1 MT assembly of Tau peptides 
The tubulin polymerization assay with Tau peptides was performed using the 
turbidity measurement in combination with electron microscopy. The systematic tubulin 
polymerization assay was done using 10uM of tubulin which is below the critical 
concentration, above which the tubulin itself can polymerize in the presence of 
polymerizing agents. The polymerization capacity of hTau40 and TauF4 was taken as the 
reference and the light scattering of these proteins in the presence of tubulin showed 
polymerization at low protein concentrations of 5 and 25 μM respectively 
(section3.4.2.2). The polymerization assay of tubulin was further tested using each Tau 
peptide by increasing the concentrations. TP2 promoted tubulin assembly at higher 
concentration of peptide and the optimum concentration was found to be 500uM 
although polymerization was visible already at 250 μM. The temporal development of 
turbidity in the solution was followed at 37ºC as shown in Figure 53a and the EM image 
of the MTs formed by TP2 induced tubulin assembly is shown in Figure 53d. The role of 
repeat domain of Tau to promote MT assembly was investigated in the similar manner 
by using the TR2, TR3 and TR23 peptides. 250µM of TR2 (green curve) and 250µM 





the presence of TR3 (Tau296-321) was not reliable due to the high scattering intensity of 
250µM TR3 peptide 
 
Figure 53: Effect of Tau peptides on microtubule assembly. Light scattering at 350nm was recorded 
over time to monitor the microtubule assembly in the presence of different Tau peptides. Assembly 
experiments were performed in the presence of 1 mM GTP at 37°C with a fixed tubulin concentration of 
10 µM. Intensities were normalized to the assembly in the presence of hTau40 (set to 100% in the plateau 
phase). (a) Tubulin polymerization assay using hTau40, TP1, TP2 and TR’ with concentration 5 µM for 
hTau40 and 500 µM each for Tau peptides. (b) 5 µM hTau40 and 250 µM each of TR2 and TR23. (c) 
Monitoring a microtubule assembly in presence of 250 µM TR3. The high scattering intensity of TR3 in 






In the absence of tubulin (orange curve), that caused interference in the measurements. 
500μM Tau peptide TP1 (magenta curve) and 500μM TR’(red curve) did not support 
MT-Assembly. The binding-deficient peptide TR4 (Tau327-353) was used as negative 
control that didn’t support the MT assembly as shown in Figure 54(grey curve). Tubulin 
by itself didn’t polymerize (violet curve, Figure 53a) since the concentration is below 
the critical tubulin concentration. 
3.7.3.2   Effect of phosphorylation in MT assembly 
The polymerization capacity of TP2 with phosphorylation of the residue T231 
which is one of the potential biomarkers in AD was checked by using turbidity 
measurement. The turbidity measurement showed complete abolishment of the MT 
assembly. The Figure 54 shows the comparison of the turbidity measurements of both 
wild type and phosphorylated TP2. 
 
Figure 54: Tubulin polymerization assay using hTau40, Tau peptides TP2, TP2_pT231, TR4 and tubulin 
itself. Light scattering at 350nm was recorded over time to monitor the microtubule assembly in the 
presence of different Tau peptides. Tubulin concentration was 10 µM, Tau concentrations were 5 µM 
(hTau40, black) and 500 µM for the Tau peptides TP2 (Tau211-242, purple), TP2_pT231 (brown) and 
TR4(Tau327-353, grey). Assembly experiments were performed in the presence of 1 mM GTP at 37°C. 
Intensities were normalized to the assembly in the presence of hTau40 (set to 100% in the plateau phase). 
Tubulin alone (dotted lines, yellow), TP2_pT231 and TR4 did not support the microtubule assembly. The 







3.7.4 Independent binding of Tau fragments to the same binding site 
The findings on the basis of interaction studies as explained in section 3.2 with 
hTau40 and F4 provided the interesting information that the binding of Tau to MTs is 
mediated by highly localized linear motifs of Tau which are separated by highly flexible 
linkers. These isolated linear motifs can bind independent of the other binding domains 
of Tau. In addition to these the competition of hTau40 and Tau peptides for MT binding 
as reflected from the HSQC spectra (section 3.7.1) give further information that TP2 and 
TR3 have the tendency to bind at one of the potential binding sites of Tau.  
3.7.4.1 Inter peptide competition for MT binding 
Tr-NOESY based competition experiment was performed using TR2 and TR3 
peptides. The NOESY spectrum of 1mM TR3 was acquired at 278K in 50mM sodium 
phosphate buffer, pH 6.8. The spectrum obtained is shown in Figure 55 b in red 
contours.  
 
Figure 55: The binding motifs in the repeat region of Tau interact with MTs independently and 
compete for the same binding site. (a) Cartoon representation of competition between TR2 (green) and 
TR3 (orange) peptides for MT binding which are targeting the same binding site on MT. (b) Overlay of the 
regions of tr-NOESY spectra of TR3 peptide alone (red), TR3 with MTs (blue) and TR3 and TR2 together 
with MTs (green) measured with a mixing time of 150ms at 5°C. The tr-NOESY peaks in the spectra upon 
interaction of TR3 with MT (blue contours) is diminished after competition with TR2 and selected 





The addition of MTs into this solution allowed to detect tr-NOESY resonances in 
the MT-bound state of TR3 as reflected from the appearance of new signals 
corresponding to the change in conformation after binding as well as enhancement of the 
signals because of the large rotational correlation time of the complex. The spectrum is 
shown in blue contours. Upon further addition of TR2 into the same solution reduces the 
tr-NOESY signal intensities of TR3 as a result of the competition of TR2 and TR3 for a 
common binding site on MT. The overlay of the three spectra clearly shows the three 
states of TR3 peptide. The schematic representation of this competition between TR2 
and TR3 for MT binding is shown as a cartoon representation in Figure 55a. 
3.7.4.2   Intrapeptide competition: INPHARMA NOEs 
It is also possible to get additional information regarding the competition between 
the binding domains within the same ligand in a similar approach as described in the 
previous section (3.7.4.1) using tr-NOESY experiments. If a ligand possesses two 
domains binding to the same binding site, the intra-ligand protein-mediated NOEs can 
provide information regarding their spatial configuration. This is the extended concept of 
INPHARMA approach, where protein-mediated interligand NOEs were detected for 
pharmacophore mapping.  
An attempt to determine the relative spatial arrangement of the linear binding 
motifs of Tau identified was done using MT-binding peptide TR23. The TR23 peptide 
that comprises both the binding regions from TR2 and TR3 peptide was allowed to bind 
to MTs and the tr-NOESY spectrum was measured. The resulting cross peaks after 
binding with MTs include cross peaks between residues in the two separate binding 
domains of TR2 and TR3 peptide indicates that these binding domains come closer 
during binding and indicates the possibility for competitive binding. The cross peaks 








Table 11: List of INPHARMA NOEs identified within the tr-NOESY spectrum of MT-bound TR23. R2 
and R3 denote the two binding regions in the TR23 peptide, that belongs to the second and third repeats in 
hTau40. 
R2 R3  R2 R3 
K267HD2 H299HE2  N279HB2 Y310HD1 
K267HG3 I297HA  K280HG2 Y310HD1 
Q269HG2 I308HD1  K281HG3 Y310HE1 
Q276HB3 Q307HE22  Q276HG3 I308HD1 
I277HA Q307HE22  N279HD22 I308HG12 
I278HG12 Q307H  K280HD2 Q307H 
I278HG2 Q307H  K281HD3 Q307HE22 
N279HD22 Q307HB3 
 
These NOEs were not observed in the absence of MTs and the NOEs primarily 
involve the two hexapeptides, indicating that they are important for binding to MTs in 
line with the 3D structures of TR2 and TR3.  This way the intraligand transferred NOEs 
described here provides the experimental basis for the relative orientation of the two 
binding domains in TR23 peptide during binding with MTs and provide strong 
experimental evidence that they are in close spatial proximity at a certain time point. 
These data indicates the presence of a common binding site located on MT/tubulin which 







3.8 Identification of binding site of Tau on tubulin/MT 
The nature of the binding site of Tau on MTs is still a matter of debate. It has 
been proposed for example that Tau binds on the outer surface of MTs or it shares the 
binding site of MT targeting drugs like taxol (Kar, Fan et al. 2003). Different approaches 
were used to identify the binding site of Tau on MTs. First, on the basis of the hypothesis 
that Tau-MT binding is mediated by the C-terminus of tubulin (Santarella, Skiniotis et al. 
2004, Lefevre, Chernov et al. 2011), we synthesized C-terminal peptides of both α- and 
β-tubulin and performed NMR titration experiments with full length Tau protein. A 
significant number of amino acid residues at the C-terminus of tubulin are completely 
unstructured in the tubulin subunit. 
  Second, with the availability of different MT binding drugs and information 
regarding their binding sites, we performed competition experiments between hTau40 
and tubulin-targeting drugs using 1H-15N HSQC experiments. Later on STD-NMR and tr-
NOESY-based competition experiments were performed to verify the findings. Third, 
and as a complementary method, chemical cross-linking in combination with mass 
spectrometry was employed to further validate the competition results. 
 
3.8.1 Interaction of Tau with C-terminal peptides of tubulin 
The tubulin C-terminal peptides were designed as, α-Tub433-451and β-Tub424-
445. The 2-D 1H-15N HSQC spectra were acquired with the C-terminal peptides of 
tubulin and compared with that of Tau-MT complex. The data show that the C-terminus 
of tubulin can bind to Tau, when present as an isolated peptide. The chemical shift 
perturbation profiles from the 2-D 1H-15N HSQC spectra were found to be similar to that 
of the Tau-MT interaction as shown in Figure 56. Hence it shows that, similar 
interaction is present both in the Tau-MT and Tau-aTubC/bTubC binding. It is evident 








Figure 56: 1H-15N combined chemical shift difference observed for the NMR signals in the MT-bound 
state of Tau (brown) is compared to the profiles of C-terminal peptide of alpha (green) and beta (blue) 
tubulin. 
 
3.8.2 Competition of Tau with MT drugs for binding 
Interpretation of the titration with the C-terminal tubulin peptides is difficult as these are 
isolated peptides. More solid approach is the use of the MT drugs. The well 
characterized MT drugs are classified into four different classes on the basis of their 
stabilizing/destabilizing properties as well as their binding sites. The MT drugs used in 
our study include Taxol (Paclitaxel), Baccatin, (-)-Thalidomide, Colchicine and 
Vinblastine. The binding regions of these compounds are highlighted in Figure 57. 
Competition experiments were done by adding the MT drugs into the Tau-MT or Tau-







Figure 57: Binding sites of MT drugs. The binding sites of vinblastine (VB), colchicine (COL), taxol 
(PTX) and thalidomide (THAL) are indicated in the crystallographic structure of T2R complex consisting 
of two tubulin heterodimers, vinblastine, colchicine and RB3 protein-stathmin like domain. The bound 
colchicine and vinblastine are shown using the stick model and a few residues involved in taxol binding 
are highlighted in pink color near the M-loop. (Figure modified from PDB 1Z2B) (Gigant, Wang et al. 
2005). 
3.8.2.1  Competition experiment with Vinblastine and hTau40 
Vinblastine binds on α-tubulin, in between two tubulin heterodimers and inhibits MT 
assembly, instead it promotes the tubulin dimers to form curved protofilaments (Gigant, 
Wang et al. 2005). The possibility for vinblastine and Tau to share the same binding site 
was explored though competition experiments monitored by 2-D 1H-15N HSQC spectra. 
Vinblastine (VB) was allowed to interfere with Tau for MT binding by titrating it against 
the Tau-MT complex up to a concentration 20 times higher than Tau. It was observed 
that the line broadening in the HSQC spectrum of Tau-MT complex is reduced upon 
addition of VB. The successive addition of vinblastine separated Tau from MTs and led 
to an ~80% gain in the intensity (Figure 58a). Repeating these experiments with 
unpolymerized tubulin results in the similar observation (section 3.8.2.6). Hence the 
result supports the possibility for Tau and vinblastine to bind at the same or nearby 






Figure 58: The competition of hatu40 and MT drugs vinblastine (a) and Thalidomide (b) are shown as the 
variation in the intensity ratios observed in the 2-D 1H-15N HSQC spectra of MT-bound state. Black bars 
represent the line broadening of specific residues in hTau40 in the MT-bound state and grey lines shows 
the residual signal intensity of MT-bound hTau40 in the presence of compounds. The elevation in the 
intensity after the addition of vinblastine shows competition with hTau40 for MT binding as a result of 
impairing of hTau40 from MT. 
 
3.8.2.2 Competition experiment with Thalidomide and hTau40 
(-)-Thalidomide promotes MT assembly by binding to the side pocket on β-tubulin 
(Amos 2011), which is accessible from the outer surface of MTs.  Addition of 
thalidomide in to the Tau-MT complex has no influence on the line broadening of 
hTau40 resonances in the 1H-15N HSQC spectra (Figure 58b) and it was concluded that 







3.8.2.3 Competition experiment with Baccatin and hTau40  
Baccatin is another taxoid, an alternative for taxol and has higher solubility than taxol in 
water. Addition of baccatin in variable concentrations upto 20 times excess of hTau40 to 
the Tau-MT complex has no influence on the line broadening of hTau40 resonances in 
the 1H-15N HSQC spectra as shown in Figure 59a. The result again ruled out the 
possibility of Tau to bind near the M-loop and taken together competition experiments 
with taxol and baccatin rules out the possibility of Tau to bind at the luminal binding site 
3.8.2.4 Competition experiment with Colchicine and hTau40 
Colchicine is responsible for the inhibition of MT assembly binding within the 
heterodimer between α and β-tubulin in a pocket near the non-exchangeable 
GTP(Nogales, Wolf et al. 1998). Addition of colchicine in variable concentrations upto 
20 times excess of hTau40 to the Tau-MT complex has no influence on the line 
broadening of hTau40 resonances in the 1H-15N HSQC spectra (Figure 59b). It 
indicates that Tau-MT interaction is not mediated by colchicine binding site. 
3.8.2.5 Competition experiment with Taxol and hTau40 for MT binding 
Taxol is one of the MT stabilizing drugs that bind in the luminal pocket (Nogales, 
Wolf et al. 1998). It has been believed that Tau and other MAPs stabilize MTs by 
binding at the taxol binding site near the M-loop of β-tubulin(Amos 2004). To verify the 
previous findings we performed the competition experiment using 2-D 1H-15N HSQC 
experiments where taxol was allowed to interfere with Tau for MT binding. Titrating 
different fractions of taxol to the Tau-MT complex didn’t affect the Tau-MT binding as 
it was observed in the line broadening profile shown in Figure 59c. By increasing the 
concentration of Taxol, there is no competition with hTau40 as the signal intensities of 
hTau40 remain unchanged. The experiments using Tau-tubulin complex also provided 






Figure 59: Inertness of Tau to compete with Baccatin, Colchicine and Taxol. No competition is 
observed as evident from the 2-D 1H-15N HSQC spectra of MT-bound hTau40 with Baccatin (a), 
Colchicine (b) and Taxol (c) for MT-binding. The intensity ratio of MT-bound hTau40 is shown as black 
bars and grey line shows the residual signal intensity of MT-bound hTau40 in the presence of compounds. 
 
It is evident from the competition experiments using hTau40 and MT drugs that only 






3.8.2.6  Vinblastine compete with hTau40 to bind to tubulin  
Repeating the competition experiments between Vinblastine and hTau40 to bind to 
unpolymerized tubulin resulted in the similar observation found in the presence of MTs 
(section 3.8.2.1). Hence the result (Figure 60) supports the possibility for Tau and 




Figure 60: Vinblastine competes with hTau40 for tubulin binding. Variation in the intensity ratios 
observed in the 2-D 1H-15N HSQC spectra of hTau40 in the tubulin-bound state. Black bars represent the 
line broadening of specific residues in hTau40 in the tubulin-bound state and red, green and purple bars 
represent the residual signal intensity of tubulin-bound hTau40 in the presence of 5, 10 and 20 fold excess 
of vinblastine. The elevation in the intensity after the addition of vinblastine shows competition with 
hTau40 for tubulin binding. 
 
All these data are in line with the presence of a single major binding site for Tau 
on MTs. At this point the question is where all these Tau domains bind. Initial 
competitions showed vinblastine compete and showed significant effect. To further 
investigate the presence of a common binding site for Tau and vinblastine we combined 
the results from competition experiments and final confirmation by NMR was done with 






3.8.3 Competition experiments using STD NMR spectroscopy 
In the next step, we used STD-NMR spectroscopy to further characterize the 
binding properties of peptides. The 1D STD-NMR method was used by saturating the 
resonances of tubulin at -0.5 ppm corresponding to the methyl protons in tubulin and 60 
ppm, far from any proton resonance in the sample, for reference. The saturation of 
methyl protons in tubulin is first spread via a network of proton-proton dipolar couplings 
to all the protons of tubulin, then transferred to ligand protons which transiently come 
spatially close to tubulin through binding. In this way, weak tubulin-ligand binding is 
detected and ligand protons involved in binding are identified. 
3.8.3.1 Competition between Tau peptides and MT drugs: binding to tubulin 
The strategy involved in identifying the binding site utilizes the availability of the 
MT/tubulin targeting drugs and the crystallographic structure of their complex. The 
peptides used in structure determination of MT-bound Tau were allowed to compete with 
different compounds for binding. One compound each was selected from the 
classification of compounds as described before (Amos 2011) for which the binding sites 
are already known. The prior information obtained from the competition experiments of 
these compounds against hTau40 for MT/tubulin binding using 1H-15N HSQC 
experiments (section 3.8.2) were expected to be complementary to the STD experiments. 
3.8.3.1.1 Competition between Vinblastine (VB) and Tau peptides 
The 1D STD NMR experiments were performed for all peptides used for 
structure determination and were compared with their 1D proton NMR spectra. It was 
noticed that the spectra clearly indicated the binding and specific residues involved in 
binding that constituted the structured region of the peptide showed highest STD effects. 
STD spectra of 1mM solution of TP1, TP2, TR1, TR2, TR3 and TR’ in presence of 
20µM tubulin were measured at 298K. The spectra showed clear evidence that each 
peptide binds to tubulin as expected. The control experiment was done using a non-
binding peptide (TN1), the sequence of which constitute the N-terminal region of 







Figure 61: (a-d) Competition between Tau peptides and MT drugs for same binding site tested using STD 
NMR experiments. All the STD experiments were done with 1mM each of peptide and compound and 
20uM of tubulin with selective saturation of the protein resonances at -0.5ppm and at 60 ppm for reference 
spectra. (a) The one-dimensional STD NMR spectra of the TR3 peptide in the presence of tubulin (blue) 
and after the addition of vinblastine (red). (b) STD NMR spectra of TR3 with tubulin (blue) and after the 
addition of thalidomide (red). Aromatic protons of thalidomide affected by the selective saturation of 
tubulin are labeled. (c) STD NMR spectra of TR3 with tubulin (blue) and after the addition of baccatin 
(red). (d) 1D-STD NMR spectra of TR’ peptide in the presence of tubulin(blue) and after the addition of 





containing TR3 reduced the signals of TR3 which are characteristic of the tubulin binding as shown in 
Figure 61a. The peaks corresponding to the side chain protons in Y310 residue at 6.7 ppm and 7.05 ppm 
were analyzed consistently. The resonance intensity reduced by 60% indicating strong competition 
between TR3 and vinblastine for the same binding site. The result is consistent with the competition of 
hTau40 and vinblastine for tubulin/MT binding (Figure 58a and Figure 60). 
The STD based competition experiments were performed with all the peptides. 
Addition of vinblastine reduced the STD intensities of TP1, TP2, TR1, TR2 and TRꞌ by 
20, 50, 30, 40 and 40% , respectively. In contrast, the control peptide TN1 did not 
modulate binding of vinblastine to MTs, as the STD intensity of vinblastine remained 
unchanged by the addition of TN1 peptide. 
3.8.3.1.2 Competition between Thalidomide (Thal) and Tau peptides 
To give further evidence that Tau doesn’t share the binding site of thalidomide, 
as observed in the 1H-15N HSQC based competition, STD experiments were performed 
with all the peptides bound to tubulin followed by thalidomide. The data acquired with 
all the peptides in the tubulin bound state underline that the binding site of Tau is 
different compared to that of thalidomide. The overlay of the STD spectra of thalidomide 
and TR3 together with tubulin and of TR3 alone with tubulin is shown in Figure 61b.   
 
3.8.3.1.3 Competition between Baccatin (Bac) and Tau peptides 
The addition of the equal concentration of the ligand baccatin to a sample 
containing TR3 with tubulin didn’t affect any characteristic tubulin binding resonances 
of TR3. The peaks corresponding to the side chain protons in Y310 residue at 6.7 ppm 
and 7.05 ppm were analyzed as shown in Figure 61c. The data clearly indicate the 
independent binding of TR3 and baccatin. Hence the data clearly show both are targeting 
two entirely different binding site. The result is consistent with the competition 
experiment of hTau40 and baccatin for MT binding (Figure 59). 
 
3.8.3.1.4 Competition between Colchicine (Col) and Tau peptides 
The STD experiments were performed with each of the binding peptides and 





as the resonance intensities of peptides remain largely unaffected. The STD NMR 
spectra of tubulin-bound TR’ and TR’ and colchicine together with tubulin are overlaid 
and is shown in Figure 61d. The resonances of Y394HE1 at 6.7 ppm and F378HD1 at 
7.15 ppm, which is one of the residues in the binding epitope, are labeled and 
comparison of both spectra clearly shows that there is no competition for tubulin 
binding. 
The STD NMR based competition experiments performed are listed in the Table 
12. The complete analysis of the STD spectra of all the combinations of peptides and MT 
drugs can be summarized as shown in the histogram Figure 62. It is evident from the 
graph that only vinblastine is competing with all the Tau binding peptides. Thalidomide 




Figure 62: Relative effect of STD signals intensities of different Tau peptides and MT drugs. The 
reduction in STD NMR signal intensities after competition between peptides and compounds is plotted. -
The variation in the 1D STD signal intensities of peptides in the presence of tubulin after the addition of 
different compounds is presented. The horizontal dotted lines on the bars show the error in comparison of 
signal intensities. All the STD experiments were performed at 298 K and ligand:tubulin ratio of 40:1. The 
relative effect of STD signals were determined by taking the intensity reduction of the signal of a residue 
that forms the binding epitope. 
The different degrees of reduction in STD NMR signal intensities suggest different 
affinities for the peptides, as TR3 and TP2 bind most strongly, followed by TR2 and TR’ 





3.8.3.2 Competition between Tau peptides and MT drugs: binding to MTs 
All the above mentioned STD based competition experiments were performed 
with unpolymerized tubulin. To further validate whether this observation is consistent 




Figure 63: STD NMR spectra of VB and Tau peptides in the presence of MTs. The one-dimensional 
STD NMR spectra of the Tau peptide in the presence of MT (blue) and after the addition of vinblastine 
(red) (a-c). Competition between TR3, TP2 and TR’ against VB as in a, b and c respectively. Selected 
protons of peptides affected by the selective saturation of MT and reflect competition with vinblastine are 
labeled. 
vinblastine. It has been found that the data are consistent with that observed in the case 





in comparison to that of tubulin. The STD NMR spectra of TP2, TR3 and TR’ are shown 
in Figure 63. 
3.8.3.3 Influence of stathmin like peptide I19L 
It has been found that the tubulin/MT binding of Tau and Tau fragments are 
interfered by the presence of vinblastine, one of the inhibitors of MT assembly. To 
further support for this finding the N-terminal stathmin peptide, I19L,(Clément, Jourdain 
et al. 2005) was used. The peptide I19L reduces the tubulin polymerization rate to MT 
protofilaments, instead it leads to a curved conformation of tubulin subunits. The 
sequence of the Tau peptides from the repeats R2, R3 and R` are aligned with that of the 
N-terminal sequence of stathmin like domain peptide, which is otherwise called I19L 
peptide. The sequence alignment is shown in Figure 64. The similarities in the 
sequences suggest the presence of a common binding site for these peptides while 
binding to tubulin.  
 
Figure 64: Sequence conservations and divergences of stathmin peptide and Tau repeats. Sequence 
of stathmin peptide is aligned with the repeats R2, R3 and R` of human Tau. 
 
Stathmin binding site and its binding mode in tubulin was characterized by 
employing STD and tr-NOESY NMR experiments (Clément, Jourdain et al. 2005). The 
STD spectrum of I19L in the tubulin bound state revealed the residues which form the 
binding epitope. The binding site was mapped to be near the helix 10 (H10) of α-tubulin 
and is in close proximity to the vinblastine binding site. This vinblastine binding site was 
revealed at high resolution using X-ray crystallography. 
We assumed that Tau peptides having the similar sequence to that of I19L may 
exhibit the similar binding features of stathmin peptide. We performed the competition 
experiments with Tau fragments and vinblastine against I19L using STD NMR method 
as explained in the previous sections. It is found that TP2, TR3 and VB compete with 





close proximity that the other ligand is affected. The comparison of the STD NMR 
spectra is shown in Figure 65(a-c). Another exciting observation is that the residues in 
TR2 and TR3 that are most conserved with I19L showed strong STD effects as well as 
the INPHARMA NOE contacts (Table 11). 
 
 
Figure 65: STD NMR competition of TR3, TP2 and VB against I19L. The one-dimensional STD NMR 
spectra of the I19L in the presence of Tubulin (red) and after the addition of TR3,TP2 and VB (blue) are 
shown in a, b and c respectively. The Phenylalanine side chain protons are highlighted to show the 
competition. 
Taken together, the competition observed between Tau peptides and I19L 
indicates all these peptides bind near the vinblastine binding site, which is verified by the 





tubulin complex reduced the STD effect of I19L to 50% (Figure 65c). The addition of 
TR3 and TP2 reduced the I19L STD signal intensity by 60% (Figure 65a) and 40% 
(Figure 65b) respectively. 
 
Table 12: Summary of the STD experiments performed between Tau peptides, MT drugs and I19L 
peptide. Here “nd” refers to the combination is not performed. Tick marks represent the competitive 
binding between ligands. 
Ligands Vinblastine Colchicine Thalidomide Baccatin     I19L 
TP1    Х  Х       Х   
TP2    Х  Х       Х   
TR1    Х  Х       Х      nd 
TR2    Х  Х       Х   
TR3    Х  Х       Х   
TR’    Х  Х        Х   
TN1      Х  Х  nd  nd      X 
Colchicine      Х  nd  nd  nd     nd 
I19L    nd  nd  nd     nd 
3.9 Mass spectrometry 
Mass spectrometry based investigation of protein structure and binding interfaces 
constitutes an increasingly utilized approach in structural biology. The NMR studies with 
the aid of HSQC and STD-NMR based competition experiments revealed the potentially 
possible binding site of Tau on MTs. In order to validate the NMR studies we used mass 
spectrometry as a complementary method to characterize the binding site. Chemical 
cross linking in combination with mass spectrometry was employed to validate the 





Mass Spectrometry, MPIBPC) group and the experiments were performed by Romina 
Hofele.  
3.9.1 Cross linking TauF4/hTau40 to tubulin 
TauF4 was cross linked to tubulin which has strong affinity for tubulin/MT 
binding, with the lysine specific cross linker bis(sulfosuccinimidyl) suberate (BS3).The 
titration of BS3 with preincubated TauF4-tubulin complex allowed the selection of 
optimal cross linking conditions, 1:25 ratio of complex:BS3. The cross-linking reaction 
was performed with increasing molar excesses of BS3, 0, 5, 10, 25, 50, 100, and 200. A 
25-fold molar excess showed maximum cross linking yield while avoiding the formation 
of larger aggregates or extensive band smearing on the gels (Figure 66). 
The cross linking was performed at room temperature and as revealed by SDS-
PAGE, the bands were visible at around 60KDa and 115 KDa represent the desired cross 
linked F4-tubulin complex in the monomeric and dimeric state respectively. The bands at 
approximately 60KDa were excised and pooled before in-gel digestion.  
 
Figure 66: Separation of cross-linked Tau-Tubulin complexes by SDS-PAGE. Samples were 
preincubated, cross linked and loaded to SDS-PAGE. MW, molecular weight marker; lane 1, non cross 
linked F4+tubulin; lane 2-5, samples cross-linked using BS3 at pH 6.8; lane 6-9, cross linked F4+tubulin at 







3.9.2  Mass spectrometric analysis of cross linked F4 and tubulin 
 Cross linked peptide pairs were identified by mass spectrometry. These reflected 
regions of Tau and tubulin in spatial proximity, as defined by the spacer arm of the cross 
linking reagent. 
Five cross-links were identified between TauF4 and alpha-tubulin and no cross 
links were identified to beta-tubulin. In addition, one cross link was found between alpha 
and beta-tubulin. Even if BS3 is highly reactive toward amino groups and lysine residues 
are abundant in tubulin (19 in α-tubulin and 15 in β-tubulin) the cross linked lysine 
residues are highly localized and the frequency of the particular cross linked lysine is 
high. The cross linked residues as identified between F4 and tubulin include K336, K338 
and K401in α-tubulin and K240, K257 and K311 in TauF4 as shown in Table 13. 
Table 13: Interprotein cross-links identified between TauF4 and tubulin (1:1) 
Protein 1 Protein 2 Peptide 1 Peptide 2 Residue 1 Residue 
2 
α-tubulin TauF4 DVNAAIATIKTK SPSSAKSR   K336 K240 
α-tubulin TauF4 DVNAAIATIKTK NVKSK K336 K257 
α-tubulin TauF4 LDHKFDLMYAKR SPSSAKSR K401 K240 
α-tubulin TauF4 TKR HVPGGGSVQIVYKPVDLSK K338 K311 
α-tubulin TauF4 TKR SPSSAKSR K338 K240 
 
The cross linking of TauF4 with tubulin was repeated by varying the 
stoichiometry of the complex. At an excess concentration of tubulin in the ratio 1:3 an 
additional cross link was identified between K336 in α-tubulin to K225 in TauF4. The 
cross links identified are listed in Table 14. 
Table 14: Interprotein cross-links identified between TauF4 and tubulin (1:3) 
Protein 1 Protein 2 Peptide 1 Peptide 2 Residue 1 Residue 2 
α-tubulin TauF4 DVNAAIATIKTK SPSSAKSR   K336 K240 
α-tubulin TauF4 DVNAAIATIKTK KVAVVR K336 K225 
α-tubulin TauF4 TKR HVPGGGSVQIVYKPVDLSK K338 K311 
α-tubulin TauF4 TKR SPSSAKSR K338 K240 
 
Next, the interaction of full length Tau (hTau40) and  tubulin was investigated 
with cross linking and mass spectrometry. The cross linked residues identified were 
K336 and K338 in α-tubulin and K225, K240, K257 and K383 in hTau40. K383 is 





an important observation that the additional cross link identified in hTau40, K383, falls 
in the pseudo repeat of Tau, which constitutes another important cross linking hot spot 
identified. Table 15 shows the cross linked peptides and residues identified between α-
tubulin and hTau40. 
Table 15: Interprotein cross-links identified between hTau40 and tubulin (1:1)  
Protein 1 Protein 2 Peptide 1 Peptide 2 Residue 1 Residue 2 
α-tubulin HTau40 DVNAAIATIKTK SPSSAKSR   K336 K240 
α-tubulin HTau40 DVNAAIATIKTK KVAVVR K336 K225 
α-tubulin HTau40 DVNAAIATIKTK NVKSK K336 K257 
α-tubulin HTau40 TKR SPSSAKSR K338 K240 
α-tubulin HTau40 DVNAAIATIKTK ENAKAK K336 K383 
 
Finally hTau40 was allowed to cross link with MTs. Pre-assembled MTs and 
hTau40 were incubated to form the complex and was cross linked as in the case of 
hTau40 and tubulin. The cross linked Tau-MT complex was further heated at 90ºC for 20 
minutes to depolymerize MTs. The cross linked Tau-MT complex was analyzed by mass 
the identified cross links reflected a similar cross linking pattern to the previous  
experiments of Tau-tubulin cross linking, where residues within the P2 and R1 region of 
Tau cross link to the K336 and K338 residues in alpha tubulin. The cross links identified 
between Tau and MTs are summarized in Table 16. 
Table 16: Interprotein cross-links identified between hTau40 and microtubules (1:1) 
Protein 1 Protein 2 Peptide 1 Peptide 2 Residue 1 Residue 2 
α-tubulin HTau40 DVNAAIATIKTK KVAVVR K336 K225 
α-tubulin HTau40 DVNAAIATIKTK NVKSK K336 K257 
α-tubulin HTau40 TKR SPSSAKSR K338 K240 
 
It is noteworthy that only a few residues in Tau and tubulin are consistently 
involved in inter protein Tau-tubulin/MT cross linking even if there are numerous lysine 
residues in both Tau and tubulin. Among the 34 lysine residues present altogether in the 
α- and β-tubulin dimer, the cross linked residues are K336, K338 and K401. K401 was 
identified only once in the case of F4 and hence predominantly K336 and K338 of α-
tubulin were cross linked. Combining the results from F4 and hTau40, it can be 
concluded that only a few lysine residues within the MT binding domain of Tau are 





were intra protein cross links identified between the lysine residues within Tau and 
tubulin.  
The cross links identified between Tau and tubulin/MT can be summarized as a 
cross linking map (Figure 67). 
 
 
Figure 67: Protein-Protein cross linking map of the Tau-Tubulin/MT complex. Chemical Cross-
linking between Tau and tubulin/MT is represented in the domain organization diagram of Tau and 
tubulin. The residues involved in cross linking of Tau and tubulin/MT are connected by dotted lines. The 
colour code in the Tau domain corresponds to the structured region of the Tau peptides. The secondary 




4  Discussion 
4.1 Towards the structure of MT-bound Tau 
The current study addresses three biological questions on MT-bound Tau, 
employing NMR as the major investigation method and supporting the findings with 
complementary biophysical studies. 1) Initially the Tau-microtubule interaction was 
characterized; extending the attempt to identify the binding hot spots involved in 
interaction. Though the Tau-MT interaction has been studied for a long time, the detailed 
mechanism involved in interaction and the structure of MT-bound Tau was not yet 
established. 2) The identification of the amino acid residues involved in binding and the 
characteristic features of the binding hot spots allowed the structure determination of 
MT-bound Tau. This shed insights into the correlation between structure of MT-bound 
Tau and neurodegenerative Tauopathies. 3) Finally NMR-based competition experiments 
provided insight into the binding region of Tau on MTs and the obtained information 
was complemented by chemical cross-linking and mass spectrometry studies. 
4.2 Interaction of Tau with microtubules 
Microtubules play a crucial role in a number of cellular processes such as cell 
division, intracellular transport and axonal stability (Weisenberg 1972, Hirokawa and 
Takemura 2005). MTs are highly dynamic in nature and the dynamic structure is 
regulated by a number of factors where microtubule-associated proteins (MAPs) play 





destabilizing proteins. Tau has been given significant attention due to the large 
dependence of MT regulation in the human brain on Tau and other MAPs. The 
dysregulations of the Tau-MT interaction such as hyperphosphorylation lead to several 
neurodegenerative diseases (Gong, Liu et al. 2005, Gong, Liu et al. 2006). Different 
techniques and approaches have been employed in the investigation of Tau-MT 
interaction. NMR has been recently used to gain new insights into the mechanism of 
Tau-MT binding, especially as NMR is capable of providing information at atomic 
resolution (Mukrasch, von Bergen et al. 2007, Mukrasch, Bibow et al. 2009, Landrieu, 
Leroy et al. 2010, Bibow, Mukrasch et al. 2011, Fauquant, Redeker et al. 2011). As the 
structure and function of proteins are related to each other, it is important to understand 
in detail the mechanism of interaction involved. Identifying the interacting region of 
those proteins and their binding interface is of primary importance. Therefore, studies on 
this interaction provide highly-detailed structural information which can reveal the 
structure-function relationship acting in Tauopathies and other Tau-related 
neurodegenerative diseases.  
In previous studies, the Tau-MT/tubulin complex formation and interaction were 
characterized using different biophysical techniques such as analytical 
ultracentrifugation (AUC), isothermal titration calorimetry (ITC) (Tsvetkov, Makarov et 
al. 2012) or fluorescence resonance energy transfer (FRET) (Jeganathan, Hascher et al. 
2008). ITC provided insights into the mode of interaction of Tau and tubulin at different 
temperature and it proposed that the mode of interaction is independent of the type of the 
polymer formed (Tsvetkov, Makarov et al. 2012). FRET was used to quantify the Tau-
tubulin interaction and to calculate the stoichiometry. AUC was used to characterize the 
oligomerization state of tubulin. Still, structural information at the atomic level was 
missing. For example, X-ray crystallography which is traditionally employed in protein 
structure determination could not give structural information of disordered proteins as 
those proteins do not crystallize easily. Previous NMR studies using tubulin and other 
MAPs (Kotani, Kawai et al. 1990, Reed, Hull et al. 1992) showed that it is possible to 
utilize the strength of NMR to extend the investigation from short fragments to full-
length protein. The interaction mechanism involved in tubulin binding was characterized 
using transferred NOE and identified the involvement of hydrophobic residues critical 





fragments to achieve the complete backbone assignment of full-length Tau protein 
(Smet, Leroy et al. 2004, Mukrasch, Biernat et al. 2005, Mukrasch, von Bergen et al. 
2007, Sillen, Barbier et al. 2007, Mukrasch, Bibow et al. 2009, Narayanan, Dürr et al. 
2010). Here we performed a detailed investigation to establish the complex structure of 
MT-bound Tau. 
4.2.1 Tau-MT interaction studies revealed the highly localized binding 
hot spots of Tau 
In spite of the very high molecular weight of the Tau-MT complex, it was 
possible to demonstrate the mode of interaction between Tau and MTs. The initial 
studies shows the feasibility to work with such high molecular weight systems like Tau-
MT complex and gather information regarding the binding residues involved (Mukrasch, 
Bibow et al. 2009). The binding of hTau40 to taxol-stabilized MTs was characterized in 
different conditions using the 2D 1H-15N HSQC experiments (section 3.2.1) and provided 
results consistent with previous results where the data was acquired at 20ºC (Mukrasch, 
Bibow et al. 2009). The line broadening observed in the spectrum of MT-bound hTau40 
(Figure 14) due to the chemical exchange between the bound and free Tau molecules 
shows the region of Tau involved in direct binding. A highly remarkable observation is 
that a few continuous stretches of amino acids showed line broadening and are separated 
by highly flexible linkers (Figure 15).  
4.2.1.1 Similar binding mode is present in both 3R and 4R Tau isoforms 
The differential regulation of both 3R and 4R Tau isoforms were investigated 
with respect to different aspects (section 1.4). Among the isoforms of Tau, both 3R and 
4R Tau bind directly to microtubules, stimulate microtubule polymerization, and regulate 
microtubule dynamics (Trinczek, Biernat et al. 1995). Several studies compared the 
efficiency of different isoforms to regulate MT dynamics and assembly by varying the 
relative concentration of Tau and tubulin. Those studies found that at low Tau: tubulin 
ratio 4R Tau is more potent than 3R Tau (Drechsel, Hyman et al. 1992, Panda, Goode et 
al. 1995, Trinczek, Biernat et al. 1995, Goode, Chau et al. 2000) whereas at high 





2005). To investigate the isoform specific nature of binding of both 3R and 4R Tau 
isoforms, the interaction of hTau23 and hTau40 with MTs was compared (section 3.2.2) 
and the line broadening profiles of both isoforms (Figure 17) revealed that similar 
residues are involved in binding. The experiments performed by varying the Tau: MT 
ratios showed a similar effect. This suggests that a similar binding mode is involved in 
both isoforms. The discrepancy in the binding efficiency between isoforms could be due 
to the difference in the number of repeats in the isoforms as the binding affinity is largely 
dependent on the number of binding domains (Butner and Kirschner 1991). The 
broadening in repeat 3 of both isoforms is highly similar (Figure 17) indicating the 
relevance of the residues between P306-D314 for MT binding. The highly similar 
binding profile of hTau40 and hatu23 shows the feature of Tau to possess highly 
localized binding domains.  
4.2.1.2 Tau:MT interaction is monophasic  
It was previously reported that at very high concentrations, Tau molecules might 
aggregate on top of each other similar to paired helical filament formation. It was 
proposed that the interaction is biphasic: 1) the initial phase involves strong interaction 
binding of Tau on the MT surface; 2) in the second phase, excess Tau molecules are 
accumulating on top of each other in a non-saturable binding mode (Ackmann, Wiech et 
al. 2000). On the basis of this hypothesis, the authors proposed a model where the paired 
helical filament aggregation of Tau is initiated on the microtubule surface by inducing an 
early conformational change.  
 
To study the effect of overloading of MTs at elevated Tau concentration, the Tau-
MT interaction was investigated in different Tau:MT ratios (Figure 19). The NMR 
measurements showed that similar regions of the spectra are affected by the interaction 
with MTs, though a few residues beyond the MT binding region show additional 
broadening at higher MT concentration. This is attributed to the fast relaxation (short T2) 
associated with the large size of the Tau-MT complex as more Tau molecules are in the 
bound state at higher MT concentration.  The resonances of residues in the N-terminal 
projection domain remained largely unaffected. The previous biphasic binding mode and 





our findings. Hence it is expected to have similar interaction mode at all Tau:MT 
concentration ratios suggesting that the interaction is monophasic. 
4.2.1.3 Tau interacts with tubulin and MTs in the similar manner 
Tau binds to tubulin and promotes MT assembly. In order to address whether the 
potential binding modes of Tau with tubulin during MT assembly and with stabilized 
MTs are different or not, the interaction of hTau40 with unpolymerized tubulin was 
probed. The results showed that similar residue stretches of Tau are involved in binding 
with tubulin and MTs (Figure 22). Hence it can be generalized that binding of Tau to 
tubulin/MT involves similar interaction mechanisms for the two situations. We highlight 
here that there are different opinions on using taxol-stabilized microtubules and Tau 
assembled microtubules to study the interaction (Kar, Fan et al. 2003). Particularly, the 
experimental evidence is being questioned depending on the type of MTs used in a 
particular study. Here we claim that when using taxol-stabilized MTs and Tau assembled 
MTs, Tau and MTs will interact in the similar manner as the Tau-tubulin interaction is 
identical to that with taxol-stabilized MTs.  
In contrast, the type of sample employed is relevant when comparing the MT 
binding properties of other microtubule associated proteins (MAP) like doublecortin 
(DCX), which is a microtubule stabilizing MAP. It was shown before that purified DCX 
has no effect on the growth rate of microtubules although it is a potent microtubule 
stabilizing agent which binds in between protofilaments and counteracts their outward 
bending in depolymerizing microtubules (Moores, Perderiset et al. 2006). Probably DCX 
is highly selective to stabilize MTs without interacting with tubulin to promote MT 
assembly.  
4.2.1.4 Tau-MT interaction is mediated by both charged and hydrophobic residues  
The role of both electrostatic and hydrophobic interactions that together 
contribute to MT binding has been previously discussed. The hypothesis is similar in the 
case of other MAPs as reported for MAP-tubulin interaction (Kotani, Kawai et al. 1990). 
The information obtained from the large dependence on the ionic strength of Tau-MT 
interaction (Figure 21) is consistent with the observation reported before for the K32-





binding were found to be broad at low salt concentration, which further confirmed the 
specific residues identified as part of the binding region.  
The assumptions and arguments behind this electrostatic interaction model 
(Serrano, Avila et al. 1984, Serrano, Delatorre et al. 1984) propose charge neutralization 
during the binding event. The acidic C-terminal tail of tubulin should be neutralized by 
the basic residues of Tau or other MAPs. In the current context, the positively charged 
residues of Tau are believed to fulfill this requirement. This kind of charge neutralization 
followed by tubulin polymerization can be considered as the first stage in MT assembly. 
Still, the role of the hydrophobic interaction can be considered important in the second 
phase of the binding that stabilizes the MT interaction. It is to be noticed that the tightest 
binding is observed for the amino acids Val, Ile, and Tyr in the active binding sites. 
Hence, specific mechanisms involving both the electrostatic and hydrophobic 
interactions are proposed. It was proposed that the hydrophobic part in the side chains of 
Lys and Arg can also play the roles of Val, Leu and Ile (Kotani, Kawai et al. 1990). 
With these results, it can be concluded that the Tau-MT interaction is mediated 
through the binding of highly localized linear motifs which are separated by highly 
flexible amino acid linkers. This observation is consistent in all the experiments 
described under the section 3.2 as indicated by the colour codes in the domain 
organization diagrams. Thus we could identify the potential binding hot spots of Tau 
involved in MT binding. It was broadly divided into an acidic N-terminal ‘Projection 
domain’ (M1-Y197) and a C-terminal ‘assembly domain’ (S198- L441) based on limited 
proteolysis and microtubule binding ability (Gustke et al., 1994).  Together with the 
identification of the binding hot spots, the Tau domains can be reorganized as N-terminal 
projection domain (1-160), MT binding and assembly domain (161-400) and C-terminal 
domain (400-441). 
4.2.1.5 Site specific mutation and pseudophosphorylation lead to local alteration in 
MT binding 
To understand the features of the Tau-MT interaction where the localized amino 
acid stretches contribute to binding as a combination of both electrostatic and 
hydrophobic interaction, the single residue mutant (Y310N) in repeat 3 of hTau40 was 





residue mutation only slightly affected the binding of hTau40 (Figure 24). The line 
broadening of only the nearby residues decreased slightly showing that this effect is 
highly localized in that particular binding domain.  
Furthermore, this specific binding feature was investigated using 
phosphorylation, as it is known that the site specific phosphorylation affects microtubule 
binding (Stoothoff and Johnson 2005, Mi and Johnson 2006). Pseudophosphorylation of 
Tau was used as it decreases its affinity for microtubules, and 
pseudohyperphosphorylated forms of Tau do not have significantly decreased levels of 
microtubule binding as compared to single and double sites (Sun and Gamblin 2009, 
Sibille, Huvent et al. 2011). The pseudophosphorylation of hTau40 at the sites which 
form epitopes for the Alzheimer’s diagnostic antibodies AT8, AT100 and PHF1 
(Jeganathan, Hascher et al. 2008) also revealed that the Tau-MT binding is highly 
localized in different binding domains (Figure 25). Only the residues near the E-
mutation sites impaired binding from MTs, without having any effect on other binding 
regions of Tau.  In summary, no considerable long-range effect in the other binding hot 
spots was observed, showing the independent nature of the different linear motifs of Tau 
which are involved in Tau-MT interaction. This result is published recently as a part of 
the phosphorylation study of Tau using MARK-2 kinase (Schwalbe, Biernat et al. 2013).  
4.2.1.6 Confirmation of the binding hot spots using Tau constructs  
The use of [2H, 15N]-labeled K18 Tau in complex with tubulin gave further 
insight in terms of the core binding region of Tau. The amino acid residues in the repeats 
R1, R2 and R3 were broadened significantly even though a deuterated protein was used. 
However, the repeat R4 was largely flexible as reflected from the intensity of the 
resonances (Figure 26).  
A new fragment of Tau, F4, comprising residues S208-S324 of the Tau sequence 
was designed by Fauquant et al. F4 has a very high affinity for MT binding (Fauquant, 
Redeker et al. 2011). The MT assembly assay of hTau40 and F4 was compared using 
turbidity measurements (Figure 23). The comparatively lower efficiency of F4 for MT 
assembly may be due to the lack of pseudo repeat R’ and the part of proline rich region 
P1. In the present study, it has been found that F4 shows very high affinity for MT 





ratios and disappearance of all resonances at high F4:MT/tubulin ratios (section 3.4.2). 
The F4-MT interaction was further probed by varying the ionic strength. The residues 
which showed broadening in the NMR spectra were visible after the addition of salt. 
Although most of the residues regained their initial intensities, those which fall in the 
binding hot spots (section 3.2) experienced line broadening. This indicates very strong 
binding of F4 to MTs. Additionally, there was no temperature dependence in the binding 
mode.   
This strong binding affinity of F4 with MTs and tubulin raised the question 
whether detection of MT-bound F4 is possible or not. An attempt to get information from 
the bound residues prompted us to perform the CRINEPT-HMQC-TROSY (Riek, Wider 
et al. 1999, Riek, Pervushin et al. 2000, Riek, Fiaux et al. 2002) experiments, which 
allow the NMR detection of high molecular weight systems above 150 kDa. To 
minimize the relaxation-induced line broadening, deuterated 15N labeled F4 was used. 
The spectra of tubulin-bound F4 showed only a part of the resonances which lie in the 
flexible linkers of Tau after binding (Figure 31a). The similar observation found in the 
case of MT-bound F4 confirmed the highly localized and independent nature of the 
linear motifs of Tau in MT binding. In the case of MT-bound F4, these flexible residues 
in-between the binding hot spots were visible only in the CRINEPT-HMQC-TROSY 
spectrum (Figure 31c) but not in the TROSY experiments. This is due to the large 
number of protons in tubulin that makes the relaxation faster, resulting in broadening of 
resonances from the bound residues. This again supported the large size of the complex 
formed between F4 and MTs as well as the advantage of using CRINEPT-based 
polarization transfer for NMR experiments of large systems. The bound residues were 
beyond detection even after employing the CRINEPT element is associated with the 
sample conditions where the deuteration of the protein was about 60% as well as fully 
protonated tubulin. Perdeuterated protein might give better results together with the 
deuterated receptors, which is not possible in the case of tubulin until now. With these 
findings, it is concluded that Tau possesses highly localized binding regions which are 





4.3 Insights into the structure of MT-bound Tau 
One of the major functions of Tau is to bind and stabilize MTs and promote 
tubulin assembly (Weingarten, Lockwood et al. 1975). The results described in sections 
3.2 and 3.4 provide evidence for the active participation of Tau in binding with MTs. As 
Tau is intrinsically disordered in its free form in solution, an important research aim is to 
understand the mechanism involved in MT stabilization. However, structural information 
is necessary for a detailed understanding of this mechanism. For instance, we are 
interested to know how Tau favours MT assembly, and what its physiological roles are 
during phosphorylation. Extracting structural information directly from the Tau-MT 
complex, which has a size on the order of MDa, is challenging due to the size limitation 
of NMR. Whether NMR will be able to provide structural information on how Tau binds 
on MTs is a key question. It was shown before that even using protein deuteration, 
spectra are beyond detection (Fauquant, Redeker et al. 2011). Alternatively, for systems 
having different and distinct binding domains where a dynamic complex is formed and 
the binding sites are independent, a divide and conquer approach may be applied.  
The data discussed under sections (3.2 and 3.4) allowed us to identify highly 
localized binding hot spots of Tau which are important for binding and promoting 
tubulin assembly. It is known from previous studies that the individual Tau repeats and 
shorter Tau domains can bind, stabilize and promote MT assembly (Lee, Cowan et al. 
1988, Aizawa and Murofushi 1989, Ennulat, Liem et al. 1989, Himmler, Drechsel et al. 
1989, Joly, Flynn et al. 1989, Joly and Purich 1990). Together with other biophysical 
data, our experiments with different isoforms of Tau and other Tau fragments F4 and 
K18 indicates that the binding hot spots identified are highly independent in nature. 
Based on these findings, it is possible to apply a “divide and conquer strategy” to 
determine the structure of MT-bound Tau. We used short synthetic Tau peptides and 
determined their structure in the MT-bound state. The obtained structures were finally 
integrated into the complex structure of full length Tau bound to MTs. 
If the ligand is weakly bound and there exists fast exchange between free and 
bound forms of the ligands, detailed structural and dynamic information can be obtained 
by employing transferred NOEs and STD measurements (section 2.6). As the binding 





(Butner and Kirschner 1991, Gustke, Trinczek et al. 1994), the exchange between free 
and MT-bound peptides is expected to be fast enough on the NMR time scale to use the 
transferred NOE method 
Tau peptides selected for structure determination (section 3.5.1) were able to bind 
to tubulin/MT as evidenced from the STD NMR spectra (section 3.6). STD stands as a 
complementary method to identify the binding events of ligands to its receptor. Further 
confirmation of the specificity in the binding of Tau peptides clearly appears when 
comparing the tr-NOESY spectra of TR3 and TR4, where TR4 is not expected to bind to 
MTs. The tr-NOESY spectrum of TR3 peptide acquired in the presence of MTs showed 
a number of intense cross-peaks in comparison to the spectrum acquired in the absence 
of MTs. This indicates that the additional peaks in the MT-bound state of TR3 are 
originating as a result of binding and that the interaction induces a change in 
conformation (Figure 35a). On the contrary, tr-NOE cross-peaks were not visible for 
TR4 in the presence of MTs (Figure 35b). The basic principle of the tr-NOESY 
experiment relies on the fast dissociation rate of the ligand between its bound and free 
forms. The cross relaxation between the protons in the peptide in the MT-bound state is 
governed by the large rotational correlation time of the complex and is transferred back 
to the peptide in the free state during chemical exchange. As a consequence, additional 
NOE cross peaks are observed in the bound state reflecting the change in conformation 
of the peptide. Prior to the structure calculation of all the peptides, the assignment of all 
the resonances in the NOESY spectrum of all the peptides was done as described 
(section 3.5.2). 
4.3.1 Characteristic structural features of the MT-bound Tau peptides 
Although Tau is unstructured in the free form in solution, with the NOESY peaks 
consisting of mostly intra-residue or sequential NOEs, interaction with MTs brings 
additional medium range or long range NOEs that define the structure that is involved in 
the change in conformation needed for MT-binding. It is noticed that most of the 
additional tr-NOE cross-peaks are observed between the residues which belongs to the 





motions of these residues as a result of binding with MTs. The most striking observation 
is the presence of many medium and long-range tr-NOE cross-peaks within the residues 
which are identified as the binding epitope. The STD NMR spectrum obtained in the 
presence of tubulin and MT further proved the involvement of the residues belonging to 
the structured region, as STD is a measure of the interaction of a ligand with its receptor. 
There is no regular secondary structure such as an α-helix or a β-sheet in the 
overall fold. Instead, there is a well-defined turn/hairpin conformation which is defined 
by the binding residues. In addition, the DLSK turn near the C-terminus of TR3, which is 
transiently populated in monomeric Tau in solution (Mukrasch, Markwick et al. 2007), 
was found to be stabilized in the MT bound state. It is to be noticed that most of the 
medium and long range NOEs observed are within the Val-300-Asp314 residues stretch 
of TR3. One of the key features observed is the presence of long range NOEs from P-301 
to I-308, V-309, and V313. The side chains of these residues stabilize the turn 
conformation adopted by TR3 in the presence of MTs (Figure 37c). Notably, the side 
chains of several hydrophobic residues are pointing outwards, supporting the importance 
of these residues for binding to MTs.  
For, TR2 a smaller number of medium and long range NOEs compared to TR3 
were detected, probably due to the difference in their binding affinities. Remarkable 
NOEs in the tr-NOESY spectrum include the long range NOEs from Q269 and P270 to 
I278, K280, K281 and D283 which defines the structure of TR2.  
The comparison of the structures of TR2 and TR3 shows the involvement of the 
two hexapeptides (VQIVYK in TR3 and VQIINK in TR2) in the MT binding. These 
hexapeptides are the core regions involved in the paired helical filament (PHF) formation 
of Tau that leads to Tau aggregation and intracellular deposits (Eckermann, Mocanu et 
al. 2007). These regions adopt a beta-sheet structure in the PHFs (von Bergen, Barghorn 
et al. 2005, Mukrasch, Bibow et al. 2009, Daebel, Chinnathambi et al. 2012). In contrast, 
there is no beta-sheet content in the MT-bound state other than the well-defined turn 
conformation of TR2 and TR3. It can be hypothesized that the disruption of the Tau 
binding from the MT surface leads to the loss of the identified structure of TR2 and TR3 





To demonstrate that the structure obtained for the MT-bound linear motifs is 
retained in a longer Tau construct, the structure of the TR23 peptide, which covers both 
TR2 and TR3, was studied. The two structured regions in TR23 were compared to the 
structure of the short individual peptides TR2 and TR3 (Figure 49). From this 
comparison, it is evident that the structures of TR2 and TR3 are conserved in TR23. 
Thus, the results validate the hypothesis that the structure obtained for shorter Tau 
fragment peptides is the same as for MT-bound Tau.  
The effective binding of TR1 is evident from the presence of 36 medium range 
and 8 long range NOEs. The obtained structure (Figure 41) highlights the important 
residues involved in MT binding. The residues T245, V248, M250 and D252 holds their 
side chains in such a spatial configuration that effective binding with MTs is possible 
while keeping the medium and long range contacts defining the structure. The three 
proline residues within this structured part play a significant role in the stabilization of 
the identified structure. 
The TR' peptide possesses a well-defined structure in the MT-bound state 
(Figure 47), which is an integral part of MT binding forming one of the ‘jaws’ for MT 
binding. The structure is defined by a significant number of medium and long-range 
NOEs with L376, F378, I392 and Y394 as key residues involved in binding. Notably, the 
region of TR’ that is well-structured in the MT-bound state has already an increased 
rigidity according to 15N R1ρ measurements in monomeric Tau prior to binding to MTs 
(Mukrasch, Bibow et al. 2009). The structure of TP1 is moderately defined in specific 
regions with a well-defined turn between residues T169-T175. The consecutive proline 
residues in the sequence increase the flexibility of the structure.  
The structure of MT-bound TP2 is defined by 45 medium-range and 6 long-range 
NOEs and showed high degree of convergence within the regions K224-V228 and V228-
P236. The structured part of the peptide (Figure 43) constitutes a turn from V228 up to 
P236. Figure 27 shows the number of NOEs present in the well-structured region. Within 
This structured part attracted significant attention since the phosphorylation of residues 
T231 and S235 was found to reduce the MT binding and polymerization abilities of Tau. 
The relevance of this turn conformation can be explained on the basis of the MT binding 





whereas TP2 with phosphorylated T231 showed a strong decrease in binding as reflected 
from the tr-NOESY data (section 3.17). In addition, the phosphorylated peptide showed 
complete abolishment of MT assembly (section 4.4), providing a mechanistic 
explanation for the pathogenic consequences of T231 phosphorylation. 
The transferred NOE intensities are a measure of the extent of interaction with the 
receptor. In this context, the intensities of side chain cross-peaks are higher for residues 
in the structured region compared to terminal residues. Taken together, the structures of 
all peptides in the MT-bound state possess a similar turn conformation which is 
especially remarkable in the highly-structured region. The sequences of TR2, TR3 and 
TR' share many identical and homologous residues as well. Although the superposition 
of all the structures exhibit slightly different backbone conformations, a high degree of 
similarities in the side chain orientations that might enhance the interaction is observed. 
This indicates that all the Tau peptides possess a similar binding pattern in line with a 
common binding site. 
4.4 Tau peptides resemble full-length Tau in their function 
The investigation of structure of MT-bound Tau is performed using shorter Tau 
fragments. This was supported by the previous findings that short Tau repeats and 
synthetic Tau peptides can promote MT assembly (Aizawa, Kawasaki et al. 1988, 
Aizawa, Kawasaki et al. 1989, Aizawa and Murofushi 1989, Ennulat, Liem et al. 1989). 
As the Tau-MT complex is highly dynamic and depends on well-defined linear motifs 
connected by flexible linkers, the 3D structures of MT-bound Tau peptides form the 
basis for the structure of full length Tau in complex with MTs. 
4.4.1 Tau peptides compete with hTau40 for MT binding 
In the current scenario the question is whether these short peptides used here 
behave in the same way as a full length Tau protein interacts with MTs? To address this 
question we investigated the MT binding ability of Tau peptides by allowing them to 





demonstrated the ability of short peptides to compete with hTau40 for Mt binding. Both 
TP2 and TR3 compete for binding as observed in the line broadening profiles of HSQC 
spectrum of MT-bound hTau40 (Figure 50). The reduction in line broadening is due to 
the interaction of TP2 and TR3 with MTs that attenuates binding of full length Tau to 
MTs. As a control TN1 from the N-terminus of Tau didn’t compete with hatu40.  
 It is to be highlighted here that a short peptide, either from proline rich region 
(PRR) or from the repeat region, from the Tau sequence can compete with full length 
Tau protein impair it from MTs independent of the binding domain. This is evident from 
the overall gain in intensity across the Tau sequence. This suggests the possibility for the 
independent binding domains to bind at a single binding site.  
4.4.2 Linear motifs in Tau cooperate in tubulin binding and 
polymerization  
It has been shown that Tau peptides bind to MTs as full length Tau protein and 
compete for binding. The ability of the individual Tau peptides to bind and promote MT 
assembly is therefore a key question. The tubulin polymerization assay of all Tau 
peptides were compared to that of hTau40 and only TP2 was found to be active in 
polymerization at concentrations of 250 μM and above (Figure 54). In contrast, TR2, 
TP1, TR’ and TR23 were found to be inactive in the concentration range up to 750 μM. 
TR3 due to the high scattering intensity – likely due to partial aggregation – caused 
interference in the measurement in the absence of tubulin itself and hence the experiment 
with it was not reliable. The data demonstrate that the linear motifs in the repeat region, 
in particular the hexapeptide motif in repeat R2, strongly bind to MTs, but are not 
sufficient for MT assembly. MT polymerization requires the linear motif in the proline-
rich region P2. 
The polymerization assay of these peptides was compared with that of hTau40 
and F4, where hTau40 was more potent for MT assembly (Figure 23). The high 
concentration of TP2 needed can be correlated to the absence of other repeat domains. In 
short in spite of the inactivity of repeat domains in MT assembly they cooperatively 





observed in the peptides from the sequence of mouse Tau (Ennulat, Liem et al. 1989) 
where only the proline rich region showed MT assembly properties and a random analog 
of the same peptide as well as peptide from the repeat domain didn’t promote tubulin 
assembly even at 800 μM concentration.  
4.4.2.1 Influence of T231 phosphorylation on TP2 in MT assembly 
Being a potent tubulin polymerizing peptide the effect of phosphorylation of 
T231 residue on TP2 was investigated and the turbidity measurement of TP2_pT231 
clearly indicates the complete abolishment of MT assembly. The results of tubulin 
polymerization assay is consistent with that of phosphorylated TauF4 reported (Sibille, 
Huvent et al. 2011) where the residues T231, S235, T212 and T217 were 
phosphorylated. The phosphorylation in the PRR was found to be stabilizing a short α-
helix starting from pS235 upto T245 (Sibille, Huvent et al. 2011). The loss of MT 
polymerizing ability of T231 phosphorylated TP2_pT231 can be due to the deficiency in 
the positive charge of this peptide as a result of the introduction of a phosphate group 
and thereby having less interaction with tubulin. 
4.4.3 Phosphorylation and mutation of specific residues reduces MT 
binding 
4.4.3.1 Influence of T231 phosphorylation on TP2 reduced its MT affinity 
The effect of site specific phosphorylation and mutation of these peptides in the 
MT binding was tested using the tr-NOESY experiments. The wild type TP2 and TR3 
interacts with MTs showing a number of tr-NOE cross peaks (section 3.7). 
Phosphorylation of T231 residue, which is a biomarker in Alzheimer disease (Hoffmann, 
Lee et al. 1997), significantly reduced their MT binding affinity. It is clear from Figure 
51 that there are no transferred NOE peaks resulting from interaction of TP2_pT231 with 
MTs. 
This is consistent with the abolishment of this peptide to promote MT assembly. 
The absence of tr-NOE peaks compared to the wt TP2 can be attributed to the specific 
conformation of MT-bound TP2. Irrespective of the highly flexible nature of free TP2, it 





between V228-P236 is disrupted by the phosphorylation of T231 and the MT binding is 
disrupted. Another possibility is the possible salt bridge formation between the side chain 
of R230 and the phosphate group. The two consecutive proline residues after T231 might 
undergo cis-trans isomerization and thereby losing the NOE contacts within the 
structured region of TP2. This leads to reduced microtubule polymerization and binding 
thereby cause Alzheimer’s symptoms. A similar cis-trans isomerization model of proline 
residues and impact on AD was proposed in a study using phosphorylated Tau peptide 
(Daly, Hoffmann et al. 2000). Hence it is to be concluded that the phosphorylation not 
only bring negative charge near the Tau binding domain but also it induces 
conformational changes that cannot support MT binding.  
4.4.3.2 P301S mutation in TR3 disrupts MT binding 
The effect of mutations linked to neurodegenerative diseases were studied using 
P301S  variant of TR3 peptide through tr-NOESY experiments. In comparison with wt-
TR3, very weak cross peaks were found in the spectra of TR3_ P301S (Figure 52). This 
observation can be linked to the specific conformation of MT-bound TR3. The structure 
of MT-bound TR3 is defined by many medium and long range NOEs involving P301 
and has many long range contacts with the residues labeled (Figure 68). Due to the 
mutation of P301 to Serine these NOE contacts are disrupted that leads to the loss of 
defined structure impairing from MT surface. This might be the reason for their reduced 
rate of MT assembly and binding. In fact different clinical phenotypes are found to be 






Figure 68: Representation of the structured region of TR3 peptide that shows the long-range contacts of 
P301 to the V309 and V313. Side chains of selected residues which stabilize the structure are highlighted. 
Together, the data corresponding to the  T231 phosphorylation and P301S and 
P301L amino acid substitutions proposes a loss-of-function model in which the peptides 
shows diminished ability to properly regulate microtubule dynamics. 
Deletion mutation of the residue K280 from the Tau sequence is found to be one 
of the hallmarks in certain neurodegenerative diseases. The mechanism involved in 
binding is highly dependent on the specific conformation adopted by Tau in the MT-
bound state. It has been shown previously that the PHF formation of wild type hTau40 
and hTau40_ΔK280 are influenced by this single residue deletion mutation. Unlike this 
observation the MT binding properties of Tau is not strongly affected by this deletion 
mutation as it is evident from the tr-NOESY spectrum of TR23_ΔK280 (Supplementary 
figure 1). This could be due to the presence of the R3 region that can bind together with 
the R2 region of TR23. Or even the K281 plays the role of K280 to keep the long range 
contact within the structured region. This observation again supports the independent 






4.4.4 Independent Tau domains target the same binding site on MT 
The Tau peptides compete with hTau40 for MT binding and relatively overall 
effect over the broadening profile indicate one binding peptide can deplete off all the 
independent binding domains of hTau40 suggesting the presence of a common binding 
site (section 4.4.1). To further verify this observation the tr-NOESY based competition 
was performed using TR3 and TR2 peptides. Addition of TR2 into the same solution 
reduces the tr-NOESY signal intensities of TR3 as a result of the competition of TR2 and 
TR3 for a common binding site on MT (Figure 55). The tr-NOE competition between 
peptides TR2 and TR3 shows the diminishing effect of NOE cross peak intensity of the 
initially bound peptide.  
These evidences that an individual Tau peptide can compete with another one as 
well as hTau40 were further supported by intra ligand competition, where the two 
binding domains within the same peptide ligand were found to be competing for the 
identical  or  nearest binding sites. We have seen Tau possess distinct binding domains 
separated by flexible linkers. To verify the competition between these domains within 
the same protein, the tr-NOESY spectrum of TR23 was analyzed. There are intra ligand 
INPHARMA NOE (section 2.6.1.3) cross peaks between residues in the two separate 
binding domains of TR2 and TR3 peptides indicating that these domains come closer 
during binding. These two binding domains within the same peptide act as two distinct 
ligands targeting MT receptor. It can be visualized as at a certain time point TR2 binds at 
the preferred binding region and later TR3 approaches MT for binding. This can be 
attributed to the presence of a common binding site for these two binding domains TR2 






Figure 69: Intraligand competition of Tau domains for MT binding. Representation of the observation 
of INPHARMA NOEs. Individual Tau domains are binding with MTs (a) only TR2 and (b) only TR3. (c) 
At a certain time point both the domains are close to each other targeting the same binding site. This 
results in the observation of intraligand INPHARMA NOEs.  
Thus consistent with all the competition experiments described in the previous 
section our findings give strong evidence for the highly independent binding domains 
which target to a single binding site on MTs.  
4.5 Variety of competition experiments revealed the binding 
site of Tau on MTs 
Till now we were able to describe the binding residues of Tau involved in MT 
binding and the structure adopted by MT-bound Tau. It is highly important to identify 
the binding interface that will shed further insights to the mechanism involved in Tau-
MT interaction and thereby open new approaches for the treatment of neurodegenerative 
Tauopathies. Previous studies concluded that Tau binds either to the outer surface of 
MTs directly at the negatively charged C-terminus of tubulin (Ackmann, Wiech et al. 
2000, Al-Bassam, Ozer et al. 2002, Santarella, Skiniotis et al. 2004, Clement, Savarin et 
al. 2010). Another widely discussed binding site is the taxol binding site on beta tubulin 
near the M-loop (Amos 2004) or positively charged proline rich region binds at the 





distinct binding sites, where Tau binds both inside and outside of MTs (Chau, Radeke et 
al. 1998, Makrides, Massie et al. 2004). High resolution metal shadowing and cryo 
electron microscopy provided information regarding the binding region of Tau on MTs, 
which is largely localized on the outer surface of MTs (Santarella, Skiniotis et al. 2004). 
Using gold nanolabelling strategy Kar et al. demonstrated that Tau binds on β-tubulin 
near the taxol binding site (Kar, Fan et al. 2003). 
Different binding regions and binding models proposed till now raises the 
question, which of the models can be biologically relevant? Different biophysical 
methods employed in the previous investigations and controversial findings make it 
rather difficult to assign a specific binding site for Tau on tubulin/MT. 
4.5.1 NMR approaches identified the potential binding site 
Our Tau-MT/tubulin interaction studies showed clear evidence that the different 
binding domains bind independent of each other. To confirm whether all these binding 
hot spots or active sites bind at a single binding pocket or not and also to see where does 
it bind different competition experiments were performed.  The attempt to obtain further 
insight into the tubulin binding site of the Tau binding domains a combination of 
methods were used.  
4.5.1.1 Tau-MT interaction involves interaction with C-terminal domain of 
tubulin 
The titration of hTau40 with the C-terminal peptides of tubulin (section 3.20.1) 
suggests that the positively charged MT binding region of Tau can transiently interact 
with the negatively charged C-terminus of tubulin. The similarities in the chemical shift 
profiles with that of hTau40 in presence of MTs (Figure 16, Figure 56) underline the 
affected regions with this interaction. By using recombinant alpha and beta-tubulin C-
terminal fragments, the involvement of both of these tubulin regions in Tau binding had 
been suggested previously (Devred, Barbier et al. 2004, Lefevre, Chernov et al. 2011). 
The data suggest that neutralization of the electrostatic field generated by the negatively 





that removal of the C-terminus of tubulin by subtilisin promotes MT-assembly (Serrano, 
Avila et al. 1984). 
4.5.1.2 MT targeting drug Vinblastine and hTau40 compete for binding 
We further used different tubulin drugs with known binding sites (Figure 57), 
which are classified into different categories based on their activities and functions 
(section 1.3.6). These compounds were allowed to compete with hTau40 or Tau peptides 
for binding with MT/Tubulin. Initially we performed the competition experiments of full 
length Tau with MT targeting drugs such as Taxol, Baccatin, Thalidomide, Colchicine 
and Vinblastine (section 3.20.2).   
 Titration of each MT drug was carried out in increasing amounts of 
concentrations to a solution of 15N-labeled hTau40 bound to MTs and the variation in the  
NMR signal line broadening caused by MT interaction in specific regions of Tau was 
observed. None of the compounds other than Vinblastine was found to be competing 
with Tau for MT binding (Figure 58 and Figure 59). The decrease in NMR line 
broadening is as a result of the impairing of Tau-MT complex as Vinblastine depletes 
Tau off from tubulin/MT binding pocket and more Tau becomes free in solution. Hence 
line broadening is less compared to the isolated Tau-MT complex. The competition 
experiments were performed with unpolymerized tubulin in the similar manner using 
Vinblastine, Taxol and Thalidomide, where only Vinblastine showed tendency to 
compete with Tau (Figure 60).  
Taxol, Baccatin, Colchicine and Thalidomide were found to be inert to compete 
with Tau for tubulin/MT binding. The fact that Vinblastine competes with Tau bound to 
MT as well as tubulin shows the mutual dependence of Tau and Vinblastine for binding 
at a single binding site on MT.  
4.5.1.3 STD NMR method revealed the potential binding site of Tau on MTs 
To further verify the competition observed between Tau and vinblastine 1D STD 
NMR based competition experiments were performed with all the peptides used in the 
structural investigation. The STD spectra of each peptide bound to tubulin indicated the 
specific residues involved in binding, which are part of the structured region of these 
peptides in the MT-bound state (section 3.6). Moreover the residues that constituted the 





tubulin. All the peptides were allowed to compete with the compounds and the STD 
NMR based competition experiments performed are listed in the Table 9. The complete 
analysis of the STD spectra of all the combinations of peptides and MT drugs shows that 
only vinblastine is competing with the Tau binding peptides (Figure 61) and the relative 
effect is different for different peptides (Figure 62) and this suggests that TR3 and TP2 
are having highest affinity for MT/tubulin binding. The similar observation was found 
when vinblastine was competing with MT-bound Tau peptides. The variation in 
intensities of different resonances in the spectrum is different depending on the residues 
which are nearby tubulin. This is possible only if the ligands are coming in the close 
proximity to share the same binding site. The extent of competition is found to be 
prominent between TR3 peptide and vinblastine where the STD signal intensities of TR3 
is reduced by 60%, where the Y310 aromatic side chain proton intensities were 
compared in the presence and absence of MT drugs. This strongly supports the 
competition between hTau40 and Vinblastine for MT/tubulin binding (Figure 61 and 
Figure 63). Till now it is evident that Tau and vinblastine target the same binding site or 
their binding is mutually dependent.  
4.5.1.4 I19L peptide from the N-terminal stathmin like domain compete with Tau 
peptides 
The conflict in these findings is the competition between MT stabilizing and 
destabilizing agents. Tau as a MT stabilizing agent is found to be competing with 
vinblastine for binding either to tubulin or MTs. The characteristic feature of vinblastine 
as a MT destabilizing agent is it induces the formation of spiral tubulin aggregates 
(Weisenberg and Timasheff 1970, Himes 1991) whereas Tau promotes the formation of 
straight protofilaments. To further support the possibility for Tau to share the vinblastine 
binding site, the I19L peptide  belongs to the N-terminal part of the stathmin like domain 
(Clément, Jourdain et al. 2005) was allowed to compete with Tau peptides. The reason 
behind this is that I19L was shown to be binding on α-tubulin at the longitudinal tubulin 
interdimer interface between the helix 10 (H10)  and β-strand S9 of the crystal 
structure determined for tubulin-colchicine/RB3-SLD crystal (Clément, Jourdain et al. 
2005). This is very close to the vinblastine binding site which also binds on α-tubulin at 
the tubulin interdimer interface. The STD based competition experiments revealed that 





b). Finally Vinblastine showed competitive binding with I19L (Figure 65c). It is to be 
noticed that the repeat domains of hTau40 have sequence identities and similarities 
(Figure 64) and hence the competition observed between I19L and Tau fragments is in 
line with the sequence similarity.  
It is highly important that Vinblastine being a MT destabilizing agent compete 
with MT stabilizing protein Tau. It was shown that the negative regulator of MT 
dynamics shows competition with the stabilizing agents. A similar observation was 
found while characterizing the binding site of antimitotic drug Tubulysin, a microtubule 
destabilizing agent, it shared the binding site of Epothilone A, which is a microtubule 
stabilizing agent (Kubicek, Grimm et al.). 
4.5.2 Chemical cross-linking and Mass spectrometry validated the 
binding site 
 Chemical cross linking in combination with mass spectrometry was employed to 
validate the identified binding site (section 3.22). The NMR competition experiments 
showed that the Tau interaction motifs bind to the vinblastine-binding domain on α-
tubulin in between two heterodimers. Our mass spectrometric studies further showed that 
the amine directed cross-linking of Tau to tubulin/MT is highly specific to the side 
chains of K336 and K338 of α-tubulin. These residues are in the close proximity to the 
vinblastine binding site (Gigant, Wang et al. 2005) where the residues P325, V328, I332, 
F351, V353 and I 355 are important for vinblastine binding.  
It is noteworthy that only a few residues in Tau and tubulin are consistently 
involved in inter protein Tau-tubulin/MT cross linking though there are numerous lysine 
residues in both Tau and tubulin. Among the 34 lysine residues present altogether in the 
α- and β-tubulin dimer, the cross linked residues are K336, K338 and K401. K401 was 
identified only once in the case of F4-tubulin cross linking and hence predominantly 
K336 and K338 of α-tubulin were cross linked. Combining the results from F4 and 
hTau40, it can be concluded that only lysine residues of tubulin in close proximity to 
where Tau binds were involved in the cross links (Figure 67). In addition to these inter 





residues within Tau and tubulin, which is expected as BS3 is a highly reactive and amine 
directed cross linker. Thus chemical cross-linking of Tau and tubulin/MT strongly 
supported the NMR revealed binding site of Tau on MTs.  
4.5.3 Tau binds to α-tubulin at the inter-dimer interface 
The previous studies where the taxol binding site is proposed for Tau considered 
the possibility of having two nearby binding site, one near the M-loop and another 
luminal pocket on β-tubulin which is close to the tubulin heterodimer interface. The 
authors considered the possibilities of having errors that can occur during the averaging 
of the image analysis (Kar, Fan et al. 2003). The proposed binding site could also be the 
similar binding site we have identified.  
Al-Bassam et al. proposed that Tau binds on outer surface either on α or β-
tubulin as the resolution of the image analysis was not sufficient enough to distinguish 
the subunits. Still only one of the units is targeted by Tau repeats and Tau binds 
longitudinally along the protofilaments (Al-Bassam, Ozer et al. 2002). Our current 
finding with Tau binding to α-tubulin at the interface of tubulin dimers is consistent with 
these previous studies. Notably, the binding site of Tau to tubulin/MT identified here 
does not overlap with that of the motor proteins kinesin and dynein, which binds on β-
tubulin (Sosa, Dias et al. 1997).  
The Tau binding site identified here serves as a bridging point of different tubulin 
heterodimers. The characteristic property of vinblastine is to promote the formation of 
curved tubulin rings instead of favouring straight protofilaments which is necessary for 
MT formation. This can be attributed to entirely different mechanism involved in the 
activities of Tau and Vinblastine. Although they are sharing the similar tubulin interface, 
vinblastine induces an orientation to impede MT assembly whereas the linear motifs of 
Tau take bind in such a way to α-tubulin that promotes a straightening of the 







Taken together the studies showed that localized interaction motifs of Tau, which 
are separated by highly flexible linkers, assume a well-defined structure upon binding to 
MTs. These binding domains compete each other for binding on α-tubulin subunit of MT 
at the interdimer interface near the binding site of Vinblastine. The binding occurs in a 
cooperative manner together with the charge neutralization at the C-terminus of tubulin. 




Figure 70: The dynamic structure of MT-bound Tau. The structure of independent binding domains of 
MT-bound Tau are presented as an ensemble of 10 conformers and are connected by flexible linkers 
generated using ModLoop web server (Fiser, Do et al. 2000, Fiser and Sali 2003). The binding site 
identified, where Vinblastine binds, at the inter dimer interface of tubulin heterodimers is highlighted with 
the structure of Vinblastine (grey) on (Tc)2R complex (PDB 1Z2B). The arrows indicate the preferred 
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Appendix Figure1: Overlay of the tr-NOESY spectra of TR23_ΔK280 in the presence (blue) and absence 
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